

# Dapagliflozin in Patients with Heart Failure and Reduced

New England Journal of Medicine

381, 1995-2008

DOI: [10.1056/nejmoa1911303](https://doi.org/10.1056/nejmoa1911303)

Citation Report

#	ARTICLE	IF	CITATIONS
3	How should we manage risks associated with chronic coronary syndromes?. <i>European Heart Journal</i> , 2020, 41, 356-358.	1.0	1
4	Impact of CVOTs in primary and secondary prevention of kidney disease. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107907.	1.1	5
5	High impact Cardiovascular Research: beyond the heart and vessels. <i>Cardiovascular Research</i> , 2019, 115, e166-e171.	1.8	4
7	The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. <i>Cell Metabolism</i> , 2019, 30, 847-849.	7.2	39
9	Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering. <i>Cmaj</i> , 2019, 191, E1128-E1135.	0.9	17
10	Treatment of heart failure with sodium glucose cotransporter inhibitors in people with type 2 diabetes mellitus: current evidence and future directions. <i>Diabetic Medicine</i> , 2019, 36, 1550-1561.	1.2	4
11	Heart-Failure Therapy – New Drugs but Old Habits?. <i>New England Journal of Medicine</i> , 2019, 381, 2063-2064.	13.9	9
12	The search for an effective HFpEF treatment continues. <i>Nature Reviews Cardiology</i> , 2019, 16, 647-647.	6.1	5
13	Dapagliflozin – a breakthrough in the search for drugs to treat HFREF. <i>Nature Reviews Cardiology</i> , 2019, 16, 700-700.	6.1	3
14	Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. <i>Postgraduate Medicine</i> , 2019, 131, 555-565.	0.9	10
15	Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. <i>Cardiovascular Diabetology</i> , 2019, 18, 129.	2.7	45
16	Highlights in heart failure. <i>ESC Heart Failure</i> , 2019, 6, 1105-1127.	1.4	109
17	Dapagliflozin in heart failure: new frontiers. <i>European Journal of Heart Failure</i> , 2019, 21, 1412-1414.	2.9	5
18	Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2019, 74, 3176-3178.	1.2	4
19	Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. <i>Cardiovascular Ultrasound</i> , 2019, 17, 26.	0.5	18
20	Insuficiencia cardíaca crónica. <i>Medicine</i> , 2019, 12, 5414-5426.	0.0	0
22	Drug therapy in elderly heart failure patients. <i>European Heart Journal Supplements</i> , 2019, 21, L8-L11.	0.0	5
23	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5853.	1.8	11

#	ARTICLE	IF	CITATIONS
24	Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. <i>JAMA Network Open</i> , 2019, 2, e1916447.	2.8	4
25	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	1.7	7
26	SGLT-2 inhibitors in heart failure: a new therapeutic avenue. <i>Nature Medicine</i> , 2019, 25, 1653-1654.	15.2	6
27	Vasodilator Therapy in Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2288.	3.8	4
28	Dapagliflozin and DAPA-HF: from glycaemic control to heart failure therapy. <i>Practical Diabetes</i> , 2019, 36, 192-193.	0.1	2
29	<p>Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2549-2557.	1.1	6
30	Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes. <i>Clinical Diabetes</i> , 2020, 38, 248-255.	1.2	7
31	Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2020, 44, 93-102.	0.4	35
32	Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2020, 44, 61-67.	0.4	13
33	Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life. <i>JAMA Cardiology</i> , 2020, 5, 184.	3.0	18
34	Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 194-196.	1.4	10
35	Challenging 2019 ESC guidelines for the management of type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 181-185.	1.4	16
36	CRENENCE: A silver lining in the dark cloud of diabetic nephropathy. <i>Journal of Diabetes Investigation</i> , 2020, 11, 527-529.	1.1	2
37	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
38	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2020, 141, 704-707.	1.6	225
39	Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. <i>Journal of Diabetes</i> , 2020, 12, 8-9.	0.8	0
40	Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-HF). <i>European Journal of Heart Failure</i> , 2020, 22, 713-722.	2.9	260
41	Hypertrophic cardiomyopathy: the future of treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 228-240.	2.9	93

#	ARTICLE	IF	CITATIONS
42	The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 883-891.	0.7	30
43	The recurring problem of heart failure hospitalisations. <i>European Journal of Heart Failure</i> , 2020, 22, 249-250.	2.9	5
44	Heart Failure With Mid-range Ejection Fraction. <i>Current Heart Failure Reports</i> , 2020, 17, 1-8.	1.3	24
46	Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. <i>Cardiovascular Diabetology</i> , 2020, 19, 7.	2.7	127
47	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. <i>Cardiovascular Diabetology</i> , 2020, 19, 5.	2.7	29
48	Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. <i>Diabetes Therapy</i> , 2020, 11, 369-386.	1.2	48
49	Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. <i>Cellular Signalling</i> , 2020, 68, 109506.	1.7	68
50	The Heart Failure High Five: Medical Therapy and Policy. <i>JACC: Heart Failure</i> , 2020, 8, 81-82.	1.9	0
51	How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?. <i>JACC: Heart Failure</i> , 2020, 8, 67-69.	1.9	5
52	Heart Failure: A Palliative Medicine Review of Disease, Therapies, and Medications With a Focus on Symptoms, Function, and Quality of Life. <i>Journal of Pain and Symptom Management</i> , 2020, 59, 1127-1146.e1.	0.6	5
53	Predicting Sudden Death in Dilated Cardiomyopathy: The Potential Power of Magnetic Resonance Imaging as a Critical Tool. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1006-1008.	0.8	0
54	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2020, 63, 221-228.	2.9	368
55	Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 97-99.	5.5	3
56	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
57	Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. <i>Circulation</i> , 2020, 141, 112-114.	1.6	11
58	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 101-115.	2.5	13
59	Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk. <i>Diabetes Therapy</i> , 2020, 11, 7-14.	1.2	18
60	SGLT2 inhibitors for primary prevention of cardiovascular events. <i>Journal of Diabetes</i> , 2020, 12, 5-7.	0.8	4

#	ARTICLE	IF	CITATIONS
61	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 336.	3.0	16
62	The year in cardiology: cardiovascular prevention. <i>European Heart Journal</i> , 2020, 41, 1157-1163.	1.0	13
63	The year in cardiology: heart failure. <i>European Heart Journal</i> , 2020, 41, 1232-1248.	1.0	11
64	Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 705-710.	2.2	3
65	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2020, 43, 487-493.	4.3	846
66	Preventing CKD in Developed Countries. <i>Kidney International Reports</i> , 2020, 5, 263-277.	0.4	72
67	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 181-205.	0.8	148
68	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. <i>Metabolism: Clinical and Experimental</i> , 2020, 104, 154045.	1.5	23
69	The DAPA-HF trial marks the beginning of a new era in the treatment of heart failure with reduced ejection fraction. <i>Cardiovascular Research</i> , 2020, 116, e8-e10.	1.8	3
70	Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge. <i>Current Opinion in Cardiology</i> , 2020, 35, 178-186.	0.8	8
71	SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 186.	1.1	71
73	Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?. <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 150-164.	3.1	21
74	Therapies for Advanced Heart Failure Patients Ineligible for Heart Transplantation: Beyond Pharmacotherapy. <i>Canadian Journal of Cardiology</i> , 2020, 36, 234-243.	0.8	6
75	Precision medicine in heart failure no longer a visual theory but a realistic opportunity. <i>European Journal of Internal Medicine</i> , 2020, 71, 20-22.	1.0	0
76	High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment. <i>Atherosclerosis</i> , 2020, 292, 60-69.	0.4	31
77	A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 566-573.	2.2	16
78	Contemporary approach to treating heart failure. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 507-518.	2.3	9
79	SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?. <i>Cardiology</i> , 2020, 145, 311-320.	0.6	19

#	ARTICLE	IF	CITATIONS
80	First Letâ€™s Try â€¦ Will the Success of New Therapies Paradoxically Challenge Outcomes in Advanced Heart Failure?. <i>Circulation: Heart Failure</i> , 2020, 13, e006610.	1.6	1
81	High Blood Pressure and Cardiovascular Disease. <i>Hypertension</i> , 2020, 75, 285-292.	1.3	728
82	Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologistâ€™s Perspective: Lessons Learned from Cardiovascular Outcome Trials. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 155.	1.2	4
83	Efficacy of Ertugliflozin on Heart Failureâ€‘Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 142, 2205-2215.	1.6	156
84	Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. <i>Cardiovascular Diabetology</i> , 2020, 19, 160.	2.7	20
85	Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 159.	2.7	28
86	Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation. <i>JACC: Heart Failure</i> , 2020, 8, 973-983.	1.9	28
87	Vericiguat in Heart Failure with Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 383, 1496-1498.	13.9	7
88	Secondary Mitral Regurgitation. <i>New England Journal of Medicine</i> , 2020, 383, 1458-1467.	13.9	35
89	Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095362.	0.9	6
90	Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research. <i>Frontiers in Pharmacology</i> , 2020, 11, 561494.	1.6	21
92	Secondary prevention after CABG: do new agents change the paradigm?. <i>Current Opinion in Cardiology</i> , 2020, 35, 664-672.	0.8	5
93	Adverse events beyond 1 year after percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2020, 35, 687-696.	0.8	4
94	Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1067-1076.	1.3	40
95	The heart of the matter at molecular level. <i>American Journal of Emergency Medicine</i> , 2020, 46, 710-711.	0.7	0
96	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€‘HF</scp> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
97	Heart Failure Trial Updateâ€‘Analysis of Recent Data. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2792-2800.	0.6	5
98	Naxos disease â€‘ a narrative review. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 801-808.	0.6	6

#	ARTICLE	IF	CITATIONS
99	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e265-e286.	1.6	107
100	Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1795-1807.	1.2	71
101	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	2.6	692
102	Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. <i>Cardiovascular Research</i> , 2020, 116, e152-e155.	1.8	8
103	Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2020, 19, 154.	2.7	21
104	Pulmonary hypertension associated with left-sided heart failure. <i>Current Opinion in Cardiology</i> , 2020, 35, 610-619.	0.8	13
105	Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial. <i>ESC Heart Failure</i> , 2020, 7, 4478-4487.	1.4	15
106	Long-term effects of empagliflozin on excitation-contraction-coupling in human induced pluripotent stem cell cardiomyocytes. <i>Journal of Molecular Medicine</i> , 2020, 98, 1689-1700.	1.7	10
107	A manifesto of collaborative longitudinal cardiovascular care in heart failure. <i>Heart Failure Reviews</i> , 2020, 25, 1089-1097.	1.7	2
108	Cardiology on the cutting edge: updates from the European Society of Cardiology (ESC) Congress 2020. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 448.	0.7	5
109	Sodium-Glucose Co-Transporter 2 Inhibitors Correct Metabolic Maladaptation of Proximal Tubular Epithelial Cells in High-Glucose Conditions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7676.	1.8	21
110	Predictive Accuracy of Heart Failure-Specific Risk Equations in an Electronic Health Record-Based Cohort. <i>Circulation: Heart Failure</i> , 2020, 13, e007462.	1.6	17
111	Addressing Comorbidities in Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 441-456.	1.0	13
112	SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 728-733.	1.4	68
113	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 137, 130-132.	0.7	2
115	Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. <i>Heart Failure Clinics</i> , 2020, 16, 433-440.	1.0	4
116	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. <i>Current Diabetes Reports</i> , 2020, 20, 63.	1.7	4
117	Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1083-1094.	1.3	44

#	ARTICLE	IF	CITATIONS
118	Clinical Implications of the Genetic Architecture of Dilated Cardiomyopathy. <i>Current Cardiology Reports</i> , 2020, 22, 170.	1.3	7
120	Indispensable but deceptive evidence-based medicine. <i>Diabetes and Metabolism</i> , 2020, 46, 415-422.	1.4	3
121	Polypharmacy in Older Adults Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006977.	1.6	102
122	More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD. <i>Kidney International</i> , 2020, 98, 1387-1389.	2.6	6
123	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , 2020, 7, 3401-3407.	1.4	14
124	Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3910-3918.	1.4	17
125	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020, 22, 2175-2186.	2.9	23
126	Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. <i>Current Atherosclerosis Reports</i> , 2020, 22, 72.	2.0	14
127	Ketone metabolism in the failing heart. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158813.	1.2	50
128	Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke. <i>Clinical Therapeutics</i> , 2020, 42, e242-e249.	1.1	30
129	SGLT-2 inhibitors as cardioprotective agents in COVID-19. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 875-876.	0.8	8
130	Effects of antidiabetic drugs that cause glucose excretion directly from the body on mortality. <i>Medicine in Drug Discovery</i> , 2020, 8, 100062.	2.3	1
132	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	13.9	2,523
133	SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution. <i>American Journal of Hypertension</i> , 2020, 33, 1071-1074.	1.0	5
134	COVID-19 and the Heart and Vasculature. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2045-2053.	1.1	25
135	Reply to Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 335.	1.8	1
136	SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. <i>Nature Reviews Cardiology</i> , 2020, 17, 761-772.	6.1	372
137	Recognizing the Significance of Outpatient Worsening Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e017485.	1.6	7



#	ARTICLE	IF	CITATIONS
138	Diabetes and Novel Coronavirus Infection: Implications for Treatment. <i>Diabetes Therapy</i> , 2020, 11, 1915-1924.	1.2	6
139	A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i). <i>Cardiology and Therapy</i> , 2020, 9, 219-225.	1.1	6
140	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	0.8	35
141	Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 660-670.	0.7	21
142	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
143	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1926-1936.	1.1	7
145	Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance. <i>Current Opinion in Pharmacology</i> , 2020, 54, 11-17.	1.7	12
146	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. <i>American Heart Journal</i> , 2020, 228, 47-56.	1.2	61
147	Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics. <i>ESC Heart Failure</i> , 2020, 7, 2340-2353.	1.4	10
149	Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2740-2751.	1.2	57
150	Understanding the Mechanistic Benefit of Heart Failure Drugs Matters. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2752-2754.	1.2	7
151	Sodium-glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes?. <i>European Heart Journal Supplements</i> , 2020, 22, L66-L71.	0.0	1
152	Effects of Canagliflozin in Patients with Baseline eGFR $\leq$ 30 ml/min per 1.73 m <sup>2</sup> . <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
153	When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?. <i>JACC: Heart Failure</i> , 2020, 8, 1056.	1.9	0
154	In heart failure, adding empagliflozin to medical therapy reduced a composite of CV death or HF hospitalization. <i>Annals of Internal Medicine</i> , 2020, 173, JC51.	2.0	0
155	Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. <i>Molecular Metabolism</i> , 2021, 50, 101122.	3.0	135
156	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , 2020, 8, 961-972.	1.9	15
157	Contemporary Management of Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2020, 43, 2895-2903.	4.3	20

#	ARTICLE	IF	CITATIONS
158	Myocardial glucotoxicity: Mechanisms and potential therapeutic targets. Archives of Cardiovascular Diseases, 2020, 113, 736-748.	0.7	16
159	When Making Your Bed Feels Like Running a Marathon. Circulation: Heart Failure, 2020, 13, e007993.	1.6	1
160	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology, 2020, 19, 196.	2.7	52
161	Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes. Journal of Clinical Medicine, 2020, 9, 3779.	1.0	1
162	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. Cardiovascular Research, 2021, 117, 1992-1994.	1.8	5
163	Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. European Journal of Preventive Cardiology, 2020, 27, 35-45.	0.8	34
164	Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad. Current Diabetes Reports, 2020, 20, 74.	1.7	20
166	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398.	2.9	19
167	Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?. Current Diabetes Reports, 2020, 20, 75.	1.7	11
168	Metformin: still the sweet spot for CV protection in diabetes?. Current Opinion in Pharmacology, 2020, 54, 202-208.	1.7	11
169	Annals for Hospitalists Inpatient Notes - Novel and Advanced Therapies for Heart Failure—What a Hospitalist Needs to Know. Annals of Internal Medicine, 2020, 173, HO2-HO3.	2.0	0
170	The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. Frontiers in Endocrinology, 2020, 11, 599355.	1.5	12
171	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in <scp>DECLARE-TIMI</scp> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	2.9	35
172	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	2.9	93
173	How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. Kidney and Blood Pressure Research, 2020, 45, 823-836.	0.9	1
174	Heart failure in the last year: progress and perspective. ESC Heart Failure, 2020, 7, 3505-3530.	1.4	52
175	Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction. Frontiers in Cardiovascular Medicine, 2020, 7, 602251.	1.1	11
176	Improving Care for Heart Failure With Reduced Ejection Fraction—A Potential Polypill-Based Strategy. JAMA - Journal of the American Medical Association, 2020, 324, 2259.	3.8	18

#	ARTICLE	IF	CITATIONS
177	The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e008030.	1.6	8
178	Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier. <i>Journal of the American Heart Association</i> , 2020, 9, e018641.	1.6	16
179	Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study. <i>Cardiovascular Diabetology</i> , 2020, 19, 189.	2.7	16
180	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 173, 278-286.	2.0	182
181	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
182	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 949-959.	5.5	41
183	Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury. <i>Pharmaceuticals</i> , 2020, 13, 379.	1.7	54
184	Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on "Dapagliflozin in Patients with Chronic Kidney Disease". <i>European Heart Journal</i> , 2020, 41, 4231-4232.	1.0	1
185	Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development. <i>Journal of the American Heart Association</i> , 2020, 9, e018889.	1.6	39
186	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1117-1145.	1.2	276
187	The Weight of Evidence for Diuretics and Parachutes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 680-683.	1.2	4
188	Kidney Disease Biomarkers Improve Heart Failure Risk Prediction in the General Population. <i>Circulation: Heart Failure</i> , 2020, 13, e006904.	1.6	22
189	Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2020, 134, 149-152.	0.7	4
190	Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 767-777.	1.2	61
191	Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus process. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1727-1738.	0.5	3
192	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. <i>Cardiology in Review</i> , 2020, 28, 219-235.	0.6	6
193	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 76-91.	1.3	8
194	Cardiac Regeneration After Myocardial Infarction: an Approachable Goal. <i>Current Cardiology Reports</i> , 2020, 22, 122.	1.3	28

#	ARTICLE	IF	CITATIONS
195	Sodium glucose cotransporter 2 inhibitors for all HFrEF patients: can we afford it? A cost-effectiveness analysis of dapagliflozin. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 973-974.	0.8	1
196	Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. <i>Diabetes Therapy</i> , 2020, 11, 1925-1934.	1.2	15
197	The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 21-27.	1.3	18
198	Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2275.	1.0	8
199	The Journal of Cardiopulmonary Rehabilitation and Prevention at 40 yr and Its Role in Promoting Preventive Cardiology: Part 2. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2020, 40, 209-214.	1.2	11
200	Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412094567.	0.9	3
201	Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2020, 14, 175394472093938.	1.0	11
202	Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus. <i>Clinical Drug Investigation</i> , 2020, 40, 991-1000.	1.1	3
203	Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE. <i>Journal of Nephrology</i> , 2020, 33, 977-983.	0.9	2
204	Empowering People Living with Heart Failure. <i>Heart Failure Clinics</i> , 2020, 16, 409-420.	1.0	4
205	Dilemmas in diagnosing and managing of type 2 diabetes. <i>Independent Nurse</i> , 2020, 2020, 18-20.	0.0	0
206	Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 488.	3.8	391
207	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 2147-2156.	2.9	91
208	Sodium-glucose cotransporter 2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51,713 individuals. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2348-2355.	2.2	33
209	Assessing the cost-effectiveness of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2364-2374.	2.2	33
210	Comment on article by Abe <i>et al</i> .. <i>Geriatrics and Gerontology International</i> , 2020, 20, 797-798.	0.7	0
211	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2125-2135.	0.9	18
213	Defragmenting Heart Failure Care. <i>Heart Failure Clinics</i> , 2020, 16, 467-477.	1.0	6

#	ARTICLE	IF	CITATIONS
214	Randomized Trials Versus Common Sense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
215	Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure. ESC Heart Failure, 2020, 7, 3320-3328.	1.4	2
216	Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care. Netherlands Heart Journal, 2020, 28, 31-38.	0.3	5
217	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. Current Opinion in Cardiology, 2020, 35, 517-523.	0.8	2
218	Quadruple Therapy Is the New Standard of Care for HFREF. JACC: Heart Failure, 2020, 8, 819-821.	1.9	13
219	Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Current Opinion in Cardiology, 2020, 35, 589-601.	0.8	3
220	Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. Journal of Hypertension, 2020, 38, 1811-1819.	0.3	17
221	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. Journal of Hypertension, 2020, 38, 1829-1840.	0.3	15
222	Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	1.8	6
223	Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. Journal of Biological Chemistry, 2020, 295, 14379-14390.	1.6	54
224	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	2.9	101
225	Importance de l'évaluation du risque cardiovasculaire pour une personnalisation des nouveaux traitements anti-hyperglycémiants en prévention cardiovasculaire. Medecine Des Maladies Metaboliques, 2020, 14, 461-471.	0.1	0
226	Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Services Research, 2020, 20, 964.	0.9	42
227	Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 185.	2.7	83
228	Inhibidores de la SGLT2. ¿Cuál es el lugar en terapéutica?. FMC Formacion Medica Continuada En Atencion Primaria, 2020, 27, 419-427.	0.0	0
229	Management of chronic heart failure. Clinics in Integrated Care, 2020, 2, 100016.	0.3	0
230	Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide. Journal of the American College of Cardiology, 2020, 76, 2076-2085.	1.2	50
231	Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care. Journal of the American College of Cardiology, 2020, 76, 2086-2088.	1.2	3

#	ARTICLE	IF	CITATIONS
233	Ketone bodies for the starving heart. <i>Nature Metabolism</i> , 2020, 2, 1183-1185.	5.1	23
234	Use of SGLT2 inhibitors during Ramadan: An expert panel statement. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108465.	1.1	16
235	Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. <i>ESC Heart Failure</i> , 2020, 7, 3582-3592.	1.4	31
236	Practical Considerations and Opportunities for SGLT2 Inhibitor Prescription in Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	2
237	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. <i>Annals of Medicine</i> , 2021, 53, 2072-2089.	1.5	27
238	Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7833.	1.8	46
239	<p>&lt;p>SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients&lt;/p>&lt;/p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2020, Volume 13, 281-296.	0.8	16
240	Editorial: Medicinal Plants for Cardiovascular and Neurodegenerative Aging-Related Diseases: From Bench to Bedside. <i>Frontiers in Pharmacology</i> , 2020, 11, 585155.	1.6	1
241	Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease. <i>Drug Safety</i> , 2020, 43, 1211-1221.	1.4	24
243	Sex-specific differences in access and response to medical and device therapies in heart failure: State of the art. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 640-648.	1.6	5
244	Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter 2 Inhibitors. <i>Pharmacotherapy</i> , 2020, 40, 1002-1011.	1.2	2
245	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 2108-2124.	1.8	108
246	Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001279.	1.2	41
247	Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care. <i>Cardiovascular Diabetology</i> , 2020, 19, 132.	2.7	2
248	Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 59-67.	1.3	0
249	A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy. <i>Current Hypertension Reports</i> , 2020, 22, 85.	1.5	13
250	Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective?. <i>Journal of Diabetes</i> , 2020, 12, 942-945.	0.8	10
251	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020, 43, 2878-2881.	4.3	20

#	ARTICLE	IF	CITATIONS
252	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
253	Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. <i>Diabetes Care</i> , 2020, 43, 2614-2623.	4.3	9
254	Victims of Success in Failure. <i>Circulation</i> , 2020, 142, 1129-1131.	1.6	12
255	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. <i>EMBO Molecular Medicine</i> , 2020, 12, e10865.	3.3	104
256	Ertugliflozin and VERTISâ€œCV : will the wheels come off the SGLT2 inhibitor bandwagon?. <i>Practical Diabetes</i> , 2020, 37, 112.	0.1	0
257	Renal function dynamics following coâ€œadministration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 3792-3800.	1.4	11
258	The Upcoming Epidemic of Heart Failure in South Asia. <i>Circulation: Heart Failure</i> , 2020, 13, e007218.	1.6	37
259	Two Tales: One Story. <i>Circulation</i> , 2020, 142, 2201-2204.	1.6	18
260	Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS). <i>ESC Heart Failure</i> , 2020, 7, 4448-4457.	1.4	9
261	Empagliflozin inhibits Na <sup>+</sup> /H <sup>+</sup> exchanger activity in human atrial cardiomyocytes. <i>ESC Heart Failure</i> , 2020, 7, 4429-4437.	1.4	67
262	<scp>EMPEROR</scp>â€œReduced: confirming sodiumâ€œglucose coâ€œtransporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1987-1990.	2.9	7
263	Ten lessons from the <scp>EMPERORâ€œReduced</scp> trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1991-1993.	2.9	6
264	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.	1.6	63
265	Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. <i>Hypertension</i> , 2020, 76, 1045-1054.	1.3	67
266	Association of treatments for acute myocardial infarction and survival for seven common comorbidity states: a nationwide cohort study. <i>BMC Medicine</i> , 2020, 18, 231.	2.3	10
267	Effects of neurohormonal antagonists on blood pressure in patients with heart failure with reduced ejection fraction (HFrEF): a systematic review protocol. <i>Systematic Reviews</i> , 2020, 9, 194.	2.5	0
268	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	2
269	Home Therapies in Advanced Heart Failure: Inotropes and Diuretics. <i>Current Heart Failure Reports</i> , 2020, 17, 314-323.	1.3	5

#	ARTICLE	IF	CITATIONS
270	Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. <i>Nature Communications</i> , 2020, 11, 4222.	5.8	61
271	Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. <i>Scientific Reports</i> , 2020, 10, 13553.	1.6	21
273	Cardiometabolic medicine – the US perspective on a new subspecialty. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 70-80.	0.5	12
274	<p>Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 715-726.	0.9	10
275	Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2020, 16, 556-577.	4.3	169
276	More Evidence for SGLT2 Inhibitors in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1481-1482.	13.9	14
277	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1413-1424.	13.9	2,821
278	Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. <i>Diabetes Therapy</i> , 2020, 11, 2207-2219.	1.2	41
279	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure. <i>Circulation</i> , 2020, 142, 1713-1724.	1.6	144
280	<scp>DAPA–HF</scp>: does dapagliflozin provide –bang for your buck™ as a treatment for <scp>heart failure with reduced ejection fraction</scp>?. <i>European Journal of Heart Failure</i> , 2020, 22, 2157-2159.	2.9	1
281	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , 2020, 396, 819-829.	6.3	816
282	Current Insights Into Secondary Mitral Regurgitation–Workup and Management. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	0
283	Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure. <i>Circulation</i> , 2020, 142, 1055-1058.	1.6	9
284	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. <i>Canadian Journal of Diabetes</i> , 2020, 44, 575-591.	0.4	98
285	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update – The User’s Guide. <i>Canadian Journal of Diabetes</i> , 2020, 44, 592-596.	0.4	12
286	Non–insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	1.4	13
287	Advances and New Insights in Post-Transplant Care: From Sequencing to Imaging. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	1
288	Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. <i>European Heart Journal</i> , 2020, 41, 3398-3401.	1.0	20



#	ARTICLE	IF	CITATIONS
289	In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes. <i>Pharmaceutics</i> , 2020, 12, 865.	2.0	16
290	Gender Differences in Health-Related Quality of Life in Patients with Systolic Heart Failure: Results of the VIDA Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2825.	1.0	16
291	Diversity and Inclusion. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1494-1497.	1.2	11
293	Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances. <i>Current Cardiology Reports</i> , 2020, 22, 143.	1.3	9
294	The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. <i>European Heart Journal</i> , 2020, 41, 3419-3420.	1.0	6
295	Repurposing Antidiabetic Drugs for Cardiovascular Disease. <i>Frontiers in Physiology</i> , 2020, 11, 568632.	1.3	25
296	Diabetes prevalence and outcomes in hospitalized cardiorenal-syndrome patients with and without hyponatremia. <i>BMC Nephrology</i> , 2020, 21, 393.	0.8	2
297	Glucose transporters in cardiovascular system in health and disease. <i>Pflugers Archiv European Journal of Physiology</i> , 2020, 472, 1385-1399.	1.3	35
298	Novel therapeutic agents for the treatment of diabetic kidney disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1277-1293.	1.9	11
299	Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis. <i>PLoS Computational Biology</i> , 2020, 16, e1008074.	1.5	11
300	Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?. <i>Frontiers in Endocrinology</i> , 2020, 11, 289.	1.5	28
301	Sodium-Glucose Cotransporter-2 Inhibitors at Discharge from Cardiology Hospitalization Department: Decoding A New Clinical Scenario. <i>Journal of Clinical Medicine</i> , 2020, 9, 2600.	1.0	4
302	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
303	Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e015103.	1.6	37
304	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	1.0	90
305	Prescribing Paradigm Shift? Damned If You Do, Damned If You Donâ€™t. <i>Diabetes Care</i> , 2020, 43, 1991-1993.	4.3	0
306	Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature. <i>Internal Medicine Journal</i> , 2022, 52, 841-847.	0.5	5
307	Heart failure documentation in outpatients with diabetes and volume overload: an observational cohort study from the Diabetes Collaborative Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 212.	2.7	3

#	ARTICLE	IF	CITATIONS
308	The New Kids on the Block: Don't Delay. <i>Journal of Cardiac Failure</i> , 2020, 26, 811-812.	0.7	0
309	Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin. <i>Renal Replacement Therapy</i> , 2020, 6, .	0.3	4
310	The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 603247.	1.3	11
311	Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF. <i>Clinical Research in Cardiology</i> , 2021, 110, 1221-1233.	1.5	5
312	Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOISTâ€WHF in perspective. <i>ESC Heart Failure</i> , 2020, 7, 3261-3267.	1.4	16
313	Sudden Cardiac Death in Hereditary Dilated Cardiomyopathy. , 2020, , .		0
314	Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction. <i>CJC Open</i> , 2020, 2, 447-453.	0.7	11
315	168 Social Stress Can Break Your Heart. <i>Heart Lung and Circulation</i> , 2020, 29, S111.	0.2	0
316	169 Sodium-glucose Co-transporter-2 (SGLT2) Inhibitor Usage in Heart Failure Patients With Type Two Diabetes. <i>Heart Lung and Circulation</i> , 2020, 29, S111.	0.2	0
317	170 Subcellular Distribution of Epac 2 in Relation to Key Excitation-Contraction Coupling Proteins in Human Atrial Tissue. <i>Heart Lung and Circulation</i> , 2020, 29, S111-S112.	0.2	0
318	605 Euglycaemic Diabetic Ketoacidosis Complicating Cardiac Surgery. <i>Heart Lung and Circulation</i> , 2020, 29, S310.	0.2	0
319	Reply. <i>JACC: Heart Failure</i> , 2020, 8, 1055-1056.	1.9	1
320	Heart failure units: State of the art in disease management. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 341-350.	0.2	1
321	Cardioprotective effects of short-term empagliflozin treatment in db/db mice. <i>Scientific Reports</i> , 2020, 10, 19686.	1.6	13
322	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108488.	1.1	4
323	VERTIS-CV. <i>Circulation</i> , 2020, 142, 2216-2218.	1.6	4
324	Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097483.	1.1	11
325	Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. <i>Frontiers in Pharmacology</i> , 2020, 11, 582680.	1.6	146

#	ARTICLE	IF	CITATIONS
326	Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification. <i>Frontiers in Endocrinology</i> , 2020, 11, 570628.	1.5	65
327	TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity. <i>Biology</i> , 2020, 9, 369.	1.3	25
329	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007879.	1.6	14
330	&lt;p&gt;SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 4775-4788.	2.0	32
331	Should CMR be the default imaging modality in clinical trials for heart failure?. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 554-558.	0.7	4
333	Insuficiencia cardiaca y medicina basada en la evidencia: no todo estÃ¡ en las guÃ­as. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 802-803.	0.6	6
334	The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. <i>Cardiovascular Diabetology</i> , 2020, 19, 188.	2.7	39
335	The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now. <i>Clinical Cardiology</i> , 2020, 43, 1376-1387.	0.7	22
336	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proofâ€ofâ€concept study. <i>ESC Heart Failure</i> , 2020, 7, 4267-4276.	1.4	3
337	Overview of Atypical Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 695-723.	1.2	8
338	DAPA-HF study: Are the benefits uniform across non-diabetic subgroups. <i>Indian Heart Journal</i> , 2020, 72, 469-470.	0.2	0
339	Risk Framing in Cardiovascular Medicine I. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2568-2569.	1.4	0
340	Diabetic cardiomyopathy. <i>Revista Cl&amp;#x00ed;nica Espan&amp;#x00f5;la</i> , 2022, 222, 100-111.	0.3	11
342	PronÃ³stico actual de la insuficiencia cardiaca en EspaÃ±a y Europa. Una llamada de atenciÃ³n. <i>REC: CardioClinics</i> , 2020, 55, 201-203.	0.1	0
343	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodiumâ€Glucose Transporter 2 Inhibitors. <i>Diabetes Care</i> , 2020, 43, 1530-1536.	4.3	16
344	<scp>VICTORIA</scp> in context. <i>European Journal of Heart Failure</i> , 2020, 22, 1747-1751.	2.9	2
345	Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2020, 37, 2620-2645.	1.3	5
346	Effects of sodium glucose co-transporter 2 inhibitors on genital infections in female patients with type 2 diabetes mellitusâ€ Real world data analysis. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107587.	1.2	4

#	ARTICLE	IF	CITATIONS
347	Reduced Diuretic Dose in Patients Treated With Eplerenone. <i>Circulation: Heart Failure</i> , 2020, 13, e006597.	1.6	11
348	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3335.	1.7	27
349	Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus. <i>Advances in Therapy</i> , 2020, 37, 3463-3484.	1.3	24
350	Empagliflozin prevents doxorubicin-induced myocardial dysfunction. <i>Cardiovascular Diabetology</i> , 2020, 19, 66.	2.7	61
351	The unbearable underreporting of comorbidities in heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 1043-1044.	2.9	5
352	β-Blocker Doses and Heart Rate in Patients with Heart Failure: Results from the National Norwegian Heart Failure Registry. <i>Biomedicine Hub</i> , 2020, 5, 1-10.	0.4	4
353	Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry. <i>Netherlands Heart Journal</i> , 2020, 28, 334-344.	0.3	11
354	Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1759-1767.	2.9	41
355	Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. <i>Gut</i> , 2020, 69, 1877-1884.	6.1	127
356	Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure. <i>Circulation: Heart Failure</i> , 2020, 13, e006667.	1.6	16
357	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1607-1618.	2.2	118
358	Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001248.	1.2	65
359	Reappraisal on pharmacological and mechanical treatments of heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 55.	2.7	27
360	Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations. <i>ESC Heart Failure</i> , 2020, 7, 1477-1487.	1.4	6
362	Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism. <i>Annals of Medicine</i> , 2020, 52, 178-190.	1.5	1
363	Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. <i>Endocrine</i> , 2020, 69, 688-691.	1.1	6
364	Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. <i>ESC Heart Failure</i> , 2020, 7, 1966-1971.	1.4	19
365	Obesity-Related Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2020, 16, 357-368.	1.0	37

#	ARTICLE	IF	CITATIONS
366	Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. <i>Circulation</i> , 2020, 141, 1800-1812.	1.6	116
367	Abnormalities of Skeletal Muscle, Adipocyte Tissue, and Lipid Metabolism in Heart Failure: Practical Therapeutic Targets. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 79.	1.1	22
368	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 88.	1.1	82
369	Refocusing on the Primary Prevention of Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	7
370	Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2020, 33, 165-174.	0.4	12
371	Proposal for New Classification and Practical Use of Diuretics According to Their Effects on the Serum Chloride Concentration: Rationale Based on the "Chloride Theory". <i>Cardiology and Therapy</i> , 2020, 9, 227-244.	1.1	3
372	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 394-404.	1.4	16
373	Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. <i>Cardiovascular Diabetology</i> , 2020, 19, 62.	2.7	67
374	SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 14.	1.0	56
375	The real world of <i>de novo</i> heart failure: the next frontier for heart failure clinical trials?. <i>European Journal of Heart Failure</i> , 2020, 22, 1786-1789.	2.9	7
376	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 570-584.	1.6	53
377	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. <i>Nature Reviews Cardiology</i> , 2020, 17, 641-655.	6.1	143
378	Empagliflozin in Heart Failure. <i>Circulation</i> , 2020, 142, 1028-1039.	1.6	252
379	Organ System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 64.	1.1	39
380	Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 948.	3.0	77
381	Therapeutic approaches to diabetic cardiomyopathy: Targeting the antioxidant pathway. <i>Prostaglandins and Other Lipid Mediators</i> , 2020, 150, 106454.	1.0	10
382	SGLT2 Inhibitors in Liver Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2168-2172.e2.	2.4	19
383	Should the cardio-protective properties of sodium-glucose cotransporter 2 inhibitors dictate therapeutic decision-making in patients with type 2 diabetes. <i>Internal Medicine Journal</i> , 2020, 50, 645-646.	0.5	1

#	ARTICLE	IF	CITATIONS
384	Single-Cell Transcriptomics. <i>Circulation</i> , 2020, 141, 1720-1723.	1.6	6
385	Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2020, 19, 69.	2.7	36
386	The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDESCENCE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1753-1766.	2.2	31
387	Basic Mechanisms of Diabetic Heart Disease. <i>Circulation Research</i> , 2020, 126, 1501-1525.	2.0	279
388	Review of the veteran affairs diabetes trial: Lessons learned. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 537-546.	2.6	0
389	Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 673-682.	1.0	8
390	The Probability of A1C Goal Attainment in Patients With Uncontrolled Type 2 Diabetes in a Large Integrated Delivery System: A Prediction Model. <i>Diabetes Care</i> , 2020, 43, 1910-1919.	4.3	30
391	Mechanisms of Sodiumâ€“Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics. <i>Diabetes Care</i> , 2020, 43, 2183-2189.	4.3	35
392	Sodiumâ€“glucose coâ€“transporter 2 inhibitors: â€“a tale of two sistersâ€™, diabetes and heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1259-1262.	2.9	2
393	Efficacy and safety of sodiumâ€“glucose coâ€“transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€“HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1247-1258.	2.9	29
394	The time has finally come to prioritize drug initiation before dose titration for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1483-1485.	2.9	3
395	Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 582-593.	5.5	155
396	New pharmacotherapy for heart failure with reduced ejection fraction. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 405-414.	0.6	4
397	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	1.3	11
398	The role of diabetes in cardiomyopathies of different etiologiesâ€”Characteristics and 1-year follow-up results of the EVITA-HF registry. <i>PLoS ONE</i> , 2020, 15, e0234260.	1.1	2
399	Consenso de expertos sobre la insuficiencia cardiaca con fracciÃ³n de eyecciÃ³n reducida: mÃ¡s allÃ¡ de las guÃ­as. <i>Revista Espanola De Cardiologia Suplementos</i> , 2020, 20, 1-46.	0.2	2
400	Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors. <i>JACC Basic To Translational Science</i> , 2020, 5, 632-644.	1.9	419
401	Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 95.	2.7	16

#	ARTICLE	IF	CITATIONS
402	Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2494-2507.	1.4	43
403	Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 219-234.	1.7	2
404	Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2020, 12, 45.	1.2	10
405	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	1.8	22
406	Left Ventricular Volume Reduction and Reshaping as a Treatment Option for Heart Failure. <i>Structural Heart</i> , 2020, 4, 264-283.	0.2	10
407	Advances in the Management of Acute Decompensated Heart Failure. <i>Medical Clinics of North America</i> , 2020, 104, 601-614.	1.1	7
408	SGLT inhibitors for type 1 diabetes: a finely balanced matter?. <i>Independent Nurse</i> , 2020, 2020, 14-17.	0.0	0
409	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	3.0	59
410	A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 36-41.	0.5	0
411	A registry-based algorithm to predict ejection fraction in patients with heart failure. <i>ESC Heart Failure</i> , 2020, 7, 2388-2397.	1.4	13
412	Recent advances in the management of secondary hypertension: chronic kidney disease. <i>Hypertension Research</i> , 2020, 43, 869-875.	1.5	9
413	Reply. <i>JACC: Heart Failure</i> , 2020, 8, 247-248.	1.9	2
414	The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 73.	2.7	58
415	Cardiometabolic Medicine: Development of a New Subspecialty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2095-2104.	1.8	15
417	The year in cardiology: heart failure. The year in cardiology 2019.. <i>SA Heart Journal</i> , 2020, 17, .	0.0	0
418	Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1678-1688.	2.2	34
419	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease's ABC Approach. <i>American Journal of Preventive Cardiology</i> , 2020, 2, 100027.	1.3	6
420	Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016173.	1.6	57

#	ARTICLE	IF	CITATIONS
421	Clinical Cardiovascular Applications of Hyperpolarized Magnetic Resonance. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 231-240.	1.3	13
422	Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes. <i>Future Cardiology</i> , 2020, 16, 77-88.	0.5	6
423	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1907.	1.8	42
424	Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empagliflozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 311-321.	1.3	10
425	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108112.	1.1	21
426	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	1.9	14
427	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 357-360.	5.5	14
428	Age and Heart Failure Trials - Lessons from DAPA-HF. <i>Journal of Cardiac Failure</i> , 2020, 26, 191-192.	0.7	1
429	Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. <i>Hypertension</i> , 2020, 75, 894-901.	1.3	91
430	Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodium-glucose cotransporter-2 inhibitors?. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 343.	0.6	3
431	Glucose transporters in the kidney in health and disease. <i>Pflügers Archiv European Journal of Physiology</i> , 2020, 472, 1345-1370.	1.3	69
432	Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. <i>Cardiology and Therapy</i> , 2020, 9, 1-4.	1.1	3
433	Which Drug Will Lead in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1142-1144.	1.2	0
434	The tubular hypothesis of nephron filtration and diabetic kidney disease. <i>Nature Reviews Nephrology</i> , 2020, 16, 317-336.	4.1	224
435	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Future Cardiology</i> , 2020, 16, 227-236.	0.5	16
436	SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165770.	1.8	62
437	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 644-646.	1.2	18
438	Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2020, 59, 981-994.	1.6	13



#	ARTICLE	IF	CITATIONS
439	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154218.	1.5	10
440	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	3.8	340
441	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
442	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	1.0	151
443	Comparing the Benefit of Novel Therapies Across Clinical Trials. <i>Circulation</i> , 2020, 142, 717-719.	1.6	46
444	Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure. <i>Cardiology</i> , 2020, 145, 321-323.	0.6	1
445	Evaluation and management of heart failure with preserved ejection fraction. <i>Nature Reviews Cardiology</i> , 2020, 17, 559-573.	6.1	339
446	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1243-1262.	2.2	13
447	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. <i>Diabetes Care</i> , 2020, 43, 1356-1359.	4.3	102
449	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020, 51, 276-288.	1.4	9
450	Can the cardiovascular risk reductions observed with empagliflozin in the EMPAâ€œREG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1151-1156.	2.2	8
451	Dapagliflozin-Induced Acute Pancreatitis: A Case Report and Review of Literature. <i>Case Reports in Endocrinology</i> , 2020, 2020, 1-4.	0.2	13
452	Monocytes and Macrophages as Protagonists in Vascular Complications of Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 10.	1.1	45
453	Acute heart failure. <i>Nature Reviews Disease Primers</i> , 2020, 6, 16.	18.1	237
454	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 972-973.	13.9	32
455	Sodiumâ€œglucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. <i>Medical Journal of Australia</i> , 2020, 212, 294.	0.8	3
456	Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. <i>Diabetes Therapy</i> , 2020, 11, 813-833.	1.2	10
457	Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure. <i>Canadian Journal of Cardiology</i> , 2020, 36, 721-731.	0.8	18

#	ARTICLE	IF	CITATIONS
458	SGLT2i: beyond the glucose-lowering effect. <i>Cardiovascular Diabetology</i> , 2020, 19, 98.	2.7	106
459	Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. <i>ESC Heart Failure</i> , 2020, 7, 2071-2073.	1.4	30
460	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2725-2733.	1.4	7
461	Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2752-2761.	1.4	9
462	Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment. <i>Diabetology International</i> , 2020, 11, 252-260.	0.7	4
463	Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 557-558.	5.5	2
464	The cytokine storm of COVID-19: a spotlight on prevention and protection. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 723-730.	1.5	84
465	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 2030.	1.0	28
466	How to slice the pie: heart failure subgroups and their clinical meaning. <i>European Heart Journal</i> , 2020, 41, 2339-2343.	1.0	0
467	A Paradigm Shift in the Treatment of Type 2 Diabetes and Heart Failure. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 727-731.	0.9	4
468	SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients. <i>Kidney Medicine</i> , 2020, 2, 359-364.	1.0	29
469	Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 553-555.	5.5	7
470	Unidades de insuficiência cardíaca: estado da arte na abordagem da insuficiência cardíaca. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 341-350.	0.2	2
471	Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812093570.	0.6	9
472	Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. <i>Cardiovascular Diabetology</i> , 2020, 19, 107.	2.7	18
473	Emerging Targets for Cardiovascular Disease Prevention in Diabetes. <i>Trends in Molecular Medicine</i> , 2020, 26, 744-757.	3.5	15
474	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 587-621.	0.6	7
475	Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria. <i>Journal of Clinical Medicine</i> , 2020, 9, 2089.	1.0	9

#	ARTICLE	IF	CITATIONS
476	Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. <i>Basic Research in Cardiology</i> , 2020, 115, 39.	2.5	77
477	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2020, 8, 811-818.	1.9	87
478	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <i>Kidney International</i> , 2020, 98, 839-848.	2.6	193
479	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , 2020, 7, 100039.	1.4	14
480	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. <i>European Heart Journal</i> , 2020, 41, 3421-3432.	1.0	138
481	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€œLed Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€œGlucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Tj ETQq1 10.7843147gBT /Over	1.3	13
482	Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001451.	1.2	48
484	Sodium-glucose co-transporter-2 inhibitors: peculiar â€œhybridâ€œdiuretics that protect from target organ damage and cardiovascular events. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1622-1632.	1.1	14
485	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. <i>Pharmacological Research</i> , 2020, 160, 105052.	3.1	34
486	Sodiumâ€œglucose coâ€œtransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	2.9	100
487	Heart failure and evidence-based medicine: not everything is in the guidelines. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 802-803.	0.4	0
488	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3075-e3089.	1.8	11
489	Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00129.	1.0	6
490	Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1890-1901.	0.8	24
491	GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 193-212.	0.8	24
492	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. <i>Diabetes Research and Clinical Practice</i> , 2020, 161, 108054.	1.1	10
493	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. <i>European Journal of Internal Medicine</i> , 2020, 74, 125-126.	1.0	1
494	Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1887-1889.	0.8	2

#	ARTICLE	IF	CITATIONS
496	Acute Decompensated Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction. <i>Heart Failure Clinics</i> , 2020, 16, 187-200.	1.0	3
497	Ambulatory levosimendan infusions. Effective and efficient in advanced heart failure?. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 345-347.	0.4	0
498	Survival rates in elderly patients with heart failure: reply. <i>European Journal of Heart Failure</i> , 2020, 22, 566-567.	2.9	0
499	Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. <i>European Journal of Heart Failure</i> , 2020, 22, 739-750.	2.9	17
500	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter 2 inhibitors. <i>Journal of Clinical Hypertension</i> , 2020, 22, 562-571.	1.0	24
501	SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?. <i>Journal of Nephrology</i> , 2020, 33, 985-994.	0.9	13
502	Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1346-1356.	1.1	35
503	Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006623.	1.6	24
504	Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. <i>Cardiovascular Diabetology</i> , 2020, 19, 19.	2.7	90
505	Sodium-glucose co-transporter 2 inhibitors and acute heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 723-725.	2.9	6
506	Sodium glucose cotransporter2 inhibitor-possible treatment for patients with diabetes, pulmonary disease and CO2 retention. <i>Medical Hypotheses</i> , 2020, 139, 109631.	0.8	5
507	Very Late Outcomes After Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 605-607.	1.2	1
508	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. <i>Nature Reviews Cardiology</i> , 2020, 17, 585-607.	6.1	353
509	Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 243-256.	1.0	19
510	Iatrogenic Decompensated Heart Failure. <i>Current Heart Failure Reports</i> , 2020, 17, 21-27.	1.3	9
511	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	2.0	121
512	Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2 inhibitor therapy. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00117.	1.0	9
513	Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?. <i>European Journal of Heart Failure</i> , 2020, 22, 576-577.	2.9	5

#	ARTICLE	IF	CITATIONS
514	Dapagliflozin in patients with heart failure and reduced ejection fraction. Internal and Emergency Medicine, 2020, 15, 515-517.	1.0	8
515	Heart Failure and Comorbiditiesâ€”Part 2. Current Emergency and Hospital Medicine Reports, 2020, 8, 69-75.	0.6	0
518	MiocardioopatÃa diabÃ©tica. Revista Clinica Espanola, 2022, 222, 100-111.	0.2	11
519	Sodiumâ€“glucose linked transporterâ€2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes, Obesity and Metabolism, 2020, 22, 1024-1034.	2.2	6
520	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovascular Diabetology, 2020, 19, 13.	2.7	42
521	Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodiumâ€“glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2020, 22, 618-628.	2.9	76
522	CaMKII and GLUT1 in heart failure and the role of gliflozins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165729.	1.8	14
523	Editorial commentary: Management of heart failure: Are we there yet?. Trends in Cardiovascular Medicine, 2020, 30, 519-520.	2.3	0
524	Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization. Heart Failure Reviews, 2020, 25, 403-408.	1.7	15
525	Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American College of Cardiology, 2020, 75, 422-434.	1.2	302
526	Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Journal of the American College of Cardiology, 2020, 75, 435-447.	1.2	65
527	Liraglutide as addâ€“on to sodiumâ€“glucose coâ€“transporterâ€2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRAâ€“ADD2SGLT2, a 26â€“week, randomized, doubleâ€“blind, placeboâ€“controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 929-937.	2.2	29
528	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation, 2020, 141, 1227-1234.	1.6	241
529	&lt;p&gt;Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence&lt;/p&gt;. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 161-174.	1.1	105
530	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	1.6	62
531	Sodiumâ€“Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Metaâ€“Analysis. Journal of the American Heart Association, 2020, 9, e014908.	1.6	161
532	CARDIOPATÃA EN EL PACIENTE ANCIANO. Revista MÃ©dica ClÃnica Las Condes, 2020, 31, 21-27.	0.2	0
533	Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1772-e1780.	1.8	23

#	ARTICLE	IF	CITATIONS
534	Use of sodium-glucose co-transporter 2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 604-617.	2.9	33
535	Beware Ketoacidosis with SGLT2 Inhibitors in Latent Autoimmune Diabetes of the Adult. <i>American Journal of Medicine</i> , 2020, 133, e422-e424.	0.6	3
536	Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 213-230.	0.8	13
537	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. <i>Journal of the American College of Cardiology</i> , 2020, 75, 539-555.	1.2	58
538	Prevention of cardiac allograft vasculopathy – A new possible indication for SGLT-2 inhibitors?. <i>Medical Hypotheses</i> , 2020, 137, 109594.	0.8	6
539	Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. <i>Cardiovascular Diabetology</i> , 2020, 19, 6.	2.7	65
540	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	0.8	89
541	Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa037.	0.1	18
542	Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. <i>PLoS ONE</i> , 2020, 15, e0232280.	1.1	28
543	Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). <i>ESC Heart Failure</i> , 2020, 7, 1585-1594.	1.4	53
544	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. <i>European Journal of Heart Failure</i> , 2020, 22, 1357-1365.	2.9	66
545	Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. <i>Obesity</i> , 2020, 28, 1068-1074.	1.5	55
546	Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107590.	1.2	24
547	Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 419-436.	1.3	16
548	Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1956-1974.	1.2	48
549	A Novel Cardioprotective Therapy That Also Improves Glycemia. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1349.	3.8	1
550	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. <i>ESC Heart Failure</i> , 2020, 7, 1168-1177.	1.4	14
551	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36

#	ARTICLE	IF	CITATIONS
552	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020, 109, 1079-1098.	1.5	74
555	Diuretic Therapy for Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1178-1195.	1.2	159
556	Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 249-262.	1.6	41
557	The effects of the wenyang huoxue method on coronary heart disease heart failure. <i>Medicine (United Tj ETQq1 1 0,784314 rgBT /Over</i>	0.4	9
558	Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. <i>British Journal of Pharmacology</i> , 2020, 177, 2906-2922.	2.7	46
559	What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 55-68.	2.2	20
560	ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 5-11.	2.2	12
561	Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CRENENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 46-54.	2.2	36
562	When ESKD complicates the management of diabetes mellitus. <i>Seminars in Dialysis</i> , 2020, 33, 209-222.	0.7	3
563	A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets. <i>Diabetes</i> , 2020, 69, 864-866.	0.3	14
564	Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 1110.	1.0	19
565	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
566	Translating the statistical benefits of SGLT-2 inhibitors on cardio-renal outcomes into clinical practice. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 545-551.	1.3	1
567	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2204-2218.	1.2	63
568	Hypoglycaemia and its management in primary care setting. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3332.	1.7	8
569	Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. <i>Clinical Pharmacokinetics</i> , 2020, 59, 949-965.	1.6	32
570	Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. <i>Journal of Cardiology</i> , 2020, 76, 123-131.	0.8	27
571	Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1481-1495.	2.2	17

#	ARTICLE	IF	CITATIONS
572	Heart failure management in dialysis patients: Many treatment options with no clear evidence. <i>Seminars in Dialysis</i> , 2020, 33, 198-208.	0.7	20
573	Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 1235-1237.	1.6	14
574	Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline. <i>Cardiovascular Diabetology</i> , 2020, 19, 38.	2.7	9
576	Anti-inflammatory Therapy in Rheumatoid Arthritis to Improve Cardiovascular Outcome. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1700-1702.	0.8	2
577	Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2192-2203.	1.1	7
578	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. <i>Gut</i> , 2020, 69, 1691-1705.	6.1	369
579	Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. <i>ESC Heart Failure</i> , 2020, 7, 856-864.	1.4	33
580	Age and biomarkers in heart failure: challenging the current model to select patients for clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2089-2092.	2.9	1
581	Health-related quality of life scores: ending the minimum 5-point difference as the clinically meaningful threshold. <i>European Journal of Heart Failure</i> , 2020, 22, 1006-1008.	2.9	4
582	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	1.7	26
583	Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 347.	1.8	1
584	Risk stratification tools for heart failure in the diabetes clinic. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1070-1079.	1.1	7
585	Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 187-199.	0.6	1
586	Second revolution in cardiovascular prevention. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 327-336.	0.6	6
587	Prognosis of patients eligible for dapagliflozin in acute heart failure. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13245.	1.7	3
588	Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2475-2486.	1.8	23
589	Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. <i>Cardiovascular Diabetology</i> , 2020, 19, 46.	2.7	43
590	Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. <i>Cardiovascular Research</i> , 2021, 117, 74-84.	1.8	51



#	ARTICLE	IF	CITATIONS
591	Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress. Antioxidants and Redox Signaling, 2021, 34, 551-571.	2.5	44
592	Improving exercise capacity and quality of life using noninvasive heart failure treatments: evidence from clinical trials. European Journal of Heart Failure, 2021, 23, 92-113.	2.9	67
593	Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G oxidation. Cardiovascular Research, 2021, 117, 495-507.	1.8	167
594	Black Oesophagus acute esophageal necrosis. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 56-57.	0.2	3
595	New-onset heart failure after acute coronary syndrome in patients without heart failure or left ventricular dysfunction. Revista Espanola De Cardiologia (English Ed ), 2021, 74, 494-501.	0.4	4
596	Sodium glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. Journal of Diabetes Investigation, 2021, 12, 6-20.	1.1	17
597	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Primary Care Diabetes, 2021, 15, 31-51.	0.9	27
598	Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease. Annals of Pharmacotherapy, 2021, 55, 252-260.	0.9	1
599	Editorial commentary: Every cardiologist should know diabetes by heart. Trends in Cardiovascular Medicine, 2021, 31, 109-110.	2.3	0
600	Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?. Cardiovascular Research, 2021, 117, 343-345.	1.8	3
601	Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. American Heart Journal, 2021, 232, 116-124.	1.2	46
602	Changing Fields-Diabetes Medications Invading the Cardiovascular Space. Current Problems in Cardiology, 2021, 46, 100736.	1.1	1
603	Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Failure Reviews, 2021, 26, 603-622.	1.7	17
604	Organ protection beyond glycaemic control with SGLT2 inhibitors. Nature Reviews Nephrology, 2021, 17, 223-224.	4.1	4
605	SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?. Expert Opinion on Pharmacotherapy, 2021, 22, 647-650.	0.9	1
606	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology, 2021, 9, 46-52.	5.5	103
607	Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors. Heart Failure Reviews, 2021, 26, 643-652.	1.7	6
608	Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor) Tj ETQq1 1,0,784314,rgBT /Ove	1.0	23

#	ARTICLE	IF	CITATIONS
609	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 322, 183-190.	0.8	31
610	MEESSI-AHF risk score performance to predict multiple post-index event and post-discharge short-term outcomes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 142-152.	0.4	26
611	Adjusted win ratio with stratification: Calculation methods and interpretation. <i>Statistical Methods in Medical Research</i> , 2021, 30, 580-611.	0.7	29
612	Dapagliflozin for heart failure: is it a class effect?. <i>Future Cardiology</i> , 2021, 17, 355-361.	0.5	4
613	Heart failure with preserved ejection fraction: insights into diagnosis and pathophysiology. <i>Cardiovascular Research</i> , 2021, 117, 999-1014.	1.8	47
614	Resistant Hypertension in People With CKD: A Review. <i>American Journal of Kidney Diseases</i> , 2021, 77, 110-121.	2.1	41
615	Metabolic inflammation in heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 423-434.	1.8	102
616	Sodium-glucose cotransporter-2 inhibitors: A drug with antidiabetic and cardioprotective properties. <i>Journal of Diabetes Investigation</i> , 2021, 12, 310-312.	1.1	3
617	Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. <i>Nature Reviews Nephrology</i> , 2021, 17, 65-77.	4.1	86
618	Sodium-glucose cotransporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 276-280.	2.2	65
619	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
620	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
621	Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study. <i>Internal and Emergency Medicine</i> , 2021, 16, 895-903.	1.0	6
622	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). <i>American Heart Journal</i> , 2021, 231, 137-146.	1.2	21
623	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. <i>American Journal of Cardiology</i> , 2021, 139, 134-136.	0.7	1
624	Sodium-glucose cotransporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.	2.2	40
625	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
626	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	13.9	1,080

#	ARTICLE	IF	CITATIONS
627	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2021, 384, 129-139.	13.9	662
628	Potential Cardiovascular Applications of Total-body PET Imaging. <i>PET Clinics</i> , 2021, 16, 129-136.	1.5	8
629	Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021, 45, 291-302.	0.4	9
630	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85
631	Myocardial ketone body utilization in patients with heart failure: The impact of oral ketone ester. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154452.	1.5	48
632	Decreased GLUT1/NHE1 RNA expression in whole blood predicts disease severity in patients with COVID-19. <i>ESC Heart Failure</i> , 2021, 8, 309-316.	1.4	11
633	Metabolic Consequences of Solid Organ Transplantation. <i>Endocrine Reviews</i> , 2021, 42, 171-197.	8.9	16
634	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 68-78.	2.9	79
635	How Diabetes and Heart Failure Modulate Each Other and Condition Management. <i>Canadian Journal of Cardiology</i> , 2021, 37, 595-608.	0.8	10
636	SGLT2-inhibitors; more than just glycosuria and diuresis. <i>Heart Failure Reviews</i> , 2021, 26, 623-642.	1.7	41
637	Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. <i>Nephrology</i> , 2021, 26, 377-390.	0.7	10
638	<scp>SOLOISTâ€ˆWHF</scp> and updated metaâ€ˆanalysis: sodiumâ€ˆglucose coâ€ˆtransporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 27-30.	2.9	14
639	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. <i>International Journal of Cardiology</i> , 2021, 327, 138-145.	0.8	19
640	Mitochondrial Ca <sup>2+</sup> , redox environment and ROS emission in heart failure: Two sides of the same coin?. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 151, 113-125.	0.9	24
641	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>JAMA Cardiology</i> , 2021, 6, 200.	3.0	18
642	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	3.0	22
643	Machine learning and statistical methods for predicting mortality in heart failure. <i>Heart Failure Reviews</i> , 2021, 26, 545-552.	1.7	16
644	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381

#	ARTICLE	IF	CITATIONS
645	Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. <i>Diabetes Therapy</i> , 2021, 12, 87-105.	1.2	17
646	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. <i>Nature Reviews Cardiology</i> , 2021, 18, 291-304.	6.1	141
647	Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. <i>Annual Review of Physiology</i> , 2021, 83, 503-528.	5.6	170
648	Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence. <i>ESC Heart Failure</i> , 2021, 8, 3-15.	1.4	16
650	Sodium-Glucose Co-Transporter <sup>2</sup> (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. <i>Diabetes Therapy</i> , 2021, 12, 55-70.	1.2	22
651	Appropriateness rating for the application of optimal medical therapy and multidisciplinary care among heart failure patients. <i>ESC Heart Failure</i> , 2021, 8, 300-308.	1.4	5
652	Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. <i>Archives of Toxicology</i> , 2021, 95, 659-671.	1.9	30
653	An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 427-437.	1.6	88
654	Contemporary Strategies to Manage High Blood Pressure in Patients with Coexistent Resistant Hypertension and Heart Failure With Reduced Ejection Fraction. <i>Cardiology and Therapy</i> , 2021, 10, 9-25.	1.1	1
655	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
656	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 385-394.	2.0	110
657	Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 243-255.	1.2	280
658	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 94-109.	2.1	88
659	Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2021, 143, 510-512.	1.6	46
660	Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study. <i>American Journal of Medicine</i> , 2021, 134, 606-613.e6.	0.6	6
661	Myopathy Associated With Statins and SGLT2 Inhibitors: A Review of Literature. <i>Current Problems in Cardiology</i> , 2021, 46, 100765.	1.1	17
662	Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. <i>IJC Heart and Vasculature</i> , 2021, 32, 100690.	0.6	15
663	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	1.9	26

#	ARTICLE	IF	CITATIONS
664	The role of sodium glucose co-transporter inhibitors in heart failure prevention. Journal of Diabetes and Its Complications, 2021, 35, 107811.	1.2	3
665	SGLT2 inhibitors in people with and without T2DM. Nature Reviews Endocrinology, 2021, 17, 75-76.	4.3	24
666	Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1052-1056.	2.2	32
667	Evaluation of dapagliflozin in the treatment of heart failure. Future Cardiology, 2021, 17, 415-425.	0.5	3
668	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. Diabetes Care, 2021, 44, S125-S150.	4.3	359
669	Treating latent autoimmune diabetes in adults in the era of cardiovascular outcomes trials: Old dog should learn new tricks. Diabetic Medicine, 2021, 38, e14496.	1.2	2
670	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology, 2021, 9, 22-31.	5.5	287
671	Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes, Obesity and Metabolism, 2021, 23, 886-896.	2.2	40
672	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	1.9	27
673	Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials. Diabetes, Obesity and Metabolism, 2021, 23, 1063-1065.	2.2	6
674	Do sodium-glucose cotransporter-2 inhibitors lead to fracture risk? A pharmacovigilance real-world study. Journal of Diabetes Investigation, 2021, 12, 1400-1407.	1.1	10
675	Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2021, 44, 595-603.	4.3	5
676	Cardiac contractility modulation for the treatment of moderate to severe HF. Expert Review of Medical Devices, 2021, 18, 15-21.	1.4	19
677	Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. Diabetes, Obesity and Metabolism, 2021, 23, 950-960.	2.2	12
678	Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study. Journal of Clinical Hypertension, 2021, 23, 860-869.	1.0	10
679	SGLT2 inhibitors may offer benefit beyond diabetes. Nature Reviews Nephrology, 2021, 17, 83-84.	4.1	29
680	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	0.7	6
681	Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients. Clinical Chemistry, 2021, 67, 79-86.	1.5	3

#	ARTICLE	IF	CITATIONS
682	Association of beta-oxohydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13468.	1.7	25
683	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 636-648.	1.0	9
684	Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials. <i>American Heart Journal</i> , 2021, 232, 10-22.	1.2	75
685	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2021, 27, 2-19.	0.7	16
686	Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3416.	1.7	7
687	Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan. <i>Annals of Pharmacotherapy</i> , 2021, 55, 805-813.	0.9	1
688	Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench. <i>Diabetes</i> , 2021, 70, 262-267.	0.3	23
689	Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2347-e2356.	1.8	22
690	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021, 70, 1-16.	0.3	53
691	Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 517-527.	0.7	18
692	A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 175-185.	2.9	30
693	Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 393-407.	2.3	114
694	Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. <i>Annals of Pharmacotherapy</i> , 2021, 55, 496-508.	0.9	17
695	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. <i>Clinical Diabetes</i> , 2021, 39, 105-116.	1.2	0
696	Renal dysfunction in cardiovascular diseases and its consequences. <i>Journal of Nephrology</i> , 2021, 34, 137-153.	0.9	32
697	Canagliflozin and cardiovascular outcomes in Type 2 diabetes. <i>Future Cardiology</i> , 2021, 17, 39-48.	0.5	1
698	Pharmacotherapeutic options for prediabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 45-54.	0.9	3
699	Lower cardiorenal risk with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 75-85.	2.2	43

#	ARTICLE	IF	CITATIONS
700	Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. <i>Heart Failure Reviews</i> , 2021, 26, 337-345.	1.7	23
701	Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 97-105.	2.2	1
702	Cardiac contractility modulation for the treatment of heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2021, 26, 217-226.	1.7	10
703	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021, 42, 1199-1202.	1.0	24
704	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 49-56.	2.3	12
705	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 101-108.	2.3	5
706	To Heart - Fail or Not? The Expanding Role of SGLT2 Inhibitors. <i>ADCES in Practice</i> , 2021, 9, 28-33.	0.2	1
707	Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis. <i>Indian Heart Journal</i> , 2021, 73, 132-134.	0.2	3
708	Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. <i>Journal of Molecular Medicine</i> , 2021, 99, 335-348.	1.7	83
709	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 741-753.	1.7	13
710	What's in a Name? Redefining Type 2 Diabetes Remission. <i>Diabetes Therapy</i> , 2021, 12, 647-654.	1.2	11
711	Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. <i>International Journal of Heart Failure</i> , 2021, 3, 205.	0.9	4
712	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. <i>European Heart Journal</i> , 2021, 42, 657-670.	1.0	25
713	Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. <i>Theranostics</i> , 2021, 11, 4502-4515.	4.6	61
714	Reverse Cardiac Remodeling and ARNI Therapy. <i>Current Heart Failure Reports</i> , 2021, 18, 71-83.	1.3	19
715	The Pleiotropic Effects of SGLT2 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2021, 77, 256-258.	1.2	6
716	The effect of three major comorbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 1417-1426.	1.4	5
717	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1267-1275.	0.9	3

#	ARTICLE	IF	CITATIONS
719	Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. <i>Drugs in Context</i> , 2021, 10, 1-5.	1.0	0
720	Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure. <i>British Journal of Cardiology</i> , 2021, , .	0.7	1
721	Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management. <i>Cureus</i> , 2021, 13, e12419.	0.2	9
722	Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. <i>Journal of Hypertension</i> , 2021, 39, 1090-1097.	0.3	22
723	Oxidized CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	40
724	Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. <i>Protein and Cell</i> , 2022, 13, 336-359.	4.8	74
725	Ageing and Renal Disease: Old Questions for New Challenges. , 2021, 12, 515.		28
726	Atrial fibrillation and chronic heart failure: interrelationship and approaches to treatment. <i>Kardiologicheskii Vestnik</i> , 2021, 16, 5.	0.1	5
727	Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 17.	2.7	27
728	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 612722.	1.3	11
729	Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. <i>Europace</i> , 2022, 24, 20-30.	0.7	39
730	Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach. <i>Postępy W Kardiologii Interwencyjnej</i> , 2021, 17, 135-140.	0.1	1
731	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	1.0	96
732	Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 351-359.	1.8	13
733	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	1.0	114
734	Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 25.	2.7	27
735	Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862199770.	1.0	9
739	Therapeutic approaches for non-alcoholic steatohepatitis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110343.	1.4	7



#	ARTICLE	IF	CITATIONS
740	Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 14.	2.7	74
741	Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis. <i>Diabetologia</i> , 2021, 64, 737-748.	2.9	20
742	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890.	1.0	11
743	Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights. <i>European Heart Journal</i> , 2022, 43, 2968-2970.	1.0	6
744	Real-world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART-Registry. <i>ESC Heart Failure</i> , 2021, 8, 1675-1680.	1.4	7
745	Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double-blind, placebo-controlled, phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1111-1120.	2.2	11
746	Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction. <i>Korean Circulation Journal</i> , 2021, 51, 251.	0.7	16
747	SGLT2 inhibitors – A new silver bullet. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 99-100.	0.4	0
748	Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2021, 33, 33-40.	0.1	1
749	Medical and Revascularization Management of Stable Ischemic Heart Disease: An Overview. <i>International Journal of Angiology</i> , 2021, 30, 083-090.	0.2	0
750	Stress hyperglycemia, cardiac glucotoxicity, and critically ill patient outcomes current clinical and pathophysiological evidence. <i>Physiological Reports</i> , 2021, 9, e14713.	0.7	18
751	Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model. <i>Journal of the American Heart Association</i> , 2021, 10, e017483.	1.6	32
752	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.	2.9	24
753	Estimated plasma volume status in heart failure: clinical implications and future directions. <i>Clinical Research in Cardiology</i> , 2021, 110, 1159-1172.	1.5	30
754	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1020-1029.	2.2	19
756	Ambulatory Management of Worsening Heart Failure: Current Strategies and Future Directions. <i>Heart International</i> , 2021, 15, 49.	0.4	3
758	Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF. <i>Cardiovascular Diabetology</i> , 2021, 20, 7.	2.7	54
759	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 372, m4573.	3.0	322

#	ARTICLE	IF	CITATIONS
760	Remote Patient Monitoring in Heart Failure: Factors for Clinical Efficacy. International Journal of Heart Failure, 2021, 3, 31.	0.9	20
761	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circulation: Heart Failure, 2021, 14, e007684.	1.6	87
762	Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1131-1139.	2.2	36
763	Diabetes and Heart Failure. Cardiovascular Prevention and Pharmacotherapy, 2021, 3, 21.	0.0	0
764	The year in cardiovascular medicine 2020: epidemiology and prevention. European Heart Journal, 2021, 42, 813-821.	1.0	18
765	Empagliflozin in Heart Failure. New England Journal of Medicine, 2021, 384, 384-388.	13.9	3
766	Considering dose in pharmacological therapies for heart failure. Lancet, The, 2021, 397, 274-275.	6.3	0
767	Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors. International Journal of Cardiovascular Imaging, 2021, 37, 1333-1341.	0.7	5
768	Heterogeneity in renal endpoints of cardiovascular outcomes trials in Type 2 diabetes. Journal of Comparative Effectiveness Research, 2021, 10, 169-173.	0.6	1
769	Pharmacotherapeutic principles of fluid management in heart failure. Expert Opinion on Pharmacotherapy, 2021, 22, 595-610.	0.9	2
770	Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. Clinical Pharmacokinetics, 2021, 60, 517-525.	1.6	6
771	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. Revista Clínica Española, 2021, 221, 101-108.	0.3	4
772	Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2021, 172, 108648.	1.1	1
773	Heart failure: From novel pharmaceutical therapies to circulation support systems. Hellenic Journal of Cardiology, 2021, 62, 452-454.	0.4	0
774	The "discordant doppelgänger dilemma": SGLT2i mimics therapeutic carbohydrate restriction - food choice first over pharma?. Journal of Human Hypertension, 2021, 35, 649-656.	1.0	7
775	Acute heart failure treatment: a light at the end of the tunnel?. European Journal of Heart Failure, 2021, 23, 698-702.	2.9	5
777	SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Cardiovascular Diabetology, 2021, 20, 39.	2.7	35
778	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. Journal of General Internal Medicine, 2021, 36, 2601-2607.	1.3	9

#	ARTICLE	IF	CITATIONS
779	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021, 64, 1226-1234.	2.9	15
780	Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. <i>ESC Heart Failure</i> , 2021, 8, 1482-1493.	1.4	16
781	Should Clinical Guidelines Incorporate Cost Pathways for Persons With Financial Hardship?. <i>AMA Journal of Ethics</i> , 2021, 23, E175-182.	0.4	0
782	Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Endocrine</i> , 2021, 73, 31-36.	1.1	19
784	Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 636152.	1.1	11
785	Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure. <i>Russian Journal of Cardiology</i> , 2021, 26, 4235.	0.4	1
786	Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?. <i>Cardiac Failure Review</i> , 2020, 7, e02.	1.2	11
787	Pathophysiology of heart failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 263-276.	0.7	91
788	Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HF <sub>r</sub> EF. <i>ESC Heart Failure</i> , 2021, 8, 1722-1724.	1.4	2
789	Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 505.	1.0	6
790	SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 75.	0.4	2
791	Beyond the myocardium: Sodium-glucose co-transporter 2 inhibitors in heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1215-1218.	2.2	0
793	Cardiac Adiposity and Arrhythmias: The Role of Imaging. <i>Diagnostics</i> , 2021, 11, 362.	1.3	11
794	Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics. <i>Kidney360</i> , 2021, 2, 742-746.	0.9	18
796	Sodium-glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction?. <i>European Journal of Heart Failure</i> , 2021, 23, 1256-1259.	2.9	2
797	SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. <i>Heart Failure Reviews</i> , 2022, 27, 935-949.	1.7	19
798	Naxos Disease: Current Knowledge and Future Advances. , 0, , .		0
799	Overview of the 84 <sup>th</sup> Annual Scientific Meeting of the Japanese Circulation Society—Change Practice! . <i>Circulation Journal</i> , 2021, 85, 323-329.	0.7	0

#	ARTICLE	IF	CITATIONS
800	Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 626375.	1.6	11
801	The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathyâ€”A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 705.	1.0	9
803	Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodiumâ€“glucose coâ€“transporter 2 inhibitors?. <i>European Journal of Heart Failure</i> , 2021, 23, 644-647.	2.9	3
804	The advantages, pitfalls and limitations of guidelineâ€“directed medical therapy in patients with valvular heart disease. <i>European Journal of Heart Failure</i> , 2021, 23, 1325-1333.	2.9	9
805	Glucosuric, renal and haemodynamic effects of licoglitflozin, a dual inhibitor of sodiumâ€“glucose coâ€“transporterâ€“1 and sodiumâ€“glucose coâ€“transporterâ€“2, in patients with chronic kidney disease: A randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1182-1190.	2.2	3
806	Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure. <i>Free Radical Biology and Medicine</i> , 2021, 163, 325-343.	1.3	48
807	SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. <i>Heart Failure Reviews</i> , 2022, 27, 951-960.	1.7	16
808	Comprehensive Care Models for Cardiometabolic Disease. <i>Current Cardiology Reports</i> , 2021, 23, 22.	1.3	21
809	Personalizing heart failure management in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2055-2062.	0.4	11
810	Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1284-1291.	2.2	42
811	Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. <i>Heart</i> , 2021, 107, 1032-1038.	1.2	90
812	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1352-1360.	0.8	26
813	New Hemodynamic Insights in Pulmonary Vascular Disease and Heart Failure with Preserved Ejection Fraction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	0
814	A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study. <i>ADCES in Practice</i> , 2021, 9, 16-23.	0.2	0
815	Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. <i>Journal of Clinical Medicine</i> , 2021, 10, 721.	1.0	19
816	Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107803.	1.2	7
817	Softening the Stiff Heart. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 408-410.	2.3	4
818	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203.	2.1	14

#	ARTICLE	IF	CITATIONS
819	Heart failure in advanced chronic kidney disease: treatment rationale. Herz, 2021, 46, 217-220.	0.4	2
820	Cliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes. Deutsches A&#x0308;rzteblatt International, 2021, 118, .	0.6	5
821	Metabolic surgery: A clinical update. Diabetes, Obesity and Metabolism, 2021, 23, 63-83.	2.2	19
822	A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovascular Diabetology, 2021, 20, 32.	2.7	34
823	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	1.2	612
825	A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure. Frontiers in Physiology, 2021, 12, 642117.	1.3	2
826	Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020. Endocrinology and Metabolism, 2021, 36, 41-50.	1.3	4
828	SGLT2 inhibitors: expanding their Empire beyond diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 59-61.	5.5	2
829	TÃ³picos Emergentes em InsuficiÃªncia CardÃaca: Inibidores do Cotransportador SÃ³dio-Glicose 2 (iSGLT2) na IC. Arquivos Brasileiros De Cardiologia, 2021, 116, 355-358.	0.3	3
830	Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible?. Cardiology, 2021, 146, 201-206.	0.6	10
831	Tratamiento mÃ©dico de la diabetes mellitus tipo 2: recomendaciones del Grupo de Diabetes, Obesidad y NutriciÃ³n de la Sociedad EspaÃ±ola de Medicina Interna. Revista Clinica Espanola, 2021, 221, 101-108.	0.2	4
832	Therapeutic transformation for diabetic kidney disease. Kidney International, 2021, 99, 301-303.	2.6	5
833	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	3.2	36
834	Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: AÂDescriptive Analysis in the UK CPRD. Clinical Therapeutics, 2021, 43, 320-335.	1.1	26
835	A New Requirement for Publication: Access to Effective Drugs for Ethical Reasons, The Example of Heart Failure. ESC Heart Failure, 2021, 8, 799-801.	1.4	1
837	Analysis of causes of death in patients with implanted defibrillators. Clinical Research in Cardiology, 2021, 110, 895-904.	1.5	3
838	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. European Journal of Preventive Cardiology, 2021, 28, 1691-1700.	0.8	26
839	A Simple Nomogram to Predict Contrast-Induced Acute Kidney Injury in Patients with Congestive Heart Failure Undergoing Coronary Angiography. Cardiology Research and Practice, 2021, 2021, 1-10.	0.5	1

#	ARTICLE	IF	CITATIONS
840	SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. <i>Heart Failure Reviews</i> , 2022, 27, 961-980.	1.7	18
841	The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. <i>Diabetes Therapy</i> , 2021, 12, 1445-1461.	1.2	5
842	Diabetes Management in Patients with Heart Failure. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 158-172.	1.8	9
843	Novel Trial Design: CHIEF-HF. <i>Circulation: Heart Failure</i> , 2021, 14, e007767.	1.6	23
844	Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?. <i>Circulation: Heart Failure</i> , 2021, 14, e008090.	1.6	5
845	Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1161-1170.	1.3	4
846	Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-12.	0.5	13
847	Sodium-glucose cotransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , 2021, 23, 826-834.	2.9	60
848	Diuretic therapy in congestive heart failure. <i>Acta Cardiologica</i> , 2022, 77, 97-104.	0.3	9
849	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	2.9	57
850	Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007048.	1.6	36
851	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	0
852	Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110110.	0.9	41
853	SGLT2 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1375-1377.	1.2	2
854	Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know. <i>European Cardiology Review</i> , 2021, 16, e12.	0.7	0
855	Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 361-368.	1.0	3
856	Commentary: SGLT2 inhibitors reduce mortality and heart failure in patients with type 2 diabetes mellitus—is metabolic reprogramming the mechanism for these favorable outcomes?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, .	0.4	0
857	Impact of Geographic Region on the COMMANDER-HF Trial. <i>JACC: Heart Failure</i> , 2021, 9, 201-211.	1.9	6

#	ARTICLE	IF	CITATIONS
858	COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1083-1092.	2.0	13
859	Anti-inflammatory potential of Empagliflozin. <i>Inflammopharmacology</i> , 2021, 29, 573-576.	1.9	11
860	Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans. <i>Clinical Cardiology</i> , 2021, 44, 646-655.	0.7	17
861	Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events. <i>American Journal of Epidemiology</i> , 2021, 190, 1572-1581.	1.6	8
862	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	1.2	105
863	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. <i>Cardiovascular Diabetology</i> , 2021, 20, 75.	2.7	9
864	Direct Cardiac Actions of the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure Overload Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e018298.	1.6	54
865	Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use. <i>Family Practice</i> , 2021, 38, 623-629.	0.8	1
866	Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. <i>Current Drug Safety</i> , 2021, 16, 32-51.	0.3	1
867	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022.	2.9	33
868	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1554-1563.	1.5	5
869	Dapagliflozin for heart failure. <i>Practical Diabetes</i> , 2021, 38, 6.	0.1	0
870	Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2021, 12, 664502.	1.5	2
871	Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 578-589.	2.9	22
872	Racial and ethnic disparities in heart failure: current state and future directions. <i>Current Opinion in Cardiology</i> , 2021, 36, 320-328.	0.8	57
873	Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e019463.	1.6	55
874	Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Frontiers in Endocrinology</i> , 2021, 12, 619586.	1.5	28
875	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13

#	ARTICLE	IF	CITATIONS
876	Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. <i>Diabetes Therapy</i> , 2021, 12, 1279-1297.	1.2	7
877	eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. <i>Kidney360</i> , 2021, 2, 1042-1047.	0.9	40
878	Effect of dapagliflozin in patients with heart failure. <i>Drug and Therapeutics Bulletin</i> , 2021, 59, 86-87.	0.3	0
879	Association of sodium-glucose cotransporter 2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the <sc>CVD-REAL</sc> 2 study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1431-1435.	2.2	12
880	Myocardial stress perfusion scintigraphy for outcome prediction in patients with severe left ventricular systolic dysfunction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3502-3511.	3.3	1
881	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1159-1167.	4.3	25
882	Glucose-Lowering Medications and Cardiovascular Outcomes. <i>Current Cardiology Reports</i> , 2021, 23, 24.	1.3	2
883	Prevention of heart failure events with sodium-glucose cotransporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk. <i>European Journal of Heart Failure</i> , 2021, 23, 1002-1008.	2.9	25
884	Abnormal Glucose Tolerance in Prediabetes Patients with Acute Myocardial Infarction: Implications for Therapy. <i>Journal of Endocrinological Science</i> , 2021, 3, 16-21.	0.1	1
885	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. <i>Cardiac Failure Review</i> , 2021, 7, e04.	1.2	7
886	Quality Matters? The Involvement of Mitochondrial Quality Control in Cardiovascular Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636295.	1.8	11
887	SGLT-2 Inhibitors in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1393-1396.	1.2	4
888	Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 146-157.	1.8	56
889	Heart failure in men. <i>Trends in Urology &amp; Men's Health</i> , 2021, 12, 15-20.	0.2	0
890	Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients. <i>Cardiovascular Drugs and Therapy</i> , 2021, , 1.	1.3	3
891	Glifozines: actions cardiovasculaires et r�nales. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2021, 2021, 9-11.	0.0	1
892	Considerations for best practices related to sodium-glucose cotransporter-2 inhibitors and serum potassium levels. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1367-1368.	0.5	0
893	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. <i>European Cardiology Review</i> , 2021, 16, e11.	0.7	2



#	ARTICLE	IF	CITATIONS
894	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021, 143, 949-958.	1.6	15
895	Management of diabetes and hyperglycaemia in the hospital. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 174-188.	5.5	127
896	Cardiovascular Disease in Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1157-1172.	1.6	680
897	SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease. <i>Seminars in Nephrology</i> , 2021, 41, 85-95.	0.6	2
898	Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 34.	1.2	16
899	Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 388-396.	1.8	13
900	SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 2210-2219.	1.4	26
901	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1426-1430.	2.2	14
902	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	7.1	80
903	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
904	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.	1.2	94
905	A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials. <i>Journal of the American Association of Nurse Practitioners</i> , 2021, Publish Ahead of Print, 1139-1147.	0.5	0
908	Overview of the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 2249-2252.	0.6	4
910	Updates in pharmacotherapy of heart failure with reduced ejection fraction. <i>Annals of Translational Medicine</i> , 2021, 9, 516-516.	0.7	5
911	Defibrillation therapies following sodium-glucose cotransporter 2 inhibitor treatment: A report of two cases. <i>HeartRhythm Case Reports</i> , 2021, 7, 338-342.	0.2	1
912	Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1505-1517.	2.2	42
913	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. <i>European Heart Journal</i> , 2021, 42, 1458-1459.	1.0	4
914	Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 991-1028.	1.2	20

#	ARTICLE	IF	CITATIONS
915	Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100144.	1.3	7
916	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1236-1241.	4.3	37
917	The resolution on empagliflozin and heart failure has been adopted by the experts of the Siberian Federal District based on the results of the EMPEROR-Reduced study. <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 103-108.	0.3	3
918	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <sc>DAPA-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.	2.9	33
919	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	2.9	630
920	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. <i>Diabetes Therapy</i> , 2021, 12, 1099-1116.	1.2	8
922	Diabetes and Heart Failure. <i>Journal of Korean Diabetes</i> , 2021, 22, 12-20.	0.1	0
924	Diuretic-induced hypokalaemia: an updated review. <i>Postgraduate Medical Journal</i> , 2022, 98, 477-482.	0.9	6
925	Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the <sc>COVID-19</sc> pandemic. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1696-1700.	2.2	4
926	Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. <i>Open Heart</i> , 2021, 8, e001585.	0.9	30
927	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. <i>Current Diabetes Reports</i> , 2021, 21, 15.	1.7	78
928	Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. <i>Cardiovascular Diabetology</i> , 2021, 20, 67.	2.7	27
929	Which Patients with Obesity Are at Risk for Renal Disease?. <i>Nephron</i> , 2021, 145, 595-603.	0.9	9
930	Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low-dose loop diuretic therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 1110-1119.	2.9	9
931	Medical Therapy of Heart Failure with Reduced Ejection Fraction—A Call for Comparative Research. <i>Journal of Clinical Medicine</i> , 2021, 10, 1803.	1.0	1
932	Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization. <i>US Cardiology Review</i> , 0, 15, .	0.5	12
933	Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 619-632.	1.3	12
934	Polypill in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1673-1677.	13.9	1

#	ARTICLE	IF	CITATIONS
935	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108737.	1.1	61
936	Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. <i>Pharmacotherapy</i> , 2021, 41, 526-536.	1.2	5
937	SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. <i>Endocrinology</i> , 2021, 162, .	1.4	35
938	Cardiovascular Risk Reduction Following Metabolic and Bariatric Surgery. <i>Surgical Clinics of North America</i> , 2021, 101, 269-294.	0.5	11
939	Evolving Cardiac Electrical Therapies for Advanced Heart Failure Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009668.	2.1	4
940	Evidence-Based Management of Acute Heart Failure. <i>Canadian Journal of Cardiology</i> , 2021, 37, 621-631.	0.8	16
941	A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 632-643.	0.8	31
942	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2-PACE/TIMI 50. <i>Journal of the American Heart Association</i> , 2021, 10, e018673.	1.6	7
943	Can biomarkers help find the "sweet spot" for treating patients with diabetes?. <i>European Journal of Heart Failure</i> , 2021, 23, 1037-1039.	2.9	0
944	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	0.8	170
945	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. <i>Current Pharmaceutical Design</i> , 2021, 27, 1289-1297.	0.9	8
946	When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease. <i>Canadian Journal of Cardiology</i> , 2021, 37, 669-673.	0.8	4
947	Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. <i>Advances in Therapy</i> , 2021, 38, 2201-2212.	1.3	23
948	The pathophysiology and management of diuretic resistance in patients with heart failure. <i>Hospital Practice (1995)</i> , 2021, , 1-9.	0.5	0
949	Moving in the right direction but not there yet: the utility, measurement, and analysis of health status in heart failure trials. <i>European Journal of Heart Failure</i> , 2021, 23, 590-592.	2.9	0
950	Blood counts: targeting anaemia in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 629-631.	2.9	0
951	Do SGLT 2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?. <i>Journal of Diabetes</i> , 2021, 13, 596-600.	0.8	5
952	Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2133-2145.	1.8	35

#	ARTICLE	IF	CITATIONS
953	Sex-Specific Differences in Heart Failure: Pathophysiology, Risk Factors, Management, and Outcomes. <i>Canadian Journal of Cardiology</i> , 2021, 37, 560-571.	0.8	40
954	Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice. <i>Clinical Science</i> , 2021, 135, 943-961.	1.8	37
955	Cardiorenal Protection in Diabetic Kidney Disease. <i>Endocrinology and Metabolism</i> , 2021, 36, 256-269.	1.3	10
956	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
957	Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. <i>Cardiovascular Diabetology</i> , 2021, 20, 78.	2.7	11
958	The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection. <i>Russian Journal of Cardiology</i> , 2021, 26, 4323.	0.4	1
959	New horizons in cardiogeriatrics: geriatricians and heart failure care – the custard in the tart, not the icing on the cake. <i>Age and Ageing</i> , 2021, 50, 1064-1068.	0.7	2
960	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 384, 1248-1260.	13.9	60
961	Noncardiovascular comorbidities in patients with heart failure and their impact on prognosis. <i>Kardiologia Polska</i> , 2021, 79, 493-502.	0.3	3
962	Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). <i>Current Opinion in Cardiology</i> , 2021, 36, 420-428.	0.8	8
964	From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 92.	2.7	28
965	Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. <i>Children</i> , 2021, 8, 322.	0.6	9
966	Rol de nuevos fármacos antidiabéticos en prevención cardiovascular e insuficiencia cardiaca. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 314-322.	0.4	0
967	Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4374.	1.8	18
968	The year in cardiovascular medicine 2020: heart failure and cardiomyopathies. <i>Cardiologia Croatica</i> , 2021, 16, 140-156.	0.0	0
969	Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis. <i>Diabetes</i> , 2021, 70, 1767-1779.	0.3	17
970	Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2021, 20, 83.	2.7	20
971	Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-nephrilysin inhibitor: an updated meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e74-e76.	1.4	8

#	ARTICLE	IF	CITATIONS
972	Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial. <i>Diabetes Care</i> , 2021, 44, 1334-1343.	4.3	32
973	Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. <i>IJC Heart and Vasculature</i> , 2021, 33, 100725.	0.6	18
974	Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. <i>JAMA Network Open</i> , 2021, 4, e216139.	2.8	187
975	Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 217.	0.7	13
976	Lipid effects of sodium-glucose cotransporter 2 inhibitors. <i>Current Opinion in Lipidology</i> , 2021, 32, 183-190.	1.2	6
977	Anemia of cardiorenal syndrome. <i>Kidney International Supplements</i> , 2021, 11, 35-45.	4.6	29
978	Coronary heart disease risk: Low-density lipoprotein and beyond. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 181-194.	2.3	56
979	Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. <i>Current Heart Failure Reports</i> , 2021, 18, 132-143.	1.3	1
980	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	0.7	362
981	The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape. <i>Canadian Journal of Cardiology</i> , 2021, 37, 644-654.	0.8	7
982	Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1616-1629.	3.0	46
983	Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2021, 7, e06.	1.2	1
984	Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-14.	1.0	6
985	Modern view on chronic heart failure therapy: guidelines'2020 key messages and adjuvant therapy. <i>Medical Alphabet</i> , 2021, , 8-16.	0.0	0
986	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>European Cardiology Review</i> , 2021, 16, e14.	0.7	4
988	One Year of Dapagliflozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2021, 12, 1677-1688.	1.2	0
989	Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2022, 46, 10-15.e2.	0.4	31
990	Heart Failure And Diabetes: Perspective Of A Dangerous Association. <i>Current Hypertension Reviews</i> , 2021, 17, 85-93.	0.5	2

#	ARTICLE	IF	CITATIONS
991	Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure. <i>Circulation</i> , 2021, 143, 1673-1686.	1.6	129
992	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	1.9	75
993	New antidiabetic therapy and HFpEF: light at the end of tunnel?. <i>Heart Failure Reviews</i> , 2022, 27, 1137-1146.	1.7	16
994	Sodium-glucose cotransporter 2 inhibitors: strength of evidence for a cardio-renal-metabolic therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 1009-1011.	2.9	0
995	SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2036.	1.0	6
996	The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: A systematic review and meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1365-1374.	1.1	7
997	Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2021, 20, 100.	2.7	92
998	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
999	Chronic kidney disease in patients with diabetes mellitus. <i>Endocrine Connections</i> , 2021, 10, R151-R159.	0.8	12
1000	Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?. <i>Future Cardiology</i> , 2021, 17, 497-506.	0.5	2
1001	Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. <i>Future Cardiology</i> , 2021, 17, 459-473.	0.5	4
1002	Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. <i>Circulation Research</i> , 2021, 128, 1468-1486.	2.0	63
1003	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease. <i>Hypertension</i> , 2021, 77, 1442-1455.	1.3	22
1004	Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1453-1464.	0.8	8
1005	Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease. <i>Nuclear Medicine Communications</i> , 2021, 42, 972-978.	0.5	4
1006	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021, 397, 2385-2438.	6.3	530
1007	Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2021, 143, e984-e1010.	1.6	928
1008	Résultats des études cliniques de sécurité cardiovasculaire avec les inhibiteurs des SGLT-2 et les agonistes des récepteurs du GLP-1: quels enseignements?. <i>Medicine Des Maladies Metaboliques</i> , 2021, 15, 252-259.	0.1	0

#	ARTICLE	IF	CITATIONS
1009	Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. <i>Russian Journal of Cardiology</i> , 2021, 26, 4436.	0.4	3
1010	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 539-546.	1.4	22
1011	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. <i>International Journal of Cardiology</i> , 2021, 330, 91-97.	0.8	10
1012	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. <i>Heart</i> , 2022, 108, 16-21.	1.2	7
1013	Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). <i>Clinical Medicine</i> , 2021, 21, 204-210.	0.8	12
1014	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108796.	1.1	11
1015	Heart failure subtypes: Pathophysiology and definitions. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108815.	1.1	9
1016	Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 697-705.	1.5	8
1017	Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107949.	1.2	4
1018	Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial. <i>Diabetes Therapy</i> , 2021, 12, 2101-2113.	1.2	6
1019	Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 882-894.	2.9	88
1020	Timely and individualized heart failure management: need for implementation into the new guidelines. <i>Clinical Research in Cardiology</i> , 2021, 110, 1150-1158.	1.5	18
1021	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 364-377.	4.3	70
1022	Fluid volume regulation in patients with heart failure – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 258.	5.5	0
1023	Recent advances in new-onset diabetes mellitus after kidney transplantation. <i>World Journal of Diabetes</i> , 2021, 12, 541-555.	1.3	4
1024	Mechanisms and Models in Heart Failure. <i>Circulation Research</i> , 2021, 128, 1435-1450.	2.0	24
1025	4. Clinical Pharmacology in Heart Failure Patients with Multiple Comorbidities. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2021, 52, 79-84.	0.1	0
1026	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35

#	ARTICLE	IF	CITATIONS
1027	Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?. <i>Current Problems in Cardiology</i> , 2022, 47, 100878.	1.1	0
1028	The impact of diabetes on heart failure development: The cardio-renal-metabolic connection. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108831.	1.1	5
1029	Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction. <i>CJC Open</i> , 2021, 3, 646-657.	0.7	2
1030	Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. <i>European Journal of Internal Medicine</i> , 2021, 87, 100-101.	1.0	3
1032	Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 474-481.	1.0	6
1033	Representation of Black patients in heart failure clinical trials. <i>Current Opinion in Cardiology</i> , 2021, 36, 329-334.	0.8	5
1034	Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples. <i>British Journal of Diabetes</i> , 2021, 21, 89-95.	0.1	4
1035	Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan. <i>International Heart Journal</i> , 2021, 62, 592-600.	0.5	7
1036	Das kardioresnale Syndrom ist die häufigste erste kardiovaskuläre Manifestation beim Typ-2-Diabetes und mit erhöhter Mortalität assoziiert: eine große multinationale Beobachtungsstudie. <i>Diabetologie Und Stoffwechsel</i> , 2021, 16, .	0.0	0
1038	Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2580-2590.	1.4	18
1039	Sodium-glucose cotransporter-2 inhibitors: where and when?. <i>Future Cardiology</i> , 2021, 17, 403-406.	0.5	1
1040	Epicardial adipose tissue in obesity-related cardiac dysfunction. <i>Heart</i> , 2022, 108, 339-344.	1.2	22
1041	De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2013.	1.0	2
1042	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients. <i>Scientific Reports</i> , 2021, 11, 10166.	1.6	14
1043	Pharmacological Management of Heart Failure: A Century of Expert Opinions in Cecil Textbook of Medicine. <i>American Journal of Therapeutics</i> , 2021, 28, e292-e298.	0.5	4
1044	A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 713-726.	1.3	6
1045	Effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 1049-1052.	2.9	2
1046	Primary Prevention Implantable Cardioverter-Defibrillator Therapy in Heart Failure with Recovered Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2021, 27, 585-596.	0.7	1



#	ARTICLE	IF	CITATIONS
1047	2021 ACC update of the heart failure guidelines. <i>Cor Et Vasa</i> , 2021, 63, 264-270.	0.1	5
1048	Revisiting the Role of Guideline-Directed Medical Therapy for Patients with Heart Failure and Severe Functional Mitral Regurgitation. <i>Cardiology Clinics</i> , 2021, 39, 255-265.	0.9	1
1049	Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats. <i>Scientific Reports</i> , 2021, 11, 9544.	1.6	18
1050	The catabolic triad: case report of fasting, major cardiac surgery and sodium-glucose co-transporter 2 inhibitors leading to perioperative euglycaemic ketoacidosis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 33, 494-495.	0.5	2
1051	Implications of SGLT Inhibition on Redox Signalling in Atrial Fibrillation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5937.	1.8	6
1052	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. <i>Mitochondrion</i> , 2021, 58, 72-82.	1.6	13
1053	SGLT2 inhibitors in cardiovascular medicine. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e67-e68.	1.4	20
1054	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	1.0	60
1055	Treating Diabetes to Prevent Stroke. <i>Stroke</i> , 2021, 52, 1557-1560.	1.0	5
1056	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 374-382.	1.9	23
1057	Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1233-1243.	0.8	16
1058	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.4	30
1059	Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction. <i>Kidney International</i> , 2021, 99, 1088-1101.	2.6	37
1060	SGLT2 inhibitors: Do we need other evidences?. <i>European Journal of Internal Medicine</i> , 2021, 87, 18-19.	1.0	0
1061	New Targets in Heart Failure Drug Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665797.	1.1	10
1062	Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. <i>World Journal of Gastroenterology</i> , 2021, 27, 1864-1882.	1.4	19
1063	NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 261-263.	5.5	0
1064	Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter 2 inhibitor tofogliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1660-1665.	2.2	5

#	ARTICLE	IF	CITATIONS
1065	Cardiac Energy Metabolism in Heart Failure. <i>Circulation Research</i> , 2021, 128, 1487-1513.	2.0	433
1066	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5863.	1.8	48
1067	Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?. <i>European Journal of Internal Medicine</i> , 2021, 87, 98-99.	1.0	3
1068	Eligibility of outpatients with chronic heart failure for sodium-glucose cotransporter-2 inhibitors. <i>ESC Heart Failure</i> , 2021, 8, 2951-2958.	1.4	8
1069	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	3.0	120
1070	Post-pancreatitis diabetes mellitus: investigational drugs in preclinical and clinical development and therapeutic implications. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 737-747.	1.9	13
1071	From Systemic Inflammation to Myocardial Fibrosis. <i>Circulation Research</i> , 2021, 128, 1451-1467.	2.0	132
1072	Impact of Dapagliflozin on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.5	1
1073	Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure—There Is No Time for Delay. <i>JAMA Cardiology</i> , 2021, 6, 507.	3.0	3
1074	Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 351-358.	1.1	0
1075	Where are we in 2021 with heart failure with reduced ejection fraction?—current outlook and expectations from new promising clinical trials. <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	8
1076	Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 1966-1968.	13.9	4
1077	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. <i>British Journal of Diabetes</i> , 2021, 21, 132-148.	0.1	0
1078	A year in diabetic nephropathy. <i>British Journal of Diabetes</i> , 2021, 21, 100-109.	0.1	0
1079	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.2	9
1081	Metformin in the era of new antidiabetics. <i>Future Cardiology</i> , 2021, 17, 475-485.	0.5	2
1082	Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome. <i>Kidney International</i> , 2021, 99, 1062-1064.	2.6	4
1083	Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e020237.	1.6	19

#	ARTICLE	IF	CITATIONS
1084	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1522-1545.	0.3	47
1085	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100183.	1.3	4
1086	Long-Term Impact of Diabetes Mellitus on Initially Conservatively Managed Patients With Severe Aortic Stenosis. <i>Circulation Journal</i> , 2021, 85, 1083-1092.	0.7	3
1087	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021, 42, 2373-2383.	1.0	9
1088	Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study. <i>Diabetes Therapy</i> , 2021, 12, 1979-1992.	1.2	4
1089	Clinical outcomes of Sodium-glucose cotransporter-2 inhibitors in patients with Type 2 Diabetes Mellitus: An observational study from Pakistan. <i>Pakistan Journal of Medical Sciences</i> , 2021, 37, 1342-1346.	0.3	2
1090	Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARS-CoV-2 infection. <i>ESC Heart Failure</i> , 2021, 8, 4026-4036.	1.4	5
1091	How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR. <i>Journal of Clinical Medicine</i> , 2021, 10, 2505.	1.0	17
1092	Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. <i>Physiological Reports</i> , 2021, 9, e14890.	0.7	13
1093	Non-invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 3696-3708.	1.4	20
1094	Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis. <i>Circulation: Heart Failure</i> , 2021, 14, e007909.	1.6	14
1095	A Review of the Role of Type 2 Diabetes and SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	1
1096	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	4.3	47
1097	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	2.9	195
1099	Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 161, 105788.	1.9	21
1100	Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 430-438.	1.9	10
1101	Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6105.	1.8	14
1103	Impact of admission hyperglycaemia on clinical outcomes in non-diabetic heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3822-3834.	1.4	3

#	ARTICLE	IF	CITATIONS
1104	Transforming the Care of Patients with Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1590-1600.	2.2	11
1105	Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 699-706.	0.7	4
1106	Sodium-glucose cotransporter 2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. <i>Nephrology</i> , 2021, 26, 858-871.	0.7	11
1107	Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin. <i>Circulation</i> , 2021, 143, 2188-2204.	1.6	105
1108	Protocolo terapéutico de la insuficiencia cardíaca crónica. <i>Medicine</i> , 2021, 13, 2054-2057.	0.0	0
1109	Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. <i>Transplant International</i> , 2021, 34, 1341-1359.	0.8	9
1110	New Aspects of Diabetes Research and Therapeutic Development. <i>Pharmacological Reviews</i> , 2021, 73, 1001-1015.	7.1	10
1111	Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019. <i>Medical Care</i> , 2021, 59, 789-794.	1.1	11
1112	Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2463-2471.	1.4	12
1113	Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1407-1421.	1.6	14
1114	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1671-1690.	1.1	5
1115	Sodium-glucose cotransporter 2 inhibitors: a practical guide for the Dutch cardiologist based on real-world experience. <i>Netherlands Heart Journal</i> , 2021, 29, 490-499.	0.3	3
1116	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 4442-4451.	1.0	38
1117	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<sc>US</sc>, <sc>UK</sc> and Sweden). <i>European Journal of Heart Failure</i> , 2021, 23, 1499-1511.	2.9	80
1118	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <sc>EMPEROR</sc>-Reduced trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1529-1538.	2.9	30
1119	Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial". <i>American Heart Journal</i> , 2021, 236, 106.	1.2	0
1120	Renin-angiotensin system and inflammation update. <i>Molecular and Cellular Endocrinology</i> , 2021, 529, 111254.	1.6	42
1121	SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials. <i>Kidney Medicine</i> , 2021, 3, 732-744.e1.	1.0	10

#	ARTICLE	IF	CITATIONS
1122	The Johns Hopkins Ciccarone Center's expanded ABC's approach to highlight 2020 updates in cardiovascular disease prevention. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100181.	1.3	0
1123	Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2631-2636.	1.4	6
1124	SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 36, 100933.	3.2	67
1125	Thrombolysis In Myocardial Infarction (TIMI) Study Group. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2822-2845.	1.2	23
1126	Metformin, Macrophage Dysfunction and Atherosclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 682853.	2.2	59
1127	Pharmacotherapy Considerations in Heart Failure with Mildly-Reduced Ejection Fraction. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110273.	0.5	0
1129	Evidence-based use of newer agents in type 2 diabetes. <i>Journal of Prescribing Practice</i> , 2021, 3, 224-234.	0.1	1
1130	An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2087-2094.	0.9	5
1131	Towards precision medicine in heart failure. <i>Nature Reviews Cardiology</i> , 2021, 18, 745-762.	6.1	34
1132	Optimising heart failure care with a multidisciplinary approach. <i>British Journal of Cardiac Nursing</i> , 2021, 16, 1-5.	0.0	0
1133	Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF $\beta$ 1/Smad signaling. <i>Cardiovascular Diabetology</i> , 2021, 20, 121.	2.7	37
1134	Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2777-2791.	1.2	49
1135	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. <i>Diabetes Care</i> , 2021, 44, 1564-1572.	4.3	43
1136	Diagnostic Thresholds for Pre-Diabetes Mellitus and Diabetes Mellitus and Subclinical Cardiac Disease in the General Population: Data From the ACE 1950 Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020447.	1.6	11
1137	Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons. <i>Current Opinion in Cardiology</i> , 2021, 36, 609-615.	0.8	6
1138	Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 685-698.	0.8	3
1139	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1847-1855.	0.9	18
1141	Treating heart failure in patients with diabetes: The view of the cardiologist. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108852.	1.1	2

#	ARTICLE	IF	CITATIONS
1142	Heart failure management; a perspective from diabetes care. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108849.	1.1	1
1143	From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6617.	1.8	6
1144	The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 2021, 2, .	0.3	6
1145	COVID-19 Global Pandemic Fight by Drugs: A Mini-Review on Hope and Hype. <i>Mini-Reviews in Organic Chemistry</i> , 2021, 18, .	0.6	0
1146	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2022, 27, 1147-1163.	1.7	8
1147	Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives. <i>Clinical Science</i> , 2021, 135, 1369-1387.	1.8	8
1148	Costs and healthcare utilisation of patients with chronic kidney disease in Spain. <i>BMC Health Services Research</i> , 2021, 21, 536.	0.9	12
1149	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. <i>Drugs</i> , 2021, 81, 1243-1255.	4.9	2
1151	Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 35-46.	1.0	4
1152	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.	3.0	26
1153	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. <i>Current Cardiology Reports</i> , 2021, 23, 75.	1.3	6
1154	Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 693-695.	0.7	6
1155	Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies. <i>JBMR Plus</i> , 2021, 5, e10522.	1.3	8
1157	The effects of antidiabetic agents on heart failure. <i>Netherlands Heart Journal</i> , 2022, 30, 65-75.	0.3	2
1158	Sodium – Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block. <i>Journal for Nurse Practitioners</i> , 2021, 17, 652-656.	0.4	2
1159	Using adjuvant pharmacotherapy in the treatment of type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2143-2148.	0.9	4
1160	Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 1-10.	0.6	6
1161	Recent advances in pharmacological treatment of heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13624.	1.7	19

#	ARTICLE	IF	CITATIONS
1162	Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 683281.	1.1	6
1164	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. <i>Heart</i> , 2021, 107, 1407-1416.	1.2	16
1165	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	6
1166	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. <i>Current Opinion in Cardiology</i> , 2021, 36, 672-681.	0.8	9
1167	Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3060-3067.	1.8	7
1168	The TIMI Study Group's Contributions to the Advancement of Cardiology -With Focus on Atherosclerotic Cardiovascular Disease-. <i>Journal of Atherosclerosis and Thrombosis</i> , 2021, 28, 563-572.	0.9	1
1169	Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials. <i>Diabetology International</i> , 2022, 13, 325-329.	0.7	2
1170	Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	20
1171	Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. <i>Scientific Reports</i> , 2021, 11, 12025.	1.6	23
1172	The real-life heart failure patient: importance of guideline-directed medical therapy. <i>Netherlands Heart Journal</i> , 2021, 29, 368-369.	0.3	0
1173	Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 690529.	1.1	9
1174	Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2021, 332, 119-126.	0.8	12
1175	Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors. <i>Journal of Korean Diabetes</i> , 2021, 22, 113-125.	0.1	0
1176	Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand. <i>Diabetes Therapy</i> , 2021, 12, 1947-1963.	1.2	5
1177	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5973.	1.8	20
1178	Patient-Reported Outcomes in Patients with Cardiomyopathy. <i>Current Cardiology Reports</i> , 2021, 23, 91.	1.3	3
1179	Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. <i>Heart</i> , 2022, 108, 312-320.	1.2	2
1180	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1164-1173.	2.3	51

#	ARTICLE	IF	CITATIONS
1181	Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells. <i>Cells</i> , 2021, 10, 1457.	1.8	60
1182	Hemodynamic arterial changes in heart failure: a proposed new paradigm of "heart and vessels failure". <i>Minerva Cardiology and Angiology</i> , 2022, 70, .	0.4	8
1183	Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK $\beta$ /TGF $\beta$ <sup>1</sup> /Smad signalling in type 2 diabetic rats. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7642-7659.	1.6	81
1184	Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. <i>Annales De Cardiologie Et D'Angeiologie</i> , 2022, 71, 41-52.	0.3	8
1185	Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. <i>Drugs</i> , 2021, 81, 1381-1395.	4.9	10
1186	Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 724405.	1.6	10
1187	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , 2021, 20, 159.	2.7	15
1188	Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis. <i>Advances in Therapy</i> , 2021, 38, 4195-4214.	1.3	3
1189	Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial $\beta$ 1AMPK. <i>Scientific Reports</i> , 2021, 11, 13700.	1.6	10
1190	Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease. <i>Diabetes and Metabolism</i> , 2022, 48, 101265.	1.4	3
1191	Review of the top 5 cardiology studies of 2019-20. <i>Canadian Pharmacists Journal</i> , 2021, 154, 388-393.	0.4	0
1192	Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure. <i>International Heart Journal</i> , 2021, 62, 885-890.	0.5	7
1193	Bexagliflozin for type 2 diabetes: an overview of the data. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2095-2103.	0.9	9
1194	Dapagliflozin for the treatment of type 2 diabetes mellitus – an update. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2303-2310.	0.9	8
1195	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
1196	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1447-1455.	0.7	14
1197	Cardioprotection by SGLT2 Inhibitors – Does It All Come Down to Na <sup>+</sup> ?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7976.	1.8	39
1198	Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. <i>Metabolism: Clinical and Experimental</i> , 2021, 120, 154799.	1.5	32



#	ARTICLE	IF	CITATIONS
1199	Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1253-1267.	1.3	8
1200	Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: A systematic review and network meta-analysis of randomized clinical trials. <i>Pharmacological Research</i> , 2021, 169, 105573.	3.1	22
1201	SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot. <i>Journal of the American Heart Association</i> , 2021, 10, e021949.	1.6	10
1203	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
1204	Heart failure with preserved ejection fraction based on aging and comorbidities. <i>Journal of Translational Medicine</i> , 2021, 19, 291.	1.8	14
1205	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2020. <i>American Journal of Medicine</i> , 2021, 134, 854-859.	0.6	1
1206	New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries) <i>TJ ETQq0 0 0 rgBT/Overlock_10 Tf 50 5</i>	0.7	5
1207	Cardiovascular Safety and Superiority of Anti-Obesity Medications. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 3199-3208.	1.1	7
1208	Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3057-3069.	2.0	11
1209	Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. <i>Heart Rhythm</i> , 2021, 18, 1098-1105.	0.3	103
1210	Imaging of Cardiac Transplantation: An Overview. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 335-348.	2.5	5
1211	Clinical inertia and medical therapy for heart failure: the unintended harms of "first, do no harm"™. <i>European Journal of Heart Failure</i> , 2021, 23, 1343-1345.	2.9	19
1212	Successful glucose lowering therapy triumphs in heart failure. <i>EClinicalMedicine</i> , 2021, 37, 100996.	3.2	1
1213	Polypharmacy definition and prevalence in heart failure: a systematic review. <i>Heart Failure Reviews</i> , 2022, 27, 465-492.	1.7	44
1214	Diabetes and Risk of Sudden Death in Coronary Artery Disease Patients Without Severe Systolic Dysfunction. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1604-1614.	1.3	4
1215	Osteopontin in Cardiovascular Diseases. <i>Biomolecules</i> , 2021, 11, 1047.	1.8	36
1216	Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 691907.	1.1	26
1217	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. <i>Current Heart Failure Reports</i> , 2021, 18, 284-289.	1.3	10

#	ARTICLE	IF	CITATIONS
1218	Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 311-321.	1.4	25
1219	Out-of-Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States. <i>Journal of the American Heart Association</i> , 2021, 10, e022164.	1.6	27
1220	Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOts. <i>American Journal of Cardiovascular Drugs</i> , 2021, , 1.	1.0	7
1221	Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4327-e4339.	1.8	5
1222	Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7170.	1.8	9
1223	Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. <i>Antioxidants</i> , 2021, 10, 1166.	2.2	37
1224	Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , 2021, 23, 1250-1255.	2.9	17
1225	Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial – a new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial. <i>Russian Journal of Cardiology</i> , 2021, 26, 4562.	0.4	3
1226	Chegou a Hora de uma Nova Terapia Padrão para a Insuficiência Cardíaca com Fração de Ejeção Reduzida?. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 149-152.	0.3	0
1227	Optimizer Smart System for the treatment of chronic heart failure: Overview of its safety and efficacy. <i>Expert Review of Medical Devices</i> , 2021, 18, 505-512.	1.4	0
1228	Extrapolating Survival From Randomized Clinical Trial Data – Possibilities and Caution. <i>JAMA Cardiology</i> , 2021, 6, 1305.	3.0	2
1229	Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 347.	0.7	4
1230	Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. <i>Life Sciences</i> , 2021, 276, 119440.	2.0	29
1232	Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. <i>Drugs</i> , 2021, 81, 1365-1371.	4.9	19
1233	Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure. <i>Antioxidants</i> , 2021, 10, 1190.	2.2	5
1234	Safety and Efficacy of the Combination of Sacubitril/Valsartan and SGLT2i in HFrEF Patients (SECSI) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	2
1235	Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 501-514.	0.8	9
1236	Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	2.9	36

#	ARTICLE	IF	CITATIONS
1237	Pharmacological secondary prevention of MI. <i>The Prescriber</i> , 2021, 32, 13-20.	0.1	0
1238	ADDITION of DAPAGliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Nepriylsin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial). <i>Indian Heart Journal</i> , 2021, 73, 605-611.	0.2	6
1239	Efficacy and safety of dapagliflozin in the treatment of chronic heart failure. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662)</i>	0.4	8
1240	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
1242	The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats. <i>Cardiovascular Diabetology</i> , 2021, 20, 132.	2.7	17
1243	Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e12-e19.	0.8	5
1244	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 836.	3.0	95
1245	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	2.9	36
1247	Which drug is best for a patient with type 2 diabetes and heart failure?. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2021, 34, 49-52.	0.1	0
1248	The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7774.	1.8	13
1249	The challenges of an aging tetralogy of Fallot population. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 581-593.	0.6	6
1250	Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 502-504.	1.8	1
1251	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2021, 4, e2114501.	2.8	49
1252	Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. <i>ESC Heart Failure</i> , 2021, 8, 4093-4118.	1.4	11
1253	Current Status of Pharmacologic and Nonpharmacologic Therapy in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2021, 17, 463-482.	1.0	4
1254	(Type 2 diabetes and heart failure - how to optimize cooperation of cardiologist and diabetologist). <i>Cor Et Vasa</i> , 2021, 63, 373-377.	0.1	2
1255	Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus. <i>International Heart Journal</i> , 2021, 62, 843-849.	0.5	2
1256	Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e020331.	1.6	13

#	ARTICLE	IF	CITATIONS
1257	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.3	5
1258	Omecamtiv Mecarbil. Journal of the American College of Cardiology, 2021, 78, 109-111.	1.2	2
1260	FDA approval of dapagliflozin for chronic kidney disease: a remarkable achievement?. Lancet, The, 2021, 398, 283-284.	6.3	16
1261	Effects of Sodium-glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice. Journal of the American Heart Association, 2021, 10, e019995.	1.6	39
1262	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	1.7	22
1263	Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?. , 2021, 70, E7-E9.		1
1264	Search for a Functional Genetic Variant Mimicking the Effect of SGLT2 Inhibitor Treatment. Genes, 2021, 12, 1174.	1.0	3
1265	Effects of canagliflozin on human myocardial redox signalling: clinical implications. European Heart Journal, 2021, 42, 4947-4960.	1.0	57
1266	Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials. Medicine (United States), 2021, 100, e26561.	0.4	1
1267	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276.	6.3	222
1268	A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro. Frontiers in Pharmacology, 2021, 12, 708177.	1.6	25
1269	SGLT2 inhibitors. Nurse Practitioner, 2021, 46, 30-37.	0.2	4
1270	Findings from the EMPEROR-Reduced study are a tool to improve care for patients with chronic heart failure with reduced ejection fraction.Resolution of the Regional Scientific Meeting of Experts of the Southern Federal District. Āno-Rossiĳskij Āurnal TerapevtiĀeskoĳ Praktiki, 2021, 2, 104-110.	0.1	1
1271	Inotropic therapies in heart failure and cardiogenic shock: an educational review. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 676-686.	0.4	13
1272	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	9
1274	Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences, 2021, , .	0.0	0
1275	Shared Care to Destination Therapy Left Ventricular Assist Device Site: a Novel Strategy to Start a Successful Mechanical Circulatory Support Program. Current Cardiology Reports, 2021, 23, 112.	1.3	2
1276	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 2352-2361.	3.0	88

#	ARTICLE	IF	CITATIONS
1277	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2320-2328.	2.2	12
1278	Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?. <i>Frontiers in Medicine</i> , 2021, 8, 712671.	1.2	11
1279	Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Heart Failure. <i>ADCES in Practice</i> , 0, , 2633559X2110344.	0.2	0
1280	Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial. <i>ESC Heart Failure</i> , 2021, 8, 4346-4352.	1.4	15
1281	Management of Obesity in Cardiovascular Practice. <i>Journal of the American College of Cardiology</i> , 2021, 78, 513-531.	1.2	36
1282	Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients. <i>Heart Failure Reviews</i> , 2023, 28, 733-744.	1.7	19
1283	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2021, 181, 1043.	2.6	32
1284	Reasons for hospitalizations in patients with type 2 diabetes in the <scp>CANVAS</scp> programme: A secondary analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2707-2715.	2.2	6
1285	Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease. <i>Acta Clinica Belgica</i> , 2021, , 1-10.	0.5	2
1286	Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	9
1287	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	1.8	23
1288	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
1289	Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. <i>Cardiovascular Diabetology</i> , 2021, 20, 169.	2.7	17
1290	How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110397.	0.5	0
1291	Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis. <i>Cells</i> , 2021, 10, 2150.	1.8	32
1292	SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1091-1108.	1.3	2
1293	Vericiguat for Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2021, 23, 144.	1.3	19
1294	Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8786.	1.8	48

#	ARTICLE	IF	CITATIONS
1295	Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2021, 34, 243-247.	0.4	1
1296	Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first-line oral therapy for type 2 diabetes: A claims-based observational cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2741-2751.	2.2	4
1297	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-13.	0.9	2
1298	Prospective association of serum adipocyte fatty acid-binding protein with heart failure hospitalization in diabetes. <i>ESC Heart Failure</i> , 2021, 8, 3964-3974.	1.4	2
1299	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. <i>Europace</i> , 2021, 23, 1873-1891.	0.7	10
1300	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	13.9	599
1301	Direct cardiac effects and mechanisms of cardiovascular action of gliflosins. <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2021, 19, 131-143.	0.2	0
1302	Association between prediabetes and adverse outcomes in heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2476-2483.	2.2	54
1304	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 975-983.	0.2	6
1305	New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. <i>Cardiology Clinics</i> , 2021, 39, 335-351.	0.9	10
1306	Contemporary etiology and prognosis of dilated non-ischemic cardiomyopathy. <i>Minerva Cardiology and Angiology</i> , 2021, , .	0.4	5
1307	Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 926.	3.0	65
1308	Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature. <i>Cardiology Research</i> , 2021, 12, 210-218.	0.5	7
1309	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
1310	Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. <i>Journal of Clinical Medicine</i> , 2021, 10, 3540.	1.0	6
1311	The Risk of Bladder Cancer in Type 2 Diabetes Mellitus with Combination Therapy of SGLT-2 Inhibitors and Pioglitazone. <i>Journal of Personalized Medicine</i> , 2021, 11, 828.	1.1	3
1312	Cardio-Oncology. <i>JACC Basic To Translational Science</i> , 2021, 6, 705-718.	1.9	21
1313	ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. <i>European Heart Journal Supplements</i> , 2021, 23, C184-C195.	0.0	5

#	ARTICLE	IF	CITATIONS
1314	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2632-2642.	2.2	30
1315	Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage. <i>European Heart Journal</i> , 2021, 42, 4961-4963.	1.0	6
1316	Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure. <i>European Heart Journal</i> , 2021, 42, 3739-3740.	1.0	16
1317	A Sweet Dream with SGLT2 Inhibitors. <i>Turkish Journal of Diabetes and Obesity</i> , 2021, 5, 237-240.	0.0	0
1318	Promoting analysis of real-world data: Prospects for preventive cardiology in Japan. <i>Global Health &amp; Medicine</i> , 2021, 3, 203-213.	0.6	0
1319	What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?. <i>Clinical Oncology</i> , 2021, 33, 483-493.	0.6	5
1320	Effect of Luseogliflozin on liver function, BNP and baPWV in diabetics with coronary artery disease. <i>Vascular Failure</i> , 2021, 4, 68-75.	0.2	0
1321	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2814-2818.	2.2	38
1322	Cardiovascular disease in diabetes, beyond glucose. <i>Cell Metabolism</i> , 2021, 33, 1519-1545.	7.2	87
1323	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895.	0.7	14
1324	What Is the Status of Regenerative Therapy in Heart Failure?. <i>Current Cardiology Reports</i> , 2021, 23, 146.	1.3	4
1325	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21
1326	New Drugs for Heart Failure: What is the Evidence in Older Patients?. <i>Journal of Cardiac Failure</i> , 2022, 28, 316-329.	0.7	1
1327	SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 1-4.	1.0	3
1329	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	1.0	125
1330	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. <i>Transplantation</i> , 2022, 106, 734-748.	0.5	6
1332	Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors. <i>Internal Medicine</i> , 2021, 60, 2367-2374.	0.3	4
1333	SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction – A Win against a Formidable Foe. <i>New England Journal of Medicine</i> , 2021, 385, 1522-1524.	13.9	14

#	ARTICLE	IF	CITATIONS
1334	Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2022, 20, 90-102.	0.4	3
1335	Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper. <i>Journal of Clinical Medicine</i> , 2021, 10, 3519.	1.0	6
1336	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. <i>Diabetes Spectrum</i> , 2021, 34, 248-256.	0.4	1
1338	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. <i>CJC Open</i> , 2021, 3, 1482-1489.	0.7	9
1341	Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, .	1.1	1
1342	Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 69, 102035.	1.1	9
1343	Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2021, 21, 1-6.	0.2	4
1344	Heart, kidney and left ventricular assist device: a complex trio. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13662.	1.7	3
1345	Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. <i>Diabetes Spectrum</i> , 2021, 34, 235-242.	0.4	0
1346	Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. <i>Diabetes Spectrum</i> , 2021, 34, 225-234.	0.4	1
1347	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
1348	Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes. <i>Circulation Reports</i> , 2021, 3, 440-448.	0.4	18
1349	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. <i>European Journal of Internal Medicine</i> , 2021, 90, 10-15.	1.0	6
1350	Closing the Glycemic Divide. <i>Journal of the American College of Cardiology</i> , 2021, 78, 465-467.	1.2	0
1351	The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 823-830.	0.9	9
1352	Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 497-504.	1.3	8
1353	The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis. <i>Cardiology Research and Practice</i> , 2021, 2021, 1-11.	0.5	22
1354	Treatment of type 2 diabetes in children: what are the specific considerations?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-15.	0.9	5



#	ARTICLE	IF	CITATIONS
1355	Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. <i>Diabetes Care</i> , 2021, 44, 2293-2301.	4.3	23
1356	Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria. <i>ESC Heart Failure</i> , 2021, 8, 3656-3662.	1.4	4
1357	Primary and Secondary Outcome Reporting in Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2021, 78, 827-839.	1.2	28
1358	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.	1.9	49
1359	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. <i>Current Heart Failure Reports</i> , 2021, 18, 253-263.	1.3	6
1360	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	0.8	220
1362	Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data. <i>European Journal of Pharmacology</i> , 2021, 907, 174320.	1.7	4
1363	Cost-utility analysis of dapagliflozin in heart failure with reduced ejection fraction in the Philippines. <i>ESC Heart Failure</i> , 2021, 8, 5132-5141.	1.4	12
1364	Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. <i>Revista Clínica Española</i> , 2022, 222, 195-204.	0.3	6
1365	The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 593-600.	1.0	12
1366	SGLT2 Inhibitors: Physiology and Pharmacology. <i>Kidney360</i> , 2021, 2, 2027-2037.	0.9	50
1367	Understanding the pharmacology of heart failure. <i>Practice Nursing</i> , 2021, 32, 363-368.	0.1	0
1368	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , 2022, 24, 529-538.	2.9	7
1369	Do background ischemic heart disease and baseline left ventricular ejection fraction affect cardiovascular efficacy of SGLT-2 inhibitors in heart failure with reduced ejection fraction?. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, e30-e32.	0.6	0
1370	Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. <i>Biomedicines</i> , 2021, 9, 1356.	1.4	45
1371	Dapagliflozin in patients with COVID-19: truth or dare. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 550-551.	5.5	3
1372	Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 457-474.	1.2	1
1373	Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108057.	1.2	1

#	ARTICLE	IF	CITATIONS
1374	Are post-hoc analyses on subgroups sufficient to support new treatment algorithms of heart failure? The case of SGLT2 inhibitors associated with sacubitril/valsartan. <i>Cardiology</i> , 2021, , .	0.6	2
1375	The sodium-glucose cotransporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. <i>European Journal of Heart Failure</i> , 2021, 23, 1673-1676.	2.9	8
1376	Sodium glucose cotransporter 2 inhibitors: New horizon of the heart failure pharmacotherapy. <i>World Journal of Cardiology</i> , 2021, 13, 464-471.	0.5	3
1377	SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 687-693.	0.2	3
1379	Potential mechanisms underlying cardiovascular protection by sodium glucose cotransporter 2 inhibitors (empagliflozin). <i>Complex Issues of Cardiovascular Diseases</i> , 2021, 10, 79-89.	0.3	2
1380	Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction. <i>Angiology</i> , 2021, , 000331972110473.	0.8	10
1381	Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, Publish Ahead of Print, 577-583.	1.0	2
1382	Is There a Diabetes-Kidney-Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 716083.	1.1	1
1383	A Comparative Study of Safety Outcomes of Sodium Glucose Cotransporter-2 Inhibitors and Loop Diuretics Among Diabetic Patients Using Real-world Data. <i>Current Problems in Cardiology</i> , 2022, 47, 100995.	1.1	4
1384	A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. <i>American Journal of Medicine</i> , 2021, 134, 1076-1084.	0.6	3
1385	SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 687-693.	0.2	6
1386	Sodium-Glucose Cotransporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022222.	1.6	38
1387	Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2021, 8, 5327-5337.	1.4	14
1388	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1321-1332.	1.2	55
1389	Prognostic predictors and echocardiographic time course after device replacement in patients treated chronically with cardiac resynchronization therapy devices. <i>Heart and Vessels</i> , 2021, , 1.	0.5	1
1390	Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. <i>Atherosclerosis</i> , 2021, 333, 16-23.	0.4	19
1391	Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9800.	1.8	11
1392	Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments. <i>Hypertension</i> , 2021, 78, 564-577.	1.3	35

#	ARTICLE	IF	CITATIONS
1393	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	1.2	52
1394	Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. , 0, , .		4
1395	Prevention of Diabetes Macrovascular Complications and Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 415-430.	1.2	3
1396	Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload. <i>Frontiers in Physiology</i> , 2021, 12, 738594.	1.3	11
1397	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. <i>Lancet</i> , The, 2021, 398, 991-1001.	6.3	218
1398	2021: The American Association for Thoracic Surgery Expert Consensus Document: Coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 829-850.e1.	0.4	34
1400	Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. <i>Drugs</i> , 2021, 81, 1599-1604.	4.9	6
1401	Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. <i>Drugs - Real World Outcomes</i> , 2022, 9, 53-62.	0.7	5
1402	Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 1232-1242.	1.3	7
1403	Risk factors and prediction models for incident heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, , .	1.4	9
1404	Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age. <i>Future Cardiology</i> , 2021, 17, 1131-1142.	0.5	9
1405	The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108052.	1.2	7
1406	Ethnic Disparities in Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 475-490.	1.2	12
1407	Incremental Value of Global Longitudinal Strain in the Long-Term Prediction of Heart Failure among Patients with Coronary Artery Disease. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 187-195.	1.2	12
1408	Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4409.	1.0	5
1409	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	1.7	15
1410	Looking for a Tailored Therapy for Heart Failure: Are We Capable of Treating the Patient Instead of the Disease?. <i>Journal of Clinical Medicine</i> , 2021, 10, 4325.	1.0	3
1411	The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 757-770.	1.3	12

#	ARTICLE	IF	CITATIONS
1412	Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Annual Review of Pharmacology and Toxicology, 2022, 62, 109-120.	4.2	6
1413	A fourth pillar for all in the treatment of heart failure. European Heart Journal, 2021, 42, 4452-4454.	1.0	3
1414	Arterial hypertension â€œ Clinical trials update 2021. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 21-31.	1.1	42
1415	Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs â€œ A systematic review. Current Diabetes Reviews, 2021, 17, .	0.6	0
1416	A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors. Cureus, 2021, 13, e18300.	0.2	4
1417	2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes. JACC Asia, 2021, 1, 129-146.	0.5	1
1418	Myocarditis and Inflammatory Cardiomyopathy. , 0, , .		1
1419	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444.	0.7	60
1420	Ischemic mitral regurgitation. Current Opinion in Cardiology, 2021, Publish Ahead of Print, 755-763.	0.8	0
1421	Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors. Diabetes Mellitus, 2021, 24, 291-299.	0.5	0
1422	Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology, the, 2021, 9, 586-594.	5.5	145
1423	Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload. Scientific Reports, 2021, 11, 18384.	1.6	18
1425	Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 180.	2.7	13
1426	External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease. Cardiovascular Diabetology, 2021, 20, 181.	2.7	0
1427	Effects of SGLT2 Inhibitors beyond Glycemic Controlâ€œFocus on Myocardial SGLT1. International Journal of Molecular Sciences, 2021, 22, 9852.	1.8	9
1428	Importance of Optimized Guideline-Based Therapy for Preventing Rehospitalization of Chronic Heart Failure Patientsâ€œ From the KUNIUMI Acute Cohort â€œ. Circulation Reports, 2021, 3, 511-519.	0.4	0
1429	Assessment of Physical Activity Using Waist-Worn Accelerometers in Hospitalized Heart Failure Patients and Its Relationship with Kansas City Cardiomyopathy Questionnaire. Journal of Clinical Medicine, 2021, 10, 4103.	1.0	1
1430	Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. American Journal of Medicine, 2021, 134, 1068-1070.	0.6	14

#	ARTICLE	IF	CITATIONS
1431	Sodium glucose co-transporter-2 inhibitor-induced diabetic ketoacidosis following tooth extraction: improving awareness among dental practitioners. <i>Australian Dental Journal</i> , 2021, 66, 444-447.	0.6	1
1432	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2022, 19, 100-116.	6.1	156
1434	Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108046.	1.2	1
1435	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. <i>Circulation Journal</i> , 2021, 85, 2252-2291.	0.7	80
1436	Drug Compatibility in Treatment of Chronic Infectious Diseases. <i>Russian Archives of Internal Medicine</i> , 2021, 11, 344-358.	0.0	0
1437	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. <i>International Journal of Cardiology</i> , 2021, 338, 248-257.	0.8	1
1438	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 746382.	1.1	23
1439	Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4497.	1.0	10
1440	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1528-1541.	2.0	52
1441	The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. <i>Diabetes and Metabolism</i> , 2021, 47, 101285.	1.4	18
1442	The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. <i>British Journal of Diabetes</i> , 0, , .	0.1	1
1443	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. <i>Current Vascular Pharmacology</i> , 2021, 19, 487-498.	0.8	1
1444	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 428-439.	1.5	22
1445	The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. <i>Diabetologia</i> , 2021, 64, 2676-2686.	2.9	44
1446	Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications. , 2021, , 107975.		16
1447	SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?. <i>Current Heart Failure Reports</i> , 2021, 18, 315-328.	1.3	43
1448	The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors. <i>Current Opinion in Cardiology</i> , 2021, Publish Ahead of Print, 764-768.	0.8	6
1449	SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. <i>Pharmacological Research</i> , 2021, 172, 105836.	3.1	26

#	ARTICLE	IF	CITATIONS
1450	Improving Quality of Life in Heart Failure. <i>Current Cardiology Reports</i> , 2021, 23, 159.	1.3	22
1451	Pathophysiology of Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 519-531.	1.0	9
1452	Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases. <i>Medicine (United States)</i> , 2021, 100, e27362.	0.4	7
1453	Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109036.	1.1	13
1454	Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress. <i>Biochemical and Biophysical Research Communications</i> , 2021, 572, 185-190.	1.0	38
1455	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. <i>American Heart Journal</i> , 2021, 240, 73-80.	1.2	1
1456	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. <i>Clinical Immunology</i> , 2021, 231, 108804.	1.4	5
1457	The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. <i>Current Cardiology Reports</i> , 2021, 23, 163.	1.3	6
1458	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021, 17, e618-e630.	1.4	3
1459	Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154838.	1.5	84
1460	Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors. <i>Cardiology Research</i> , 2021, 12, 324-326.	0.5	2
1461	RNA interference therapeutics for cardiac regeneration. <i>Current Opinion in Genetics and Development</i> , 2021, 70, 48-53.	1.5	5
1462	Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-nepriylsin inhibitor: An updated meta-analysis. <i>Annals of Medicine and Surgery</i> , 2021, 70, 102796.	0.5	1
1463	Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021, 341, 56-59.	0.8	13
1464	Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts. <i>Biochemical Pharmacology</i> , 2021, 192, 114674.	2.0	20
1465	Disease-modifier Drugs in Patients with Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 561-573.	1.0	2
1466	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112169.	2.5	22
1467	Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102282.	1.8	1

#	ARTICLE	IF	CITATIONS
1468	Multi-Spectroscopic, thermodynamic and molecular dynamic simulation studies for investigation of interaction of dapagliflozin with bovine serum albumin. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2022, 264, 120298.	2.0	37
1469	Group 2 Pulmonary Hypertension: Clinical Features and Treatment. , 2022, , 665-677.		0
1470	Significance of Glycemic Variability in Diabetes Mellitus. <i>Internal Medicine</i> , 2022, 61, 281-290.	0.3	10
1471	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. <i>Scientific Reports</i> , 2021, 11, 732.	1.6	14
1472	The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease. <i>Complex Psychiatry</i> , 2021, 1, 21-33.	1.3	11
1473	Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic. <i>European Journal of Heart Failure</i> , 2021, 23, 79-82.	2.9	10
1474	Ambient Temperature and Cardiorenal Connection in Elderly Patients with Stable Heart Failure. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 254, 81-87.	0.5	0
1476	Cardiac Myosin Activation for the Treatment of Systolic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 4-10.	0.8	5
1477	Should metformin remain the first-line therapy for treatment of type 2 diabetes?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882098022.	1.4	58
1478	Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. <i>Cardiovascular Diabetology</i> , 2021, 20, 13.	2.7	46
1479	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. <i>Cardiovascular Diabetology</i> , 2021, 20, 6.	2.7	42
1480	Glucose-dependent diuresis in relation to improvements in renal-tubular markers of sodium-glucose cotransporter-2 inhibitors in hospitalized heart failure patients with diabetes. <i>Heart and Vessels</i> , 2021, 36, 978-985.	0.5	3
1481	Diamonds in the Rough. <i>Circulation</i> , 2021, 143, 350-353.	1.6	0
1482	AtualizaÃ§Ã£o de TÃ³picos Emergentes da Diretriz Brasileira de InsuficiÃªncia CardÃaca â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 1174-1212.	0.3	13
1483	Positive Inotropic Drugs for Treating Heart Failure. , 2021, , .		0
1484	SelecciÃ³n de lo mejor del aÃ±o 2020 en insuficiencia cardiaca. <i>REC: CardioClinics</i> , 2021, 56, 66-71.	0.1	0
1485	Â¿Son los inhibidores del receptor SGLT2 fÃ¡rmacos antidiabÃ©ticos o cardiovasculares?. <i>ClÃnica E InvestigaciÃ³n En Arteriosclerosis</i> , 2021, 33, 33-40.	0.4	2
1486	Hipoglucemiantes y riesgo cardiovascular. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2021, 28, 4-13.	0.0	0

#	ARTICLE	IF	CITATIONS
1487	SGLT2 Inhibitors: the Gift that Keeps on Giving. Korean Circulation Journal, 2021, 51, 263.	0.7	0
1489	SCORED and SOLOIST: the next scores for SGLT2 inhibitors. Cardiovascular Research, 2021, 117, e49-e51.	1.8	0
1490	Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?. International Journal of Heart Failure, 2021, 3, 106.	0.9	3
1491	Targeting the Vascular Endothelium in the Treatment of COVID-19. Journal of Cardiovascular Pharmacology, 2021, 77, 1-3.	0.8	4
1492	Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants. Advances in Therapy, 2021, 38, 1352-1363.	1.3	9
1493	Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2020, 11, 604250.	1.5	9
1494	Heart failure drug treatment: the fantastic four. European Heart Journal, 2021, 42, 681-683.	1.0	131
1495	Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state. Archives of Medical Sciences Atherosclerotic Diseases, 2021, 6, 57-78.	0.5	11
1496	The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction. Therapeutic Advances in Cardiovascular Disease, 2021, 15, 175394472110026.	1.0	10
1497	Sodium-glucose Cotransporter 2 Inhibitors™ Rise to the Backbone of Heart Failure Management: A Clinical Review. Heart International, 2021, 15, 42.	0.4	0
1498	Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention. Current Atherosclerosis Reports, 2021, 23, 4.	2.0	5
1499	Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment. Korean Circulation Journal, 2021, 51, 399.	0.7	9
1500	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	3.9	102
1501	Using Patient-Reported Outcomes to Assess Healthcare Quality: Toward Better Measurement of Patient-Centered Care in Cardiovascular Disease. Methodist DeBakey Cardiovascular Journal, 2021, 17, 1.	0.5	5
1502	Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure. Clinical Pharmacology and Therapeutics, 2021, 110, 149-158.	2.3	11
1503	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure, 2020, 7, 3298-3309.	1.4	76
1504	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	1.7	3
1505	Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis. Clinical Drug Investigation, 2020, 40, 665-669.	1.1	5



#	ARTICLE	IF	CITATIONS
1506	A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?. <i>International Review of Neurobiology</i> , 2020, 155, 113-140.	0.9	27
1507	Myocardial Ketones Metabolism in Heart Failure. <i>Journal of Cardiac Failure</i> , 2020, 26, 998-1005.	0.7	36
1508	Heart failure: From novel pharmaceutical therapies to circulation support systems. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 359-361.	0.4	2
1509	Diabetes Mellitus. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 559-561.	1.3	2
1510	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480.	1.9	47
1511	Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy. , 2020, 213, 107584.		22
1512	Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. <i>Pharmacological Research</i> , 2020, 158, 104870.	3.1	113
1513	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , 2020, 396, 121-128.	6.3	376
1514	Assessing the lifetime benefit of heart failure therapies. <i>Lancet, The</i> , 2020, 396, 75-77.	6.3	2
1515	Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. <i>Scientific Reports</i> , 2020, 10, 22396.	1.6	29
1517	Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 85-93.	1.9	12
1518	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
1519	EMPEROR-REDUCED reigns while EMPERIAL whimpers. <i>European Heart Journal</i> , 2021, 42, 711-714.	1.0	8
1520	Sinergy between drugs and devices in the fight against sudden cardiac death and heart failure. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 110-123.	0.8	20
1521	Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 69-75.	0.8	19
1522	Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i48-i55.	0.4	18
1523	Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i33-i42.	0.4	43
1524	Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, i43-i47.	0.4	9

#	ARTICLE	IF	CITATIONS
1525	The Role of Testosterone in Patients With Heart Failure: A Systematic Review. <i>Cardiology in Review</i> , 2021, 29, 156-161.	0.6	6
1526	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. <i>Journal of Hypertension</i> , 2021, 39, 749-758.	0.3	38
1527	Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?. <i>American Journal of Therapeutics</i> , 2021, 28, e96-e110.	0.5	2
1528	How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.5	8
1529	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001238.	1.2	43
1530	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 506-522.	1.1	39
1531	Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions. <i>Circulation: Heart Failure</i> , 2020, 13, e007094.	1.6	22
1532	Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882097044.	1.4	26
1533	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes: A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society. <i>Circulation Journal</i> , 2020, 85, 82-125.	0.7	16
1534	Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension. <i>Medical Science Monitor</i> , 2020, 26, e925987.	0.5	5
1535	Recent advances in the treatment of chronic heart failure. <i>F1000Research</i> , 2019, 8, 2134.	0.8	7
1536	Systematic examination of a heart failure risk prediction tool: The pooled cohort equations to prevent heart failure. <i>PLoS ONE</i> , 2020, 15, e0240567.	1.1	4
1537	Course and treatment of diabetes mellitus in the context of COVID-19. <i>Diabetes Mellitus</i> , 2020, 23, 132-139.	0.5	8
1538	Diabetes mellitus type 2 in adults. <i>Diabetes Mellitus</i> , 2020, 23, 4-102.	0.5	16
1539	Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. <i>Cardiac Failure Review</i> , 2020, 6, e28.	1.2	7
1540	Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice. <i>Cardiac Failure Review</i> , 2020, 6, e31.	1.2	17
1541	Asymptomatic Left Ventricle Systolic Dysfunction. <i>European Cardiology Review</i> , 2020, 15, e13.	0.7	20
1542	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	229

#	ARTICLE	IF	CITATIONS
1543	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	32
1544	Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 467-477.	0.4	3
1545	Cardiorenal Syndrome in Type 2 Diabetes Mellitus – Rational Use of Sodium–glucose Cotransporter-2 Inhibitors. European Endocrinology, 2020, 16, 113.	0.8	8
1546	Management of heart failure with preserved ejection fraction. Australian Prescriber, 2020, 43, 12-17.	0.5	6
1547	Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome Trials. Current Diabetes Reviews, 2020, 16, 917-921.	0.6	2
1548	Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?. Current Diabetes Reviews, 2020, 17, e122820189511.	0.6	3
1549	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. Current Hypertension Reviews, 2021, 17, 94-111.	0.5	9
1550	Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 70-78.	2.2	54
1551	Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1433-1444.	2.2	40
1553	SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Diabetes, 2021, 70, 800-808.	0.3	32
1554	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	4.3	50
1555	The Treatment of Heart Failure with Reduced Ejection Fraction. Deutsches A&#x0308;rztblatt International, 2020, 117, 376-386.	0.6	37
1556	Small and Intermediate Calcium Activated Potassium Channels in the Heart: Role and Strategies in the Treatment of Cardiovascular Diseases. Frontiers in Physiology, 2020, 11, 590534.	1.3	14
1557	Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 2021, 11, 22.	1.3	72
1558	Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules, 2020, 25, 495.	1.7	17
1559	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. Cardiovascular Prevention and Pharmacotherapy, 2020, 2, 113.	0.0	12
1560	Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease. , 2020, 2, 17-25.		4
1561	Paradigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?. International Journal of Heart Failure, 2020, 2, 145.	0.9	20

#	ARTICLE	IF	CITATIONS
1562	The Role of Arterial Stiffness and Central Hemodynamics in Heart Failure. <i>International Journal of Heart Failure</i> , 2020, 2, 209.	0.9	15
1563	Heart failure with preserved ejection fraction: insights from recent clinical researches. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 514-534.	0.7	10
1565	Current status of heart failure: global and Korea. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 487-497.	0.7	27
1566	Mitochondrial Mechanisms in Diabetic Cardiomyopathy. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 33.	1.8	62
1567	Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. <i>World Journal of Diabetes</i> , 2020, 11, 150-154.	1.3	1
1568	Sodium-glucose cotransporter 2 inhibitors's mechanisms of action in heart failure. <i>World Journal of Diabetes</i> , 2020, 11, 269-279.	1.3	19
1569	Range of adiposity and cardiorenal syndrome. <i>World Journal of Diabetes</i> , 2020, 11, 322-350.	1.3	13
1570	Familial Dilated Cardiomyopathy: Risk Stratification for Sudden Cardiac Death. , 0, , .		1
1571	DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. <i>Drugs in Context</i> , 2020, 9, 1-7.	1.0	20
1572	Management of type 2 diabetes: consensus of diabetes organizations. <i>Drugs in Context</i> , 2020, 9, 1-25.	1.0	19
1573	SGLT2 inhibitors: the statins of the 21st century. <i>European Heart Journal</i> , 2022, 43, 1029-1030.	1.0	45
1574	Puesta al día sobre el empleo de dapagliflozina en insuficiencia cardiaca con fracción de eyección reducida. <i>Revista Espanola De Cardiologia Suplementos</i> , 2021, 21, 1-9.	0.2	0
1575	Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1961-1973.	0.8	37
1576	Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1680.	1.8	17
1577	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154918.	1.5	42
1578	Understanding the pharmacology of heart failure. <i>Journal of Prescribing Practice</i> , 2021, 3, 404-410.	0.1	0
1579	Diabetes Mellitus in Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 503-508.	0.7	3
1580	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. <i>European Cardiology Review</i> , 2021, 16, e40.	0.7	9

#	ARTICLE	IF	CITATIONS
1581	Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds" Approach?. <i>Current Cardiology Reports</i> , 2021, 23, 171.	1.3	2
1582	Diabetic Kidney Disease. , 2022, , 87-102.		0
1583	Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. <i>Pharmacoeconomics</i> , 2021, 39, 1343-1354.	1.7	20
1584	The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. <i>Cells</i> , 2021, 10, 2699.	1.8	7
1585	Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use. <i>Clinical Endocrinology</i> , 2021, , .	1.2	1
1586	Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<sc>AMULET</sc> study): a randomised controlled trial. <i>European Journal of Heart Failure</i> , 2022, 24, 565-577.	2.9	23
1587	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008072.	0.9	2
1588	Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (<sc>DapaTAVI</sc>) randomized trial. <i>European Journal of Heart Failure</i> , 2022, 24, 581-588.	2.9	13
1589	The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study. <i>Cardiology and Therapy</i> , 2021, 10, 561-568.	1.1	6
1590	Effects of dapagliflozin on peripheral sympathetic nerve activity in standard chow- and high-fat-fed rats after a glucose load. <i>Journal of Pharmacological Sciences</i> , 2022, 148, 86-92.	1.1	2
1591	Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress. <i>Current Atherosclerosis Reports</i> , 2021, 23, 76.	2.0	4
1592	A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond. <i>Journal of Osteopathic Medicine</i> , 2021, 122, 55-63.	0.4	2
1593	Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 655-663.	0.7	7
1594	The role of hyperglycaemia in the development of diabetic cardiomyopathy. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 748-760.	0.7	24
1595	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA&REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	1.4	46
1596	Nitric oxide "soluble guanylate cyclase" cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 3035.	0.4	2
1597	Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 383-390.	1.8	9
1598	SGLT2 inhibitors in heart failure with reduced ejection fraction. <i>Egyptian Heart Journal</i> , 2021, 73, 93.	0.4	8

#	ARTICLE	IF	CITATIONS
1599	GLP-1 receptor agonists vs. SGLT-2 inhibitors:Âthe gap seems to be leveling off. Cardiovascular Diabetology, 2021, 20, 205.	2.7	18
1600	Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. International Journal of Molecular Sciences, 2021, 22, 10822.	1.8	66
1601	Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction. Circulation Journal, 2023, 87, 1039-1046.	0.7	6
1602	Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Failure Reviews, 2023, 28, 709-721.	1.7	14
1603	Dapagliflozin Versus Sacubitrilâ€Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American Journal of Cardiovascular Drugs, 2022, 22, 325-331.	1.0	4
1604	SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failureâ€further evidence for improved hemodynamics by continuous pressure monitoring. Clinical Research in Cardiology, 2021, 111, 469.	1.5	1
1605	Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 2021, 12, 664533.	1.5	6
1606	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Diseaseâ€From Bench to Bedside. Frontiers in Physiology, 2021, 12, 755060.	1.3	13
1607	Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. Journal of Endocrinological Investigation, 2022, 45, 489-495.	1.8	17
1609	Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death. Cardiovascular Diabetology, 2021, 20, 199.	2.7	38
1611	Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. American Journal of Cardiovascular Drugs, 2021, 21, 701-710.	1.0	9
1612	Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: A systematic review and meta-analysis. International Journal of Cardiology, 2021, 345, 83-88.	0.8	8
1613	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. International Journal of Cardiovascular Imaging, 2021, , 1.	0.7	6
1615	Sodiumâ€glucose coâ€transporterâ€2 inhibitors in the nonâ€diabetic heart failure patient. British Journal of Clinical Pharmacology, 2021, , .	1.1	0
1616	Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes. European Heart Journal Supplements, 2021, 23, E40-E44.	0.0	8
1617	The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?. , 2022, 232, 108008.		19
1618	Trends in inpatient admissions and emergency department visits for heart failure in adults with versus without diabetes in the USA, 2006â€2017. BMJ Open Diabetes Research and Care, 2021, 9, e002377.	1.2	2
1619	Mineralocorticoid receptor antagonists in diabetic kidney disease â€ mechanistic and therapeutic effects. Nature Reviews Nephrology, 2022, 18, 56-70.	4.1	87

#	ARTICLE	IF	CITATIONS
1620	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	1.5	28
1622	Medication Optimization for New Initiators of Empagliflozin for Diabetic Kidney Disease. Clinical Diabetes, 2022, 40, 158-167.	1.2	1
1623	<i>JAK2</i> wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood, 2021, 138, 2886-2889.	0.6	12
1624	EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction. Global Cardiology Science & Practice, 2021, 2021, e202117.	0.3	8
1625	Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart, 2021, 8, e001704.	0.9	3
1626	Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Research and Clinical Practice, 2022, 183, 109080.	1.1	12
1627	One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. British Journal of Clinical Pharmacology, 2022, 88, 1598-1612.	1.1	4
1628	SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Failure, 2021, 8, 4693-4700.	1.4	45
1629	Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region. Cardiovascular Diabetology, 2021, 20, 204.	2.7	13
1630	Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis. International Urology and Nephrology, 2021, , 1.	0.6	1
1631	Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 778284.	1.1	2
1632	Treating the Chronic Disease of Obesity. Medical Clinics of North America, 2021, 105, 983-1016.	1.1	15
1633	Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine, 2021, 41, 101163.	3.2	33
1634	Drug Layering in Heart Failure. JACC: Heart Failure, 2021, 9, 775-783.	1.9	32
1636	Chronic Heart Failure. , 2017, , .		0
1638	An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?. Diabetes and Metabolism Journal, 2019, 43, 578.	1.8	0
1640	Novel Design and Evaluation of an Automatic and Portable Phototherapy Device Using for Newborn Jaundice Treatment. Recent Research in Endocrinology and Metabolic Disorder, 2019, 1, 22-31.	0.0	1
1641	New Trends in Heart Disease Treatment: Arrhythmia and Heart Failure. The Japanese Journal of Rehabilitation Medicine, 2019, 56, 968-978.	0.0	0

#	ARTICLE	IF	CITATIONS
1642	Pathology and Treatment of Cardiac Insufficiency Due to Diabetes Mellitus. Journal of the Japanese Association of Rural Medicine, 2020, 68, 687.	0.0	0
1643	The management of worsening heart failure. South African General Practitioner, 2020, 1, 65-68.	0.0	0
1645	Review of the evidence base of representatives of the group of sodium-glucose co-transporter 2 inhibitors available at the Ukrainian market (literature review). МАНародний Ендокринологічний Журнал, 2020, 16, 237-244.	0.1	1
1646	MANAGEMENT OF HEART FAILURE PATIENTS (UPDATE 2019) â€“ PHARMACOLOGICAL THERAPY. In A Good Rythm, 2020, 1, 30-32.	0.0	0
1647	Infusiones ambulatorias de levosimendán: Eficaces y eficientes en la insuficiencia cardiaca avanzada?. Revista Espanola De Cardiologia, 2020, 73, 345-347.	0.6	1
1648	Old and New Drugs for Treatment of Advanced Heart Failure. Current Pharmaceutical Design, 2020, 26, 1571-1583.	0.9	2
1650	Profil de tolérance des inhibiteurs de SGLT2: le point en 2020. Medecine Des Maladies Metaboliques, 2020, 14, 331-341.	0.1	0
1651	Cardiovascular risk predictionâ€“Are we missing something?. European Journal of Heart Failure, 2020, 22, 1291-1293.	2.9	1
1652	Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data. Russian Journal of Cardiology, 2020, 25, 3870.	0.4	6
1654	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology, 2020, 25, 3919.	0.4	3
1655	Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?. British Journal of Diabetes, 2020, 20, 5-8.	0.1	1
1656	Importance of modern antidiabetic drugs for the cardiologist and diabetologist. Intervencni A Akutni Kardiologie, 2020, 19, 97-100.	0.0	0
1657	The year in cardiology: heart failureâ€“The year in cardiology 2019. Cardiologia Croatica, 2020, 15, 167-188.	0.0	1
1658	Propos de lâ€™expérience belge avec les inhibiteurs des SGLT2. Medecine Des Maladies Metaboliques, 2020, 14, 320-330.	0.1	3
1659	Pharmacological Treatment of Chronic Heart Failure. Journal of the Nihon University Medical Association, 2020, 79, 209-215.	0.0	0
1660	Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis. Cardiovascular Endocrinology and Metabolism, 2021, 10, 89-98.	0.5	4
1661	First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases. Cardiology Journal, 2020, 27, 639-641.	0.5	0
1662	Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter) Tj ETQq1 1 0,784314 rgBT /Overlo	0,2	0



#	ARTICLE	IF	CITATIONS
1664	New Insight into the Regulation of Glucose Metabolism in the Pathophysiology of Ischemic Heart Diseases. The Journal of Japanese College of Angiology, 2020, 60, 127-134.	0.1	0
1665	Cost to Save a Life in Heart Failure: Health Disparity Costs Lives. Cureus, 2020, 12, e10081.	0.2	1
1666	Perspective of the $\beta$ -blockers for the patients with diabetes and heart failure. Endocrinology&Metabolism International Journal, 2020, 8, 97-99.	0.1	0
1669	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
1670	Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Network Open, 2021, 4, e2130762.	2.8	32
1671	Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region. Frontiers in Cardiovascular Medicine, 2021, 8, 750381.	1.1	25
1672	Endocrine system dysfunction and chronic heart failure: a clinical perspective. Endocrine, 2021, , 1.	1.1	9
1673	Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients. Cardiology Journal, 2021, , .	0.5	0
1674	Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure. Journal of the American Heart Association, 2021, 10, e022637.	1.6	13
1675	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. Circulation: Heart Failure, 2021, 14, e008548.	1.6	11
1676	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. American Journal of Cardiology, 2021, , .	0.7	0
1677	The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, 2021, 27, 1954-1960.	15.2	299
1678	Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. Joint Commission Journal on Quality and Patient Safety, 2022, 48, 25-32.	0.4	1
1680	Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure. Annals of Palliative Medicine, 2021, 10, 10887-10895.	0.5	7
1681	Admission Glucose Levels and Associated Risk for Heart Failure After Myocardial Infarction in Patients Without Diabetes. Journal of the American Heart Association, 2021, 10, e022667.	1.6	6
1682	Cardiovascular medicine: a year in review. Minerva Cardiology and Angiology, 2021, , .	0.4	4
1683	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. Journal of the American Heart Association, 2021, 10, e021230.	1.6	2
1684	The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?. Expert Opinion on Pharmacotherapy, 2021, , 1-10.	0.9	1

#	ARTICLE	IF	CITATIONS
1685	Relationship between hemoglobin A1c level and flow-mediated vasodilation in patients with type 2 diabetes mellitus receiving antidiabetic drugs. <i>Journal of Diabetes Investigation</i> , 2022, 13, 677-686.	1.1	2
1686	Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 728089.	1.2	30
1687	Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings. <i>Cureus</i> , 2021, 13, e19194.	0.2	0
1688	Cardiorenal outcomes in eligible patients referred for bariatric surgery. <i>Obesity</i> , 2021, 29, 2035-2043.	1.5	4
1689	Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 756226.	1.6	8
1690	Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. <i>Heart Failure Reviews</i> , 2023, 28, 683-695.	1.7	3
1691	DAPA-HF trial signals the birth of "diabetic cardiology" and more. <i>Global Cardiology Science &amp; Practice</i> , 2020, 2020, e202022.	0.3	1
1692	The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support. <i>Global Cardiology Science &amp; Practice</i> , 2020, 2020, e202031.	0.3	1
1693	Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition. <i>Diabetes Care</i> , 2021, 44, 541-548.	4.3	16
1694	Prevention of Heart Failure. <i>Contemporary Cardiology</i> , 2021, , 489-512.	0.0	1
1695	Angiotensin Receptor-Nepriylsin Inhibition for Doxorubicin-Mediated Cardiotoxicity. <i>JACC: CardioOncology</i> , 2020, 2, 788-790.	1.7	0
1696	The role of SGLT-2 inhibitors in managing type 2 diabetes. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 47-58.	0.6	13
1697	Sodium-glucose cotransporter-2 inhibitors in heart failure patients: an appraisal of recent cardiovascular outcome trials. <i>Minerva Cardioangiologica</i> , 2020, 68, 629-651.	1.2	2
1698	Cardiometabolism: Reducing Risks to Optimize Cardiovascular Disease Outcomes. <i>Contemporary Cardiology</i> , 2021, , 227-248.	0.0	0
1700	Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial. <i>Russian Journal of Cardiology</i> , 2020, 25, 4167.	0.4	1
1701	The role of sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: from clinical research to real practice. <i>Al'manah Kliničeskoj Mediciny</i> , 2020, 48, 500-509.	0.2	0
1702	Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. <i>British Journal of Diabetes</i> , 2020, 20, 85-88.	0.1	4
1703	Heart Failure in Diabetes Mellitus: An Updated Review. <i>Current Pharmaceutical Design</i> , 2020, 26, 5933-5952.	0.9	3

#	ARTICLE	IF	CITATIONS
1704	Series: Cardiovascular outcome trials for diabetes drugs Empagliflozin and EMPA-REG OUTCOME. British Journal of Diabetes, 2020, 20, 138-141.	0.1	1
1705	EMPEROR-Reduced trial: empagliflozin in patients with heart failure and low ejection fraction. Intervencni A Akutni Kardiologie, 2020, 19, 238-241.	0.0	0
1706	Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106159.	0.7	17
1707	Classification of Heart Failure: A Farewell to Ejection Fraction?. Anatolian Journal of Cardiology, 2020, 25, 2-6.	0.5	0
1708	Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease. Korean Circulation Journal, 2020, 50, 458.	0.7	1
1709	Novel pharmacotherapies for heart failure. , 2020, , 359-380.		0
1710	SGLT2 Inhibitors. Stroke Revisited, 2021, , 155-166.	0.2	0
1713	Antidiabetika. , 2020, , 339-358.		0
1715	Cardiovascular Impact of Newer Diabetes Medications. , 2020, , 735-745.		0
1717	Chronic Heart Failure. , 2020, , 137-154.		0
1718	The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection. Arhiv Za Farmaciju, 2020, 70, 198-223.	0.2	0
1719	An updated perspective and pooled analysis of Cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. Anatolian Journal of Cardiology, 2020, 25, 61-76.	0.5	1
1720	Contemporary therapies for chronic heart failure with reduced ejection fraction. South African General Practitioner, 2020, 1, 146-150.	0.0	0
1721	Analysis of Cardiac Metabolic Remodeling in Heart Failure Using Nuclear Medicine and Its Application: Japanese Society of Nuclear Cardiology Award. Annals of Nuclear Cardiology, 2020, 6, 91-94.	0.0	0
1722	Treatment of Diabetes and Heart Failure. , 2020, , 719-733.		0
1723	The Effects and the Mechanisms of Sodium Glucose Cotransporter-2 Inhibition in Heart Failure. Interventions in Obesity & Diabetes, 2020, 3, .	0.0	0
1725	Heart Failure with Preserved Ejection Fraction: Can Device Therapy Be Our Option?. Cureus, 2020, 12, e7323.	0.2	0
1728	The position of SGLT2 inhibitors in current medicine. Vnitri Lekarstvi, 2020, 66, 82-88.	0.1	0

#	ARTICLE	IF	CITATIONS
1729	The year in cardiology: cardiovascular prevention. The year in cardiology 2019.. SA Heart Journal, 2020, 17, .	0.0	0
1730	Response to letter: "Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for SGLT-2 inhibitors?" <sup>TM</sup> . Journal of Cardiovascular Medicine, 2020, 21, 344.	0.6	0
1731	Victoria Trial: Vericiguat Joins the Big League, or Does it?. International Cardiovascular Forum Journal, 0, 19, .	1.1	0
1732	GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients. Current Hypertension Reviews, 2021, 17, 149-158.	0.5	2
1733	"Time is prognosis" <sup>TM</sup> in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Failure, 2021, 8, 4444-4453.	1.4	37
1734	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers, 2021, 13, 5527.	1.7	4
1735	Cardiovascular benefits beyond urinary glucose excretion: <scp>A hypothesis generated from two meta-analyses</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 550-554.	2.2	3
1736	Gender Differences in Implantable Cardioverter-Defibrillator Utilization for Primary Prevention of Sudden Cardiac Death. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.4	0
1737	A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Advances in Therapy, 2022, 39, 33-43.	1.3	57
1738	EMPEROR-Preserved: A promise fulfilled. Cell Metabolism, 2021, 33, 2099-2103.	7.2	8
1739	SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence. Journal of Diabetes Research, 2021, 2021, 1-17.	1.0	1
1740	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. ESC Heart Failure, 2021, , .	1.4	4
1742	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	2.7	38
1743	Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	3
1744	Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 712-720.	1.4	6
1745	Effectiveness and safety of empagliflozin in routine care patients: Results from the <scp>EMPagliflozin compaRative effectiveness</scp> and <scp>SafEty</scp> (<scp>EMPRISE</scp>) study. Diabetes, Obesity and Metabolism, 2022, 24, 442-454.	2.2	29
1746	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 78, 2004-2012.	1.2	48
1747	SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. American Journal of Kidney Diseases, 2022, 79, 858-867.e1.	2.1	29

#	ARTICLE	IF	CITATIONS
1748	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
1749	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7797-7805.	0.8	2
1750	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	17
1751	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	3.0	77
1752	SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 601-606.	0.6	2
1753	Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 2021, 12, 752370.	1.3	12
1755	Congestion and Diuretic Resistance in Acute or Worsening Heart Failure. <i>Cardiac Failure Review</i> , 2020, 6, e25.	1.2	16
1756	Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 1283-1288.	0.3	1
1757	Evidence-based Appraisal of the DAPA-HF Trial. <i>Journal of Contemporary Pharmacy Practice</i> , 2020, 67, 24.	0.2	0
1758	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <i>PLoS ONE</i> , 2020, 15, e0240166.	1.1	2
1759	Diabetic Kidney Disease. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020, 19, 110-139.	3.0	1
1760	Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction. <i>Russian Journal of Cardiology</i> , 2020, 25, 4049.	0.4	1
1762	Chronic and End-Stage Heart Failure. , 2021, , 517-533.		0
1763	Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases. <i>Russian Journal of Cardiology</i> , 2020, 25, 4142.	0.4	3
1764	Tópicos Emergentes em Insuficiência Cardíaca: Nova Era do Tratamento Farmacológico. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 956-960.	0.3	1
1766	By half decrease of cardiovascular mortality in a Western country between 2000 and 2015: A contrasted picture advocating for a better management of comorbidities. <i>International Journal of Cardiology</i> , 2020, 318, 145-146.	0.8	0
1768	Routine periodic fasting reduces all-cause mortality and heart failure incidence: new insights on old habits. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1782-1783.	0.8	0
1769	2020 Focused Update of the 2012 Guidelines of the Taiwan Society of Cardiology for the Management of ST-Segment Elevation Myocardial Infarction. <i>Acta Cardiologica Sinica</i> , 2020, 36, 285-307.	0.1	12

#	ARTICLE	IF	CITATIONS
1770	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. <i>Echo Research and Practice</i> , 2020, 7, L1-L4.	0.6	3
1771	Harms and benefits of sodium-glucose co-transporter 2 inhibitors. <i>Australian Prescriber</i> , 2020, 43, 168-171.	0.5	0
1772	SGLT2 INHIBITORS - SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?. <i>Ulster Medical Journal</i> , 2020, 89, 113.	0.2	0
1773	Ertugliflozin in the treatment of type 2 diabetes mellitus. <i>Drugs in Context</i> , 2020, 9, .	1.0	0
1774	ARNI and SGLT2i: a promising association to be used with caution. <i>Journal of Geriatric Cardiology</i> , 2020, 17, 728-732.	0.2	1
1776	Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in elderly patients with comorbid coronary heart disease and diabetes mellitus. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 440-448.	0.2	0
1777	Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets. <i>Conditioning Medicine</i> , 2020, 3, 82-97.	1.3	3
1778	Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials. <i>American Journal of Cardiovascular Disease</i> , 2021, 11, 262-272.	0.5	1
1779	The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, e176-e181.	0.5	0
1780	Dysfunction of resolution receptor triggers cardiomyopathy of obesity and signs of non-resolving inflammation in heart failure. <i>Molecular and Cellular Endocrinology</i> , 2022, 542, 111521.	1.6	0
1781	Left Heart Disease-Related Pulmonary Hypertension. <i>Cardiology Clinics</i> , 2022, 40, 69-76.	0.9	5
1782	Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i). <i>Endocrine</i> , 2022, 75, 654-658.	1.1	2
1783	Recent and Upcoming Drug Therapies for Pediatric Heart Failure. <i>Frontiers in Pediatrics</i> , 2021, 9, 681224.	0.9	9
1784	Representation of Chronic Kidney Disease in Randomized Controlled Trials Among Patients With Heart failure With Reduced Ejection Fraction: A Systematic Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101047.	1.1	5
1785	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 754499.	1.1	30
1786	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. <i>Med</i> , 2021, 2, 1203-1230.	2.2	17
1787	The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 1249.	1.1	7
1788	Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12677.	1.8	6

#	ARTICLE	IF	CITATIONS
1789	Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2-I) Use in an Underserved Ambulatory Care Population With Type 2 Diabetes. <i>ADCES in Practice</i> , 0, , 2633559X2110569.	0.2	1
1790	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 263-270.	1.0	7
1791	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> ,the, 2022, 10, 24-34.	5.5	40
1792	Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction. <i>Clinical Drug Investigation</i> , 2021, 41, 1027-1036.	1.1	3
1793	Very Long-Term Follow-Up in Cardiac Resynchronization Therapy: Wider Paced QRS Equals Worse Prognosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1176.	1.1	1
1794	Cholinergic Elicitation Prevents Ventricular Remodeling via Alleviations of Myocardial Mitochondrial Injury Linked to Inflammation in Ischemia-Induced Chronic Heart Failure Rats. <i>Mediators of Inflammation</i> , 2021, 2021, 1-17.	1.4	3
1796	Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. <i>Cardiovascular Diabetology</i> , 2021, 20, 219.	2.7	30
1797	Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008365.	1.6	30
1798	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> ,the, 2022, 10, 35-45.	5.5	29
1799	Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 862-871.	1.3	10
1800	The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2021, 7, e18.	1.2	22
1801	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	1.9	41
1802	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	2.9	33
1804	Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1191-1203.	1.8	6
1805	Impact of Sodium-Glucose Cotransporter-2 Inhibitor Initiation in a Safety-net Hospital. <i>Critical Pathways in Cardiology</i> , 2021, Publish Ahead of Print, .	0.2	0
1806	Expert consensus on the practical aspects of the cooperation of cardiologist and diabetologist in the management of the patients with chronic heart failure and reduced ejection fraction. <i>Vnitřní Lekarství</i> , 2021, 67, 404-410.	0.1	1
1807	Transcatheter mitral valve interventions. <i>Progress in Cardiovascular Diseases</i> , 2021, 69, 84-88.	1.6	1
1808	Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials. <i>American Journal of Therapeutics</i> , 2022, 29, e199-e204.	0.5	6

#	ARTICLE	IF	CITATIONS
1809	Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 555-565.	0.9	8
1810	Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, e145-e152.	0.8	27
1811	Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China. <i>Frontiers in Pharmacology</i> , 2021, 12, 733681.	1.6	22
1812	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32
1813	Sodium-glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice. <i>Journal of Diabetes Investigation</i> , 2022, 13, 638-646.	1.1	7
1814	Kidney Disease as Risk of In-Hospital Mortality in Patients With Acute Coronary Syndrome. <i>Cureus</i> , 2021, 13, e19557.	0.2	1
1815	Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome. <i>Nutrients</i> , 2021, 13, 4088.	1.7	12
1816	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	1.6	21
1817	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
1818	Sex Differences in Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 477-498.	0.7	62
1819	The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 321-325.	0.9	7
1820	Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 614-617.	0.5	24
1821	Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, .	0.9	27
1822	Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction. <i>Scientific Reports</i> , 2021, 11, 22342.	1.6	12
1823	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	3
1824	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	0.7	4
1825	Cardiovascular benefit of SGLT2 inhibitors. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 142-155.	2.7	6
1826	Multicentre prospective observational study of sodium-glucose cotransporter-2 inhibitor-associated postoperative ketoacidosis: the SAPKA study protocol. <i>BMJ Open</i> , 2021, 11, e049592.	0.8	5



#	ARTICLE	IF	CITATIONS
1827	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. <i>Clinical Drug Investigation</i> , 2022, 42, 1-16.	1.1	4
1828	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 1999-2007.	2.9	22
1829	Rationale and Design of a Pharmacist-led Intervention for the Risk-Based Prevention of Heart Failure: The FIT-HF Pilot Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 785109.	1.1	1
1830	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 52-64.	1.9	10
1831	Clinical relevance of recent outcome trials with antidiabetic drugs. <i>Practical Diabetes</i> , 2021, 38, 3-6.	0.1	0
1832	Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies. <i>Nature Medicine</i> , 2021, 27, 1872-1873.	15.2	1
1833	Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. <i>European Journal of Internal Medicine</i> , 2022, 96, 26-33.	1.0	7
1834	Role of newer antidiabetic drugs on cardiovascular prevention and heart failure. <i>Clínica E Investigaci3n En Arteriosclerosis (English Edition)</i> , 2021, 33, 314-314.	0.1	0
1835	Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	1
1836	Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 35-46.	1.2	8
1837	Association between body mass index and survival in Taiwanese heart failure patients with and without diabetes mellitus. <i>Medicine (United States)</i> , 2021, 100, e28114.	0.4	1
1838	Acute heart failure and iron deficiency: a prospective, multicentre, observational study. <i>ESC Heart Failure</i> , 2022, 9, 398-407.	1.4	11
1839	Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction. <i>Nefrologia</i> , 2021, , .	0.2	0
1840	Translation of New and Emerging Therapies for Genetic Cardiomyopathies. <i>JACC Basic To Translational Science</i> , 2022, 7, 70-83.	1.9	20
1841	Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. <i>Antioxidants</i> , 2021, 10, 1935.	2.2	15
1843	Response to the comment "SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes". <i>Pharmacological Research</i> , 2021, 174, 105876.	3.1	0
1844	Diabetes and treatment of chronic heart failure in a large real-world heart failure population. <i>ESC Heart Failure</i> , 2022, 9, 353-362.	1.4	13
1845	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. <i>Heart Failure Reviews</i> , 2023, 28, 667-681.	1.7	14

#	ARTICLE	IF	CITATIONS
1846	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2021, 161, 118-120.	0.7	2
1847	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. <i>Frontiers in Endocrinology</i> , 2021, 12, 743807.	1.5	7
1849	Reply. <i>JACC: Heart Failure</i> , 2021, 9, 942-943.	1.9	0
1850	Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H117-H128.	1.5	12
1853	Evolution of Glycemic Targets in Management of Diabetes. <i>Journal of Diabetes Mellitus</i> , 2021, 11, 208-220.	0.1	0
1854	Diuretic Agents. , 2021, , .		0
1855	Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era. <i>Electrolyte and Blood Pressure</i> , 2021, 19, 19.	0.6	4
1856	The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, 176-181.	0.5	3
1857	Diuretika. , 2021, , 443-453.		0
1858	Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die. <i>Europace</i> , 2022, 24, 1052-1057.	0.7	9
1859	Effect of Dapagliflozin on Prognosis of Patients with Heart Failure with Reduced Ejection Fraction. <i>Advances in Clinical Medicine</i> , 2021, 11, 5322-5326.	0.0	0
1860	Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease. <i>JAMA Network Open</i> , 2022, 5, e2142078.	2.8	31
1861	Current and future therapeutic perspective in chronic heart failure. <i>Pharmacological Research</i> , 2022, 175, 106035.	3.1	31
1862	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008594.	1.6	7
1863	Mitochondrial dysfunction and mitochondrial therapies in heart failure. <i>Pharmacological Research</i> , 2022, 175, 106038.	3.1	35
1864	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. <i>Cardiovascular Diabetology</i> , 2022, 21, 4.	2.7	4
1865	Atypical Presentations. , 2022, , 219-241.		0
1867	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from <sc>EMPEROR&lt;/sc>Reduced. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.	2.9	32

#	ARTICLE	IF	CITATIONS
1868	Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 180-191.	1.2	46
1869	Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112606.	2.5	14
1870	Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges. <i>Pharmacological Research</i> , 2022, 176, 106049.	3.1	7
1871	Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. <i>American Heart Journal</i> , 2022, 245, 110-116.	1.2	3
1872	Diabetische Nephropathie: Die neue Rolle der Niere. , 0, , .		0
1873	Herzinsuffizienz als Komorbidität: Kardioprotektion ist möglich. , 0, , .		0
1874	Pharmacologic heart failure treatment: A case-based review of current guidelines. <i>Journal of the American Association of Nurse Practitioners</i> , 2021, 33, 1042-1049.	0.5	0
1876	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. <i>Echo Research and Practice</i> , 2020, 7, L1-L4.	0.6	4
1877	1. Development of Pathophysiological Research and Therapeutic Innovation in Heart Failure. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1685-1697.	0.0	0
1878	Aktualisierte Leitlinien: Therapiealgorithmen werden neu geschrieben. , 0, , .		0
1879	The Impact of SGLT2i Therapy on the Onset and Prognosis of Heart Failure in Patients with Type 2 Diabetes. <i>Timisoara Medical Journal</i> , 2020, 2020, 1.	0.1	0
1880	Harms and benefits fo sodium-glucose co-transporter 2 inhibitors. <i>Australian Prescriber</i> , 2020, 43, 168-171.	0.5	9
1881	Ertugliflozin in the treatment of type 2 diabetes mellitus. <i>Drugs in Context</i> , 2020, 9, 1-10.	1.0	27
1882	Glycaemic Control in Diabetes. <i>Handbook of Experimental Pharmacology</i> , 2021, , 47-71.	0.9	1
1883	Antidiabetika. , 2021, , 241-260.		0
1884	Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure. , 2021, 1, 33-43.		1
1885	Diuretics and Clinical Management of Congestion in Heart Failure: A Review. , 2021, 1, 55-62.		1
1886	Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 298-308.	0.6	6

#	ARTICLE	IF	CITATIONS
1887	What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 290-297.	0.6	1
1888	Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 361-370.	0.6	1
1889	The Novel Data Collection and Analytics Tools for Remote Patient Monitoring in Heart Failure (Nov-RPM-HF) Trial: Protocol for a Single-Center Prospective Trial. <i>JMIR Research Protocols</i> , 2022, 11, e32873.	0.5	2
1890	Effect of SGLT2 Inhibitors on Patients with Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2021, 14, 20200502.	0.5	1
1891	Checklist para A PrÃ©-Alta de Internamento por InsuficiÃªncia CardÃ¡ca. <i>Revista De MedicinÃ¡f InternÃ¡f, Neurologie, Psihiatrie, Neurochirurgie, Dermato-venereologie MedicinÃ¡f InternÃ¡f</i> , 2021, 28, 76-81.	0.0	0
1892	(Expert consensus on the practical aspects of collaboration between cardiologists and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	0.1	0
1893	(Practical aspects of establishing of heart failure clinics). <i>Cor Et Vasa</i> , 2021, 63, 619-625.	0.1	1
1894	Endpoints in Heart Failure Drug Development. <i>Cardiac Failure Review</i> , 2022, 8, e01.	1.2	10
1895	Three Sides to the Story: Adherence Trajectories During the First Year of SGLT2 Inhibitor Therapy Among Medicare Beneficiaries. <i>Diabetes Care</i> , 2022, 45, 604-613.	4.3	6
1896	Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis. <i>ESC Heart Failure</i> , 2022, 9, 1338-1350.	1.4	13
1897	The effect of modern hypoglycemic therapy on the course of chronic kidney disease in patients with type 2 diabetes mellitus. <i>MA-Ã¼narodnij EndokrinologÃ¼nij Å½urnal</i> , 2021, 17, 624-632.	0.1	0
1899	Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1247-1256.	1.8	27
1900	Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 11.	7.1	104
1901	Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1513-1526.	1.3	3
1902	Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure. <i>International Journal of Heart Failure</i> , 2022, 4, 75.	0.9	10
1903	Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future. <i>Journal of Human Hypertension</i> , 2022, 36, 695-704.	1.0	2
1904	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 557-567.	1.4	20
1905	Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, , 1-10.	0.5	3

#	ARTICLE	IF	CITATIONS
1906	Care of the patient after valve intervention. <i>Heart</i> , 2022, 108, 1516-1523.	1.2	2
1907	Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787810.	1.1	6
1908	Are High- or Low-dose SGLT2 Inhibitors Associated With Cardiovascular and Respiratory Adverse Events? A Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 655-662.	0.8	9
1909	Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers. <i>Frontiers in Pharmacology</i> , 2021, 12, 786706.	1.6	10
1910	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. <i>Journal of Lipid and Atherosclerosis</i> , 2022, 11, 1.	1.1	25
1911	The Evolving Evidence Base of Implantable Cardiac defibrillators: Past, Present, and Future. <i>European Medical Journal Innovations</i> , 0, , 33-39.	2.0	1
1912	Dapagliflozin post-transcatheter aortic valve implantation: the need for further evidence. <i>European Journal of Heart Failure</i> , 2022, 24, 589-590.	2.9	0
1913	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. <i>Pulmonary Circulation</i> , 2022, 12, e12028.	0.8	8
1914	Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors. <i>Diabetes Therapy</i> , 2022, 13, 241-250.	1.2	11
1915	Targeting mitochondrial dysfunction with elamipretide. <i>Heart Failure Reviews</i> , 2022, 27, 1925-1932.	1.7	9
1916	Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	2.9	67
1917	Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF- $\kappa$ B. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	0.7	4
1918	Pre-heart failure at 2D and 3D speckle tracking echocardiography: A comprehensive review. <i>Echocardiography</i> , 2022, 39, 302-309.	0.3	6
1919	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, 938-946.	4.3	20
1920	Where the Action Is "Leukocyte Recruitment in Atherosclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 813984.	1.1	24
1921	Manifestation of Heart Failure and Chronic Kidney Disease are Associated with Increased Mortality Risk in Early Stages of Type 2 Diabetes Mellitus: Analysis of a Japanese Real-World Hospital Claims Database. <i>Diabetes Therapy</i> , 2022, 13, 275-286.	1.2	6
1922	Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip. <i>Cureus</i> , 2022, 14, e21768.	0.2	1
1923	The role of SGLT2 inhibitors in heart failure. , 0, 1, 2.		0

#	ARTICLE	IF	CITATIONS
1924	A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0
1925	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. <i>Journal of Clinical Medicine</i> , 2022, 11, 784.	1.0	4
1926	Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction. <i>Clinical Medicine</i> , 2022, 22, 75-76.	0.8	2
1927	Is it time to revisit ICD indications?. <i>Heart Failure Reviews</i> , 2022, , 1.	1.7	2
1928	Non-alcoholic fatty liver disease and type-2 diabetes: An update. <i>Journal of Diabetes Investigation</i> , 2022, 13, 930-940.	1.1	25
1929	Characterizing a Clinical Trial – Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction. <i>Clinical Epidemiology</i> , 2022, Volume 14, 39-49.	1.5	1
1930	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 348.	1.0	5
1931	Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension. <i>Heart Failure Reviews</i> , 2023, 28, 745-755.	1.7	3
1932	Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes. <i>Heart Failure Reviews</i> , 2022, , 1.	1.7	4
1934	<sc>Angiotensin–neprilysin</sc> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
1935	A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1030-1040.	0.9	2
1936	Vericiguat. <i>Cardiology in Review</i> , 2022, Publish Ahead of Print, ,	0.6	3
1937	Hypertension and heart failure with preserved ejection fraction. A past, present, and future relationship. <i>Hypertension Y Riesgo Vascular</i> , 2022, 39, 34-41.	0.3	1
1938	Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient Benefit. <i>Biomedicines</i> , 2022, 10, 270.	1.4	3
1939	Treatment of heart failure with reduced ejection fraction. <i>Journal of the Korean Medical Association</i> , 2022, 65, 9-17.	0.1	0
1940	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 303-320.	0.9	1
1941	Coronary blood flow in heart failure: cause, consequence and bystander. <i>Basic Research in Cardiology</i> , 2022, 117, 1.	2.5	46
1942	SGLT2 Inhibitors and Their Antiarrhythmic Properties. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1678.	1.8	24

#	ARTICLE	IF	CITATIONS
1944	Robustness of outcomes in trials evaluating sodium-glucose cotransporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	1.4	4
1945	SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 822968.	1.1	3
1946	Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0261986.	1.1	15
1947	Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. <i>Cell Death Discovery</i> , 2022, 8, 12.	2.0	18
1948	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 91-102.	1.0	17
1949	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001040.	1.6	193
1950	Combined sodium glucose cotransporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 816-826.	2.2	10
1951	Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction. <i>Current Heart Failure Reports</i> , 2022, 19, 15-25.	1.3	5
1953	The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2022, 27, 107424842110586.	1.0	7
1954	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 1066-1076.	2.9	28
1955	Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. <i>Diabetes</i> , 2022, 71, 812-820.	0.3	5
1956	SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. <i>International Journal of Cardiology</i> , 2022, 351, 66-70.	0.8	9
1959	Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes. <i>Journal of Cardiac Failure</i> , 2022, 28, 682-683.	0.7	5
1960	Protective effects of Dapagliflozin on the vulnerability of ventricular arrhythmia in rats with pulmonary artery hypertension induced by monocrotaline. <i>Bioengineered</i> , 2022, 13, 2697-2709.	1.4	8
1961	Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice. <i>Biochemical Journal</i> , 2022, 479, 425-444.	1.7	17
1964	A Systematic Review and Meta-analysis of Randomized Placebo-controlled Trials 1 Year after Starting Sodium-glucose Transporter-2 Inhibitors in Heart Failure Patients with Reduced Ventricular Ejection Fraction. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 1-6.	0.1	0
1965	Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 1-11.	1.9	9
1966	The 2021 European Heart Failure Guidelines: The Case for Personalised Therapeutics. <i>European Cardiology Review</i> , 2022, 17, e01.	0.7	0

#	ARTICLE	IF	CITATIONS
1967	Drug Treatment of Heart Failure in Children: Gaps and Opportunities. <i>Paediatric Drugs</i> , 2022, 24, 121-136.	1.3	3
1968	Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD. <i>Pediatric Nephrology</i> , 2022, , 1.	0.9	1
1969	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
1971	Reverse re-modelling chronic heart failure by reinstating heart rate variability. <i>Basic Research in Cardiology</i> , 2022, 117, 4.	2.5	23
1972	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. <i>Current Diabetes Reports</i> , 2022, 22, 39-52.	1.7	55
1973	The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic $\hat{\text{I}}^2$ -oxidation, and induces ketosis. <i>Journal of Lipid Research</i> , 2022, 63, 100176.	2.0	29
1974	2022 Summary of recommendations for long-term secondary prevention after myocardial infarction. <i>Cor Et Vasa</i> , 2022, 64, 7-28.	0.1	0
1975	Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. <i>ESC Heart Failure</i> , 2022, 9, 942-946.	1.4	23
1976	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
1977	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. <i>Drugs</i> , 2022, 82, 375-405.	4.9	7
1978	Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective. <i>International Journal of Cardiology</i> , 2022, 349, 96-98.	0.8	1
1979	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.	1.9	5
1980	Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept. <i>Clinical Drug Investigation</i> , 2022, 42, 113-125.	1.1	2
1981	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	1.9	115
1982	Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor. <i>Annals of Hematology</i> , 2022, 101, 1373-1374.	0.8	4
1983	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	1.2	21
1984	New therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure. <i>Advances in Medical Sciences</i> , 2022, 67, 95-102.	0.9	3
1985	Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASE-trial) – A phase III study. <i>American Heart Journal</i> , 2022, 246, 152-160.	1.2	9



#	ARTICLE	IF	CITATIONS
1986	Risk of outcomes in a Spanish population with heart failure. REC: CardioClinics, 2022, 57, 85-96.	0.1	1
1987	Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 425-438.	1.2	5
1988	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. Heart Failure Reviews, 2022, , .	1.7	0
1989	Angiotensin Receptor-Nephrilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine, 2022, 386, 603-603.	13.9	1
1990	Four-Drug Therapy For Heart Failure with Reduced LV Ejection Fraction - Here and Now. Journal of Cardiac Failure, 2022, , .	0.7	0
1991	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	28
1992	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 281-295.	1.1	35
1993	Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 800-811.	1.4	4
1994	SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction. Drugs and Aging, 2022, 39, 185-190.	1.3	4
1995	Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Canadian Journal of Physiology and Pharmacology, 2022, 100, 93-106.	0.7	11
1996	Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology, 2022, 18, 294-306.	4.1	64
1997	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). Clínica e Investigaci3n En Arteriosclerosis (English Edition), 2022, , .	0.1	0
1998	Mitochondria as Therapeutic Targets in Heart Failure. Current Heart Failure Reports, 2022, 19, 27-37.	1.3	23
1999	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. Heart Failure Reviews, 2022, 27, 1761-1777.	1.7	3
2000	Sodium-glucose cotransporter-2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature. Clinical Case Reports (discontinued), 2022, 10, e05440.	0.2	2
2001	Dapagliflozin effect on heart failure with prevalent or new-onset atrial fibrillation. European Journal of Heart Failure, 2022, 24, 526-528.	2.9	4
2002	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. Journal of the American Heart Association, 2022, 11, e022376.	1.6	14
2003	Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals, 2022, 15, 203.	1.7	0

#	ARTICLE	IF	CITATIONS
2004	Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 831734.	1.1	20
2005	Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, 20.	2.7	36
2006	Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India. <i>Cureus</i> , 2022, 14, e22141.	0.2	0
2007	Drug therapy for heart failure with reduced ejection fraction: what is the "right" dose?. <i>European Journal of Heart Failure</i> , 2022, 24, 421-430.	2.9	9
2008	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 228-239.	2.2	4
2009	SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. <i>Internal and Emergency Medicine</i> , 2022, 17, 1243-1245.	1.0	7
2010	Prognostic differences in long-standing vs. recent-onset dilated cardiomyopathy. <i>ESC Heart Failure</i> , 2022, , .	1.4	2
2011	IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> , 2022, 91, 140-160.	0.2	4
2012	Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis. <i>Diabetes Care</i> , 2022, 45, 919-927.	4.3	11
2013	Response to The Letter to The Editor. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106271.	0.7	0
2014	Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6.	1.0	4
2015	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2022, 43, 416-424.	1.0	144
2016	Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. <i>Pharmacology</i> , 2022, 107, 123-130.	0.9	9
2017	Prognosis of chronic Chagas heart disease and other pending clinical challenges. <i>Memorias Do Instituto Oswaldo Cruz</i> , 0, 117, .	0.8	10
2018	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2022. <i>Diabetes Care</i> , 2022, 45, S144-S174.	4.3	282
2019	Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 437.	1.8	18
2020	Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. <i>Medicina (Lithuania)</i> , 2021, 57, 1376.	0.8	1
2022	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2022, 52, 173.	0.7	9

#	ARTICLE	IF	CITATIONS
2024	Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 927.	0.3	23
2026	Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. <i>Archives of Endocrinology and Metabolism</i> , 2022, 66, 68-76.	0.3	6
2027	Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus. <i>International Journal of Medical Sciences</i> , 2022, 19, 729-739.	1.1	13
2029	Congestive Nephropathy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2499.	1.2	3
2030	New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?. <i>Journal of Cardiology</i> , 2023, 81, 26-32.	0.8	3
2031	Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level. <i>Frontiers in Pharmacology</i> , 2022, 13, 837993.	1.6	2
2032	Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 265-271.	1.0	2
2033	Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?. <i>Cardiology Journal</i> , 2022, 29, 166-169.	0.5	0
2034	Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?. <i>Heart Failure Reviews</i> , 2022, 27, 1973-1990.	1.7	5
2035	Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2022, 37, 26-37.	1.3	20
2036	Growing role of SGLT2i in heart failure: evidence from clinical trials. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 147-159.	1.3	8
2037	Clinical Observation of SGLT2 Inhibitor Therapy for Cardiac Arrhythmia and Related Cardiovascular Disease in Diabetic Patients with Controlled Hypertension. <i>Journal of Personalized Medicine</i> , 2022, 12, 271.	1.1	10
2038	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. <i>Frontiers in Pharmacology</i> , 2022, 13, 800490.	1.6	21
2039	Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity. <i>Frontiers in Physiology</i> , 2021, 12, 785879.	1.3	3
2040	Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The <scp>EXCEED</scp> randomized controlled multicenter study. <i>Geriatrics and Gerontology International</i> , 2022, 22, 298-304.	0.7	13
2041	Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2022, 46, 487-494.	0.4	4
2042	Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 977.	1.0	0
2043	Diabetes mellitus and heart failure: an update on pathophysiology and therapy. <i>Minerva Cardiology and Angiology</i> , 2022, , .	0.4	5



#	ARTICLE	IF	CITATIONS
2065	An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3651.	1.8	67
2066	Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases. <i>Clinical Diabetes</i> , 2022, 40, 401-412.	1.2	3
2067	Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1277-1287.	2.2	15
2068	Cluster Scheme Approach to Foundational Heart Failure With Reduced Ejection Fraction Therapy. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.4	0
2069	Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin. <i>World Journal of Diabetes</i> , 2022, 13, 224-239.	1.3	2
2070	Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1317-1329.	0.4	58
2071	Myocardial Fatigue: a Mechano-energetic Concept in Heart Failure. <i>Current Cardiology Reports</i> , 2022, 24, 711-730.	1.3	8
2072	Diabetes Mellitus and the Heart. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, , .	0.6	1
2073	Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. <i>Archives of Cardiovascular Diseases</i> , 2022, , .	0.7	0
2074	SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1470.	1.0	16
2075	Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 223-232.	0.6	4
2076	Moving the Paradigm Forward for Prediction and Risk-Based Primary Prevention of Heart Failure in Special Populations. <i>Current Atherosclerosis Reports</i> , 2022, 24, 343-356.	2.0	1
2077	Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt. <i>Journal of Medical Economics</i> , 2022, 25, 450-456.	1.0	6
2078	Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2021. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
2079	Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. <i>Drug Safety</i> , 2022, 45, 287-295.	1.4	7
2080	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. <i>Circulation</i> , 2022, 145, 693-712.	1.6	57
2081	Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002708.	1.2	2
2082	Angiotensin Receptor-Nephrilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 794707.	1.1	9

#	ARTICLE	IF	CITATIONS
2083	Age-Adjusted Survival Extrapolationsâ€™ Results May Differ From Those Generated by the Weibull Model. JAMA Cardiology, 2022, , .	3.0	0
2084	Geroscienceâ€™guided repurposing of FDAâ€™approved drugs to target aging: A proposed process and prioritization. Aging Cell, 2022, 21, e13596.	3.0	32
2085	Renal effects of guidelineâ€™directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
2086	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153.	2.9	11
2087	Postoperative Ketoacidosis With Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report. A&A Practice, 2022, 16, e01570.	0.2	8
2088	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e10.	1.2	0
2089	Advances in the Treatment Strategies in Hypertension: Present and Future. Journal of Cardiovascular Development and Disease, 2022, 9, 72.	0.8	12
2090	Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Current Hypertension Reports, 2022, 24, 67-74.	1.5	11
2091	Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials. American Journal of Cardiovascular Drugs, 2022, 22, 299-323.	1.0	16
2092	The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review. Diabetes Therapy, 2022, 13, 847-872.	1.2	5
2093	Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. International Journal of Molecular Sciences, 2022, 23, 2812.	1.8	9
2094	Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiology and Therapy, 2022, 11, 203-230.	1.1	4
2095	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	1
2096	Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations. Therapeutics and Clinical Risk Management, 2022, Volume 18, 315-322.	0.9	13
2097	Role of new drug therapies and innovative procedures in older patients with heart failure: from trials to clinical practice. Minerva Medica, 2022, , .	0.3	2
2098	Optimizing Foundational Therapies in Patients With HFrEF. JACC Basic To Translational Science, 2022, 7, 504-517.	1.9	47
2099	Advanced heart failure: guidelineâ€™directed medical therapy, diuretics, inotropes, and palliative care. ESC Heart Failure, 2022, 9, 1507-1523.	1.4	26
2100	Sodiumâ€™glucose cotransporterâ€™2 inhibitors in heart failure: an updated metaâ€™analysis. ESC Heart Failure, 2022, 9, 1942-1953.	1.4	9

#	ARTICLE	IF	CITATIONS
2101	Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction. <i>Journal of Internal Medicine</i> , 2022, 292, 333-349.	2.7	10
2102	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>JACC Asia</i> , 2022, . . .	0.5	2
2103	Current challenges in the treatment of cardiac fibrosis: Recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33. <i>British Journal of Pharmacology</i> , 2023, 180, 2916-2933.	2.7	6
2104	Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1187-1196.	2.2	12
2105	Heart Failure and Drug Therapies: A Metabolic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2960.	1.8	7
2106	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	2.9	16
2107	Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1072-1083.	2.2	20
2108	Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications. <i>Diabetes Therapy</i> , 2022, 13, 873-888.	1.2	4
2110	Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 850836.	1.5	5
2111	Effects of mokuboito, a Japanese Kampo medicine, on long-term clinical outcomes in patients with heart failure. <i>Traditional &amp; Kampo Medicine</i> , 2022, 9, 49-56.	0.2	0
2112	Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis. <i>Frontiers in Endocrinology</i> , 2022, 13, 818537.	1.5	2
2113	Tirzepatide for diabetes: on track to SURPASS current therapy. <i>Nature Medicine</i> , 2022, 28, 450-451.	15.2	4
2114	Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. <i>Kidney360</i> , 2022, 3, 954-967.	0.9	9
2115	TÁ»NG QUAN Há»† THÁ»NG Vá»€ CHI PHÃ»á»€ HIá»†U QUá»¢ Cá»   A DAPAGLIFLOZIN TRONG Ă»TRÁ»Š SUY TIM PHÃ»,N SUá»T Tá»† <i>Hoc Viet Nam</i> , 2022, 510, .	0.0	0
2116	Direct cardiac effects of SGLT2 inhibitors. <i>Cardiovascular Diabetology</i> , 2022, 21, 45.	2.7	62
2120	Heart failure in adults with congenital heart disease. <i>International Journal of Cardiology</i> , 2022, 357, 39-45.	0.8	17
2121	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. <i>Diabetes Therapy</i> , 2022, 13, 889-911.	1.2	2
2122	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. <i>Diabetes Care</i> , 2022, 45, 1007-1012.	4.3	4

#	ARTICLE	IF	CITATIONS
2123	The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1904.	1.0	4
2124	The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. <i>ESC Heart Failure</i> , 2022, 9, 2007-2012.	1.4	14
2125	A comparison of medical therapy and ablation for atrial fibrillation in patients with heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 169-183.	0.6	3
2126	Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction. <i>Journal of Pharmacy Practice</i> , 2023, 36, 905-914.	0.5	4
2127	Baseline characteristics of outpatients with heart failure according to phenotype: preliminary analysis from SMYRNA-HF registry. <i>The European Research Journal</i> , 2022, 8, 266-274.	0.1	1
2128	Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3587.	1.8	48
2129	Short-Chain Carbon Sources. <i>JACC Basic To Translational Science</i> , 2022, 7, 730-742.	1.9	8
2130	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 673-680.	0.9	3
2131	SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitor-Mediated Blunting of Blood Volume Redistribution: A Candidate Mechanism for Attenuating Cardiac Filling Pressures and Exercise Intolerance in Heart Failure—How Do the Data Stack up?. <i>Circulation: Heart Failure</i> , 2022, 15, e009344.	1.6	1
2132	New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature. <i>Frontiers in Surgery</i> , 2022, 9, 828649.	0.6	5
2133	Potential roles of sodium-glucose cotransporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure. <i>Journal of Cellular Physiology</i> , 2022, 237, 2404-2419.	2.0	8
2135	Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index. <i>PLoS Genetics</i> , 2022, 18, e1010093.	1.5	1
2136	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of Cardiac Failure</i> , 2022, 28, 810-830.	0.7	42
2137	Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 319-320.	1.9	0
2139	Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 869272.	1.1	6
2140	SGLT-2 Inhibitor Use in Heart Failure. <i>Critical Care Nursing Quarterly</i> , 2022, 45, 189-198.	0.4	2
2141	A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 831-834.	0.7	24
2142	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109837.	1.1	5



#	ARTICLE	IF	CITATIONS
2143	Relationship of Dapagliflozin With Serum Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318.	1.9	10
2144	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. <i>Canadian Journal of Hospital Pharmacy</i> , 2022, 75, 104-107.	0.1	1
2145	Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2203-2213.	1.2	86
2146	Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 369-379.	1.9	8
2147	Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. <i>Cardiovascular Research</i> , 2023, 119, 668-690.	1.8	11
2148	Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 150,000 individuals. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1390-1393.	2.2	0
2149	Friedreich's Ataxia related Diabetes: Epidemiology and management practices. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109828.	1.1	8
2150	Representativeness of the GALACTIC-HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2022, 11, e023766.	1.6	4
2151	Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. <i>Lancet</i> , 2022, 399, 1391-1400.	6.3	67
2152	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1757-1780.	1.2	314
2153	Effects of 1,5-anhydro-D-glucitol on insulin secretion both in <i>in vitro</i> and <i>ex vivo</i> pancreatic preparations. <i>Journal of Pharmacological Sciences</i> , 2022, 149, 66-72.	1.1	1
2154	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001063.	1.6	756
2155	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001062.	1.6	133
2156	Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 341-350.	5.5	33
2157	Glycated Hemoglobin as an Integrator of Cardiovascular Risk in Individuals Without Diabetes: Lessons from Recent Epidemiologic Studies. <i>Current Atherosclerosis Reports</i> , 2022, 24, 435-442.	2.0	3
2158	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. <i>Cardiovascular Diabetology</i> , 2022, 21, 50.	2.7	8
2159	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFREF. <i>JACC: Heart Failure</i> , 2022, 10, 415-427.	1.9	4
2160	An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 2020.	1.0	6

#	ARTICLE	IF	CITATIONS
2161	Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?. Journal of Diabetes Investigation, 2022, 13, 1114-1121.	1.1	7
2162	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	1.2	774
2163	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines. , 2022, 238, 108185.		16
2165	Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. Journal of Molecular and Cellular Cardiology, 2022, 167, 17-31.	0.9	52
2166	Case presentation and panel discussion: Cardiometabolic risk mitigation. Journal of Parenteral and Enteral Nutrition, 2021, 45, 93-99.	1.3	0
2167	Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics?. Japanese Journal of Clinical Pharmacology and Therapeutics, 2021, 52, 157-164.	0.1	0
2168	Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?. European Heart Journal Quality of Care & Clinical Outcomes, 2021, , .	1.8	0
2169	Heart failure and its treatment from the perspective of sympathetic nerve activity. Journal of Cardiology, 2022, 79, 691-697.	0.8	14
2170	New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs, 2022, 82, 97-108.	4.9	4
2171	Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium. Europace, 2022, 24, 538-551.	0.7	16
2172	Primary and Secondary Prevention of CAD: A Review. International Journal of Angiology, 2022, 31, 016-026.	0.2	2
2173	Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine. Journal of Cardiovascular Pharmacology, 2021, Publish Ahead of Print, .	0.8	2
2174	Empagliflozin Protects against Pulmonary Ischemia/Reperfusion Injury via an Extracellular Signal-Regulated Kinases 1 and 2-Dependent Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 230-241.	1.3	13
2175	Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population. Cardiovascular Therapeutics, 2021, 2021, 1-8.	1.1	9
2176	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Advances in Therapy, 2022, 39, 845-861.	1.3	13
2177	Three new categories of hypoglycaemic agents and various cardiovascular diseases: A meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 636-642.	0.7	3
2178	Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nature Reviews Rheumatology, 2022, 18, 97-111.	3.5	45
2179	Life-threatening ventricular arrhythmia and left ventricular dysfunction associated with anti-mitochondrial antibody-positive myositis: a case report. European Heart Journal - Case Reports, 2021, 5, ytab469.	0.3	3

#	ARTICLE	IF	CITATIONS
2180	Heart failure treatment in patients with cardiac implantable electronic devices: Opportunity for improvement. <i>Heart Rhythm</i> O2, 2021, 2, 698-709.	0.6	4
2181	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 865-872.	1.4	16
2182	Renal Tubular Handling of Glucose and Fructose in Health and Disease. , 2021, 12, 2995-3044.		10
2183	A year in heart failure: an update of recent findings. <i>ESC Heart Failure</i> , 2021, 8, 4370-4393.	1.4	28
2184	Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 810791.	1.1	12
2185	Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 205-211.	1.0	1
2186	Long-term mechanical circulatory support for chronic heart failure - real life practice. <i>Vnitřní Lekarství</i> , 2021, 67, E3-E6.	0.1	1
2187	New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiovascular Emergencies</i> , 2021, 7, 88-99.	0.1	0
2188	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2021, 40, 975-983.	0.2	0
2190	Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure. <i>Russian Journal of Cardiology</i> , 2022, 26, 4800.	0.4	2
2191	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. <i>Cardiovascular Diabetology</i> , 2021, 20, 236.	2.7	63
2192	Empagliflozin Reduces Renal Hyperfiltration in Response to Uninephrectomy, but Is Not Nephroprotective in UNx/DOCA/Salt Mouse Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 761855.	1.6	12
2193	Type 2 diabetes mellitus and chronic heart failure: new treatment strategies. <i>Cardiosomatics</i> , 2021, 12, 234-238.	0.2	1
2194	Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study. <i>Canadian Journal of Diabetes</i> , 2022, 46, 392-403.e13.	0.4	6
2195	Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 135-141.	1.0	4
2196	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. <i>Medicine (United States)</i> , 2021, 100, e28448.	0.4	2
2197	Improvement of left ventricular function with surgical revascularization in patients eligible for implantable cardioverter-defibrillator. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 244-251.	0.8	3
2198	Empagliflozin - A New Chance for Patients with Chronic Heart Failure. <i>Pharmaceuticals</i> , 2022, 15, 47.	1.7	6

#	ARTICLE	IF	CITATIONS
2199	Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations. <i>Russian Journal of Cardiology</i> , 2022, 26, 4807.	0.4	0
2200	Series: Cardiovascular outcome trials for diabetes drugs Canagliflozin and the CANVAS Program, dapagliflozin and DECLARE-TIMI 58, ertugliflozin and VERTIS CV. <i>British Journal of Diabetes</i> , 0, , .	0.1	0
2201	Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. <i>Frontiers in Medicine</i> , 2021, 8, 777861.	1.2	55
2202	ABCD debate at the annual ABCD virtual meeting 18 December 2020. <i>British Journal of Diabetes</i> , 2021, 21, 286-288.	0.1	0
2203	Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. <i>Advances in Therapy</i> , 2022, 39, 193-220.	1.3	12
2204	Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 441.	1.8	18
2205	Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 768-776.	1.4	8
2206	N-terminal pro-B-type natriuretic peptide testing patterns in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 87-99.	1.4	3
2208	Dapagliflozin Improves Cardiac Function, Remodeling, Myocardial Apoptosis, and Inflammatory Cytokines in Mice with Myocardial Infarction. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 786-796.	1.1	15
2209	Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , 2021, , .	0.2	1
2211	Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. <i>Journal of Clinical Medicine</i> , 2022, 11, 137.	1.0	15
2212	SGLT-2 Inhibitor—Versatile Newcomer in Heart Failure Management. <i>Indian Journal of Clinical Cardiology</i> , 2021, 2, 193-194.	0.3	0
2213	What can machines learn about heart failure? A systematic literature review. <i>International Journal of Data Science and Analytics</i> , 2022, 13, 163-183.	2.4	3
2214	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	1.0	8
2215	Opportunities of Antidiabetic Drugs in Cardiovascular Medicine. <i>Hypertension</i> , 2020, 76, 420-431.	1.3	6
2216	Diuretics in Treatment of Heart Failure. , 2022, 2, 86-93.		0
2217	Diuretics In Stable Outpatients with Mild Heart Failure — May I Discontinue Them?. , 2022, 2, 94-98.		0
2218	Treatment of Heart Failure with reduced Ejection Fraction in 2022: The Essential Pillars. , 2022, 2, 15-23.		0

#	ARTICLE	IF	CITATIONS
2219	Pharmacological Treatment Sequencing for Heart Failure with Reduced Ejection Fraction. , 2022, 2, 31-35.		0
2220	Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2573-2587.	1.0	41
2221	SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. , 2022, 2, 67-71.		0
2222	Sequencing of Pharmacotherapy for Heart Failure with Reduced Ejection Fraction: A Clinical Profile-Based Approach. , 2022, 2, 36-40.		0
2223	Chronic heart failure – modification of treatment paradigm. Consilium Medicum, 2022, 24, 13-19.	0.1	1
2224	Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. European Heart Journal, 2022, 43, 2549-2561.	1.0	136
2225	Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882210900.	1.4	16
2226	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. JAMA Cardiology, 2022, 7, 540.	3.0	20
2227	Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial. Russian Journal of Cardiology, 2022, 27, 4945.	0.4	1
2228	Heart Failure in Older Adults: Medical Management and Advanced Therapies. Geriatrics (Switzerland), 2022, 7, 36.	0.6	2
2229	Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Failure, 2022, , .	1.4	2
2230	Sodium – Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure. Annals of Internal Medicine, 2022, 175, 851-861.	2.0	23
2231	Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations. Journal of Diabetes, 2022, 14, 315-333.	0.8	4
2232	Sex-Based Differences in Heart Failure. Journal of the American College of Cardiology, 2022, 79, 1530-1541.	1.2	22
2233	Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review. Frontiers in Pharmacology, 2022, 13, 860109.	1.6	10
2234	Medications Associated with Occurrence of Urinary Tract Infections in Patients with Diabetes, Heart Failure or Both. Current Drug Safety, 2022, 17, .	0.3	1
2235	Management of atrial fibrillation: two decades of progress – a scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2022, 65, 287-326.	0.6	20
2236	Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy. ESC Heart Failure, 2022, 9, 2070-2083.	1.4	10

#	ARTICLE	IF	CITATIONS
2237	Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology. <i>European Journal of Internal Medicine</i> , 2022, 100, 13-20.	1.0	4
2238	The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 2243.	1.0	6
2239	Practical outpatient management of worsening chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 750-761.	2.9	27
2240	Development and Validation of a Novel Nomogram to Predict Improved Left Ventricular Ejection Fraction in Patients With Heart Failure After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 864366.	1.1	0
2241	Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. <i>Diagnostics</i> , 2022, 12, 989.	1.3	9
2242	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
2243	Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials. <i>International Journal of Cardiology</i> , 2022, 359, 76-83.	0.8	2
2244	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	0.6	40
2245	Premature Mortality in Type 2 Diabetes Mellitus Associated with Heart Failure and Chronic Kidney Disease: 20 Years of Real-World Data. <i>Journal of Clinical Medicine</i> , 2022, 11, 2131.	1.0	2
2246	Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. <i>Revista Española De Cardiología</i> , 2022, 75, 429.e1-429.e104.	0.6	27
2247	Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction. <i>JACC Asia</i> , 2022, 2, 154-156.	0.5	0
2248	Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. <i>Archives of Toxicology</i> , 2022, 96, 2021-2032.	1.9	13
2249	Tipping the scale toward a more accurate and equitable assessment of heart failure with reduced ejection fraction pharmacotherapy eligibility: a call to incorporate cystatin C in estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 867-870.	2.9	3
2250	Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2022, 22, 142.	0.8	11
2251	Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2022, 187, 109871.	1.1	7
2266	A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 743-755.	1.3	9
2267	The Fontan Circulation: From Ideal to Failing Hemodynamics and Drug Therapies for Optimization. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1059-1071.	0.8	7
2268	Signaling cascades in the failing heart and emerging therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 134.	7.1	18

#	ARTICLE	IF	CITATIONS
2269	Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, e23-e24.	1.4	12
2270	History and evolution of pacing and devices. <i>Heart</i> , 2022, 108, 794-799.	1.2	6
2271	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. <i>Circulation</i> , 2022, 145, 1460-1470.	1.6	97
2274	Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 783-795.	0.2	7
2276	Sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. <i>Canadian Family Physician</i> , 2021, 67, 678-678.	0.1	0
2278	Medication management for heart failure with reduced ejection fraction. <i>Canadian Family Physician</i> , 2021, 67, 915-922.	0.1	1
2280	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	2.0	56
2281	Impact of Pharmacists in Therapeutic Optimization Relative to the 2020 American Diabetes Association Standards of Medical Care in Diabetes Guidelines in Patients with Clinical Atherosclerotic Cardiovascular Disease.. <i>Hawai'i Journal of Health &amp; Social Welfare</i> , 2022, 81, 13-20.	0.2	0
2286	SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist. , 2022, 2, .		4
2287	Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 643-654.	2.2	10
2289	Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 882181.	1.1	5
2290	Insulin Therapy is Associated With Increased Myocardial Interstitial Fibrosis and Cardiomyocyte Apoptosis in a Rodent Model of Experimental Diabetes. <i>Frontiers in Physiology</i> , 2022, 13, 890907.	1.3	4
2292	Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 843-854.	1.8	4
2293	Advances in Clinical Cardiology 2021: A Summary of Key Clinical Trials. <i>Advances in Therapy</i> , 2022, 39, 2398-2437.	1.3	6
2294	Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor. <i>Frontiers in Pharmacology</i> , 2022, 13, 799915.	1.6	3
2295	Macrovascular Complications. <i>Primary Care - Clinics in Office Practice</i> , 2022, 49, 255-273.	0.7	2
2296	Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from <scp>DAPASALT</scp> and <scp>DIAMOND</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1578-1587.	2.2	11
2297	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. <i>Cardiovascular Diabetology</i> , 2022, 21, 63.	2.7	19

#	ARTICLE	IF	CITATIONS
2298	Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0
2299	Vericiguat in heart failure: From scientific evidence to clinical practice. <i>Revista Clínica Española</i> , 2022, 222, 359-369.	0.3	5
2300	Plin5, a New Target in Diabetic Cardiomyopathy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-20.	1.9	3
2301	The position of SGLT2 inhibitors in current medical practice - update 2022. <i>Vnitřní Lékarství</i> , 2022, 68, 96-103.	0.1	1
2302	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e16.	1.2	6
2303	Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing. <i>Cancers</i> , 2022, 14, 2105.	1.7	18
2304	Therapeutic Approaches in Heart Failure with Preserved Ejection Fraction (HFpEF) in Children: Present and Future. <i>Paediatric Drugs</i> , 2022, 24, 235-246.	1.3	3
2305	Systemic arterial pulsatility index (SAPI) predicts adverse outcomes in advanced heart failure patients. <i>Heart and Vessels</i> , 2022, 37, 1719-1727.	0.5	3
2306	20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 149.	0.8	7
2307	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 867-885.	1.4	12
2308	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
2309	Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. <i>BMC Nephrology</i> , 2022, 23, 168.	0.8	4
2310	National Trends in Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020. <i>Journal of the American Heart Association</i> , 2022, 11, e023811.	1.6	40
2311	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
2312	Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	13
2313	Management strategies in heart failure with preserved ejection fraction. <i>Herz</i> , 2022, 47, 332-339.	0.4	2
2314	Reply. <i>JACC: Heart Failure</i> , 2022, 10, 366-367.	1.9	0
2315	Sodium-glucose cotransporter 2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management. <i>Internal Medicine Journal</i> , 2022, 52, 876-879.	0.5	2



#	ARTICLE	IF	CITATIONS
2316	Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, . .	1.2	1
2317	Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 273.	2.4	40
2318	A Bibliometric Analysis of Heart Failure with Preserved Ejection Fraction From 2000 to 2021. <i>Current Problems in Cardiology</i> , 2022, 47, 101243.	1.1	10
2319	Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009521.	1.6	25
2320	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2022, 28, 1050-1062.	0.7	19
2321	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. <i>American Heart Journal</i> , 2022, 250, 57-57.	1.2	1
2322	New therapies for the treatment of heart failure with preserved ejection fraction. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1424-1430.	0.5	4
2323	Daily ambulatory remote monitoring system for drug escalation in chronic heart failure with reduced ejection fraction: pilot phase of DAVID-HF study. <i>European Heart Journal Digital Health</i> , 2022, 3, 284-295.	0.7	5
2324	Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. <i>Kidney International Reports</i> , 2022, 7, 1463-1476.	0.4	59
2325	Different Sodium-Glucose Cotransporter-2 Inhibitors: Can They Prevent Death?. <i>Endocrine Practice</i> , 2022, 28, 795-801.	1.1	5
2326	Sodium-glucose cotransporter 2 inhibition, uric acid, and heart failure: correlation without causation?. <i>European Journal of Heart Failure</i> , 2022, 24, 1077-1079.	2.9	0
2327	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1434-1441.	0.8	2
2328	The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2022, 180, 106243.	3.1	25
2329	Effect of pulmonary artery pressure-guided therapy on heart failure readmission in a nationally representative cohort. <i>ESC Heart Failure</i> , 2022, 9, 2511-2517.	1.4	5
2330	Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. <i>Diabetes Research and Clinical Practice</i> , 2022, 188, 109927.	1.1	18
2331	Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF- $\beta$ 1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	8
2332	Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat. <i>Journal of Cardiac Failure</i> , 2022, 28, 1298-1308.	0.7	8
2333	Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril-valsartan. <i>Scientific Reports</i> , 2022, 12, 8186.	1.6	2

#	ARTICLE	IF	CITATIONS
2334	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e024833.	1.6	7
2335	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2058-2068.	1.2	41
2336	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. <i>Acta Cardiologica</i> , 2023, 78, 552-564.	0.3	2
2338	Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. <i>American Heart Journal</i> , 2022, 253, 86-98.	1.2	48
2339	Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?. <i>Basic Research in Cardiology</i> , 2022, 117, 27.	2.5	21
2340	Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?. <i>Journal of Nephrology</i> , 2022, , .	0.9	5
2341	Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1759-1769.	0.8	6
2342	Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1927-1938.	2.2	10
2343	Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. <i>Cardiovascular Diabetology</i> , 2022, 21, 77.	2.7	76
2345	Empagliflozin as a part of optimal medical therapy for chronic heart failure. <i>Kardiologicheskii Vestnik</i> , 2022, 17, 16.	0.1	0
2346	Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study. <i>Cardiovascular Innovations and Applications</i> , 2022, 6, .	0.1	1
2347	The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	2
2348	A significant dilemma in the treatment of heart failure patients with sacubitril/valsartan or sodium-glucose co-transporter 2 inhibitors: Whether to add mineralocorticoid receptor antagonists. <i>Revista Portuguesa De Cardiologia</i> , 2022, , .	0.2	0
2350	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. <i>ESC Heart Failure</i> , 2022, 9, 2753-2761.	1.4	7
2351	Impact of Bâ€šlinesâ€š-guided intensive heart failure management on outcome of discharged heart failure patients with residual Bâ€šlines. <i>ESC Heart Failure</i> , 2022, 9, 2713-2718.	1.4	4
2352	Pulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapyâ€šObservations from an Advanced Elderly German Heart Failure Cohort. <i>Life</i> , 2022, 12, 766.	1.1	0
2353	The PONTE (<u>P</u><u>DTA FOR INTEGRATED F<u>O</u><u>LLOW-UP TERRITORY HOSPITAL OF THE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 increased adherence to guideline-recommended therapies through web-based shared clinical database. <i>European Heart Journal Supplements</i> , 2022, 24, C221-C224.	0.0	0
2354	The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	51

#	ARTICLE	IF	CITATIONS
2355	Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (<scp>DAPA-CHO</sub></sub></scp>): a randomized clinical trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1816-1826.	2.9	22
2356	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2233-2238.	1.4	15
2357	Carbohydrate-based drugs launched during 2000~2021. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3783-3821.	5.7	68
2358	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. <i>Circulation</i> , 2022, 146, 808-818.	1.6	33
2359	SGLT2 inhibitors in acute decompensated heart failure, what do we know?. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 565-571.	0.2	1
2360	Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment. <i>European Journal of Heart Failure</i> , 2022, 24, 959-975.	2.9	23
2361	Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	5
2362	Direct and indirect costs of heart failure in relation to diabetes status - A nationwide study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1880-1885.	1.1	2
2363	SGLT2 Inhibitors and Peripheral Vascular Events. <i>Heart Failure Clinics</i> , 2022, 18, 609-623.	1.0	5
2364	Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice. <i>Current Research in Physiology</i> , 2022, 5, 232-239.	0.8	8
2365	Paradigm change in the treatment of chronic heart failure according to ESC Guide 2021: New innovative drugs in focus. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 40-47.	0.0	1
2366	Association of ambulatory blood pressure with coronary microvascular and cardiac dysfunction in asymptomatic type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	5
2367	Temporal patterns of multi-morbidity in 570157 ischemic heart disease patients: a nationwide cohort study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	4
2368	Sodium-glucose co-transporter 2 inhibitors in the treatment of diabetes with heart failure. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	6
2369	Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	9
2370	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1829-1839.	2.2	23
2371	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. <i>Current Diabetes Reports</i> , 2022, 22, 317-332.	1.7	4
2372	Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. <i>Open Heart</i> , 2022, 9, e001936.	0.9	12

#	ARTICLE	IF	CITATIONS
2374	Disease-Modifying Therapy of Chronic Heart Failure on the Background of Heart Rhythm and Conductivity Disorders (Clinical Case). , 2022, 2, 31-40.		0
2375	ANMCO statement on the use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a practical guide for a streamlined implementation. <i>European Heart Journal Supplements</i> , 2022, 24, C272-C277.	0.0	4
2376	Gliflozins in the Management of Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2022, 386, 2024-2034.	13.9	113
2377	Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	15
2378	Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective. <i>Journal of Thoracic Disease</i> , 2022, 14, 1588-1597.	0.6	15
2379	Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 3112.	1.0	2
2380	Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2935.	1.0	4
2381	The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	1
2382	Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. <i>American Heart Journal</i> , 2022, 251, 127-136.	1.2	5
2383	Responders to Sodium-Glucose Cotransporter 2 Inhibitors in Improving Left Ventricular Function. <i>International Heart Journal</i> , 2022, 63, 550-557.	0.5	0
2384	Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2385	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. <i>Diabetes Care</i> , 2022, 45, 1670-1690.	4.3	109
2386	Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 3192.	1.0	10
2387	Promise of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced ejection fraction. <i>ESC Heart Failure</i> , 0, , .	1.4	2
2389	Ischemic Mitral Regurgitation. <i>Journal of Coronary Artery Disease</i> , 2022, 28, 24-31.	0.1	0
2390	Prevention of complications in the treatment of chronic heart failure in 2022: results of a survey of specialists. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 33.	0.2	0
2391	Avaliaç~o de V~arias Vias Fisiopatol~gicas no Progn~stico da Insufici~ncia Card~aca com Fraç~o de Ejeç~o Reduzida: Vendo Al~om do Coraç~o. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, 118, 1116-1117.	0.3	0
2393	Use of Guideline-Based Therapy for Diabetes, Coronary Artery Disease, and Chronic Kidney Disease After Acute Kidney Injury: A Retrospective Observational Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812211036.	0.6	0

#	ARTICLE	IF	CITATIONS
2394	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of the Nihon University Medical Association, 2022, 81, 73-76.	0.0	0
2396	Heart failure with preserved ejection fraction update: A review of clinical trials and new therapeutic considerations. Cardiology Journal, 0, , .	0.5	3
2397	Cardiorenal prevention as the key player in the reduction of all-cause mortality. Nefrologia, 2022, , .	0.2	0
2398	Diabetes and Progression of Heart Failure. Journal of the American College of Cardiology, 2022, 79, 2285-2293.	1.2	19
2399	Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Advances in Therapy, 2022, 39, 3472-3487.	1.3	4
2400	Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review. Diabetes Therapy, 2022, 13, 19-34.	1.2	3
2401	Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D. Diabetes Therapy, 2022, 13, 35-49.	1.2	5
2402	Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy. Diabetes Therapy, 2022, 13, 1281-1298.	1.2	5
2403	Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Cardiovascular Diabetology, 2022, 21, .	2.7	7
2404	Risk of volume depletion events with concomitant use of sodium glucose co-transporter 2 inhibitors and loop diuretics: A self-controlled case series study. Pharmacoepidemiology and Drug Safety, 2022, 31, 1102-1109.	0.9	1
2405	Value-Based Prices Could Establish Common Ground on Heart Failure Drug Pricing and Coverage. Journal of the American College of Cardiology, 2022, 79, 2526-2528.	1.2	1
2406	Long-term Survival Following Heart Transplantation for Chagas Versus Non-Chagas Cardiomyopathy: A Single-center Experience in Northeastern Brazil Over 2 Decades. Transplantation Direct, 2022, 8, e1349.	0.8	2
2407	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. European Journal of Internal Medicine, 2022, 103, 29-35.	1.0	5
2408	Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial. Therapeutic Innovation and Regulatory Science, 2022, 56, 785-794.	0.8	9
2409	Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. JACC Asia, 2022, 2, 287-293.	0.5	6
2410	A multidisciplinary approach to heart failure care in the hospital: improving the patient journey. Hospital Practice (1995), 0, , .	0.5	0
2411	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Frontiers in Pharmacology, 0, 13, .	1.6	7
2412	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. Journal of Evidence-Based Medicine, 2022, 15, 168-179.	0.7	3

#	ARTICLE	IF	CITATIONS
2413	Animal Models of Dysregulated Cardiac Metabolism. <i>Circulation Research</i> , 2022, 130, 1965-1993.	2.0	9
2414	Effects of SGLT2 inhibitors on cardiac structure and function. <i>Heart Failure Reviews</i> , 2023, 28, 697-707.	1.7	5
2415	Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. <i>Current Heart Failure Reports</i> , 2022, 19, 191-199.	1.3	2
2416	Combination of <i>Salviae Miltiorrhizae Radix et Rhizoma</i> and <i>Carthami Flos</i> improves cardiac function of diabetic cardiomyopathy mice by regulating the unfolded protein response signaling pathway. <i>Phytotherapy Research</i> , 2022, 36, 3571-3583.	2.8	4
2417	Implementation of Multiple Evidence-Based Heart Failure Therapies. <i>Current Problems in Cardiology</i> , 2022, , 101293.	1.1	0
2418	Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021). <i>Aging Medicine (Milton (N S W))</i> , 2022, 5, 78-93.	0.9	7
2419	Hypertension and Type 2 Diabetesâ€”The Novel Treatment Possibilities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6500.	1.8	13
2420	Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors â€” Lessons From a Case Series and Strategies to Decrease Incidence. <i>Endocrine Practice</i> , 2022, 28, 884-888.	1.1	16
2421	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
2422	Significant reduction in chronic kidney disease progression with sodiumâ€”glucose cotransporterâ€”2 inhibitors compared to dipeptidyl peptidaseâ€”4 inhibitors in adults with type 2 diabetes in a <scp>UK</scp> clinical setting: An observational outcomes study based on international guidelines for kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2138-2147.	2.2	4
2424	Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction. <i>Clinical Drug Investigation</i> , 2022, 42, 567-579.	1.1	7
2425	New Advances in Cardiorenal Syndromeâ€”Ready for Prime Time?. <i>Journal of Clinical Medicine</i> , 2022, 11, 3460.	1.0	0
2426	Early changes in estimated glomerular filtration rate postâ€”initiation of empagliflozin in <scp>EMPERORâ€”Reduced</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 1829-1839.	2.9	19
2427	Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	6
2428	Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. <i>American Heart Journal Plus</i> , 2022, 18, 100154.	0.3	2
2429	Body fluid regulation via chronic inhibition of sodiumâ€”glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 87-97.	1.5	7
2430	Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodiumâ€”Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan. <i>Diabetes Therapy</i> , 2022, 13, 1367-1381.	1.2	9
2431	The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	3

#	ARTICLE	IF	CITATIONS
2432	Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. <i>Current Heart Failure Reports</i> , 2022, 19, 290-302.	1.3	11
2433	Updated NICE guidelines on type 2 diabetes – what's new?. <i>Independent Nurse</i> , 2022, 2022, 12-16.	0.0	0
2435	Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
2436	Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na <sup>+</sup> /H <sup>+</sup> exchanger-1. <i>International Journal of Cardiology</i> , 2022, , .	0.8	7
2437	Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta–analysis. <i>European Journal of Heart Failure</i> , 2022, 24, 1625-1632.	2.9	10
2438	Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2516-2525.	1.2	34
2439	SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D. <i>Diabetes Therapy</i> , 0, , .	1.2	0
2440	Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
2441	Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	6
2442	Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 1652-1660.	0.7	2
2443	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1472-1488.	1.1	2
2444	Association of Age with Optimal Medical Therapy in Patients with Chronic Heart Failure. , 2022, 2, 138-145.		0
2445	Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2022, 10, 232470962211117.	0.3	1
2446	Treating Cardiometabolic Continuum by SGLT2 Inhibitors: From Diabetes Mellitus to Heart Failure. <i>Cardiometabolic Syndrome Journal</i> , 0, 2, .	1.0	0
2447	Profile of nonischemic dilated cardiomyopathy patients with long-term survival ≥10 years on medical therapy alone. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 2389.	0.3	0
2448	SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-cofilin pathways. <i>Theranostics</i> , 2022, 12, 5034-5050.	4.6	35
2449	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. <i>European Heart Journal</i> , 2022, 43, 5006-5016.	1.0	15
2450	The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2511-2521.	1.8	7

#	ARTICLE	IF	CITATIONS
2451	An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations. <i>Diabetes Therapy</i> , 0, , .	1.2	1
2452	Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review. <i>CJC Open</i> , 2022, 4, 802-809.	0.7	2
2453	Comparison of 10 mg and 25 mg of Empagliflozin in Patients With Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1641-1642.	0.8	3
2454	Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2017-2030.	2.0	6
2455	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7261.	1.8	4
2456	Cardiometabolism: Newer Pharmacologic Strategies for Reducing Cardiovascular Disease Risks. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	0
2458	Improving implementation of evidence-based therapies for heart failure. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	2
2459	New strategies and therapies for the prevention of heart failure in high-risk patients. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	4
2460	Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	8
2461	Current Updates in the Pharmacotherapy of Heart Failure with a Preserved Ejection Fraction. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2022, 22, 87-95.	0.2	1
2462	In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	9
2463	What have we learned so far from the sex/gender issue in heart failure? An overview of current evidence. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	2
2464	Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. <i>JACC: Heart Failure</i> , 2022, 10, 559-567.	1.9	32
2465	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. <i>Endocrinology and Metabolism</i> , 2022, 37, 415-429.	1.3	3
2466	Drugs for heart failure and arrhythmias. <i>Medicine</i> , 2022, , .	0.2	0
2467	The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients. <i>Transplantation</i> , 2022, 106, e404-e412.	0.5	35
2468	Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. <i>International Journal of Cardiology</i> , 2022, 366, 51-56.	0.8	9
2469	A survey-based triage tool to identify patients potentially eligible for referral to an advanced heart failure centre. <i>ESC Heart Failure</i> , 2022, 9, 3643-3648.	1.4	3



#	ARTICLE	IF	CITATIONS
2470	The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. <i>Clinical Science</i> , 2022, 136, 1005-1017.	1.8	5
2471	Reshaping Treatment of Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 3706.	1.0	2
2472	Dapagliflozin use in type 1 diabetes: industry, business and ethics. <i>British Journal of Diabetes</i> , 2022, 22, 47-48.	0.1	0
2473	Insights into foundational therapies for heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	7
2475	Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. <i>JACC: Heart Failure</i> , 2022, 10, 543-555.	1.9	7
2477	Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	8
2478	Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?. <i>European Journal of Heart Failure</i> , 2022, 24, 1460-1466.	2.9	12
2479	Sodium-glucose cotransporter 2 inhibitors: An additional management option for patients with atrial fibrillation?. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1897-1900.	2.2	2
2480	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
2481	Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	3
2482	Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2023, 112, 111-122.	1.5	8
2483	Dapagliflozin for the treatment of chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 275-291.	1.2	7
2485	Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue molecules and SGLT2i dapagliflozin. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4416-4427.	1.6	5
2486	Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation. <i>European Journal of Heart Failure</i> , 2022, 24, 2152-2161.	2.9	14
2487	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1614-1622.	2.9	15
2488	Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1953-1962.	2.9	15
2489	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S80-S112.	0.6	5
2490	Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 0, , .	1.8	2

#	ARTICLE	IF	CITATIONS
2491	Chronic heart failure: epidemiology, investigation and management. <i>Medicine</i> , 2022, , .	0.2	0
2492	Renin-angiotensin-aldosterone inhibition in chronic heart failure: From theory into practice. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0
2493	Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. , 2022, 37, 251-259.		1
2494	Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 123-136.	0.4	0
2495	Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2319-2330.	2.2	6
2496	Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?. <i>Molecular Metabolism</i> , 2022, 64, 101549.	3.0	23
2497	The use of sodium-glucose cotransporter 2 inhibitor in heart failure: <i>The rise of the Roman Empire!</i>. <i>The National Medical Journal of India</i> , 0, 34, 347-350.	0.1	0
2498	Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study. <i>International Journal of General Medicine</i> , 0, Volume 15, 5915-5918.	0.8	2
2499	Cardiorenal Interactions: A Review. <i>CJC Open</i> , 2022, 4, 873-885.	0.7	2
2500	Association between Empagliflozin Use and Electrocardiographic Changes. <i>Clinics and Practice</i> , 2022, 12, 557-564.	0.6	1
2501	Assessing Pharmacologic Treatment Effect From a Meta-Analysis in Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 527.	1.9	0
2502	Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	7
2504	Diabesity in Elderly Cardiovascular Disease Patients: Mechanisms and Regulators. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7886.	1.8	5
2506	Preventative effects of dapagliflozin on early ventricular dysfunction and remodeling in patients with acute anterior STEMI - The PREDOMINACE trial. <i>American Heart Journal Plus</i> , 2022, , 100181.	0.3	0
2507	Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 225.	0.8	3
2508	Cardiovascular complications of diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 383-388.	1.2	8
2509	New Insights Into Diuretic Use to Treat Congestion in the ICU: Beyond Furosemide. , 0, 2, .		1
2510	Guideline-directed medical therapy in heart failure patients with reduced ejection fraction in Oman: utilization, reasons behind non-prescribing, and dose optimization. <i>Pharmacy Practice</i> , 2022, 20, 01-08.	0.8	0

#	ARTICLE	IF	CITATIONS
2511	Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial. <i>Biomedicines</i> , 2022, 10, 1656.	1.4	0
2512	Update on Hypertension Research in 2021. <i>Hypertension Research</i> , 2022, 45, 1276-1297.	1.5	13
2513	Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 529-541.	0.6	3
2514	Subjective Financial Hardship due to Medical Bills Among Patients With Heart Failure in the United States: The 2014-2018 Medical Expenditure Panel Survey. <i>Journal of Cardiac Failure</i> , 2022, 28, 1424-1433.	0.7	8
2516	The Potential Role of Renal Denervation in the Management of Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 4147.	1.0	4
2517	Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 577-590.	1.0	12
2518	Unequitable Heart Failure Therapy for Black, Hispanic and American-Indian Patients. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	16
2519	Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2071-2080.	2.2	16
2520	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	1.2	21
2521	SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. <i>Hypertension</i> , 2022, 79, 1633-1643.	1.3	67
2524	Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 381-393.	1.5	7
2525	Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	12
2526	Dapagliflozin Improves Cardiac Autonomic Function Measures in Type 2 Diabetic Patients with Cardiac Autonomic Neuropathy. , 0, , .		4
2527	Contrast-Induced Acute Kidney Injury in Diabetic Patients and SGLT-2 Inhibitors: A Preventive Opportunity or Promoting Element?. <i>Journal of Cardiovascular Pharmacology</i> , 2022, Publish Ahead of Print, .	0.8	6
2528	Dapagliflozin Improves Diabetic Cardiomyopathy by Modulating the Akt/mTOR Signaling Pathway. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	2
2529	SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy. <i>Circulation</i> , 2022, 146, 299-302.	1.6	6
2530	An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan. <i>Current Medical Research and Opinion</i> , 0, , 1-19.	0.9	0
2531	Progress in the management of patients with diabetes and chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 456-463.	1.0	1

#	ARTICLE	IF	CITATIONS
2532	Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). <i>Circulation</i> , 2022, 146, 289-298.	1.6	62
2533	Efficacy of three novel drugs in the treatment of heart failure: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29415.	0.4	0
2534	Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 9, 18-25.	1.4	11
2535	Post-transplant diabetes mellitus following heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1537-1546.	0.3	6
2536	Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through $\beta_3$ Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	13
2537	Guideline-Directed Medical Therapy and the Risk of Death in Primary Prevention Defibrillator Recipients. <i>JACC: Clinical Electrophysiology</i> , 2022, , .	1.3	4
2538	Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2 <sup>Â</sup> â€”TIMI 50 trial. <i>Clinical Cardiology</i> , 2022, 45, 831-838.	0.7	4
2539	Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. <i>American Journal of Medicine</i> , 2022, 135, 1336-1341.	0.6	1
2540	Functional and Metabolic Imaging in Heart Failure with Preserved Ejection Fraction: Promises, Challenges, and Clinical Utility. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 379-399.	1.3	2
2541	Sacubitril/valsartan adherenceâ€” because the best is sometimes difficult to replace the good. <i>European Journal of Heart Failure</i> , 2022, 24, 1516-1518.	2.9	3
2542	Impact analysis of heart failure across European countries: an ESCâ€”EHFA position paper. <i>ESC Heart Failure</i> , 2022, 9, 2767-2778.	1.4	17
2543	Vericiguat and NTâ€”proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial. <i>ESC Heart Failure</i> , 2022, 9, 3791-3803.	1.4	14
2544	Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction. <i>Life</i> , 2022, 12, 1112.	1.1	0
2545	Risk factors, mortality trends, and cardiovascular diseases in people with Type 1 diabetes and controls in Sweden: An observational cohort study. <i>Lancet Regional Health - Europe, The</i> , 2022, 21, 100469.	3.0	4
2546	Risk Factors, Outcomes and Healthcare Utilisation in Individuals with Multimorbidity Including Heart Failure, Chronic Kidney Disease and Type 2 Diabetes Mellitus - a National Electronic Health Record Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2547	A study on the beneficial evidence and mechanism of the therapeutic effect of dapagliflozin on heart failure. , 0, , 17-23.		1
2548	Consensus statement on the current pharmacological prevention and management of heart failure. <i>Medical Journal of Australia</i> , 2022, 217, 212-217.	0.8	14
2549	Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 543-551.	1.8	10

#	ARTICLE	IF	CITATIONS
2550	Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2551	Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 259.	3.8	29
2552	Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF). <i>Scientific Reports</i> , 2022, 12, .	1.6	11
2553	New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review. <i>Pharmaceutics</i> , 2022, 14, 1569.	2.0	0
2554	Effects of guideline-directed medical therapy in patients with left bundle branch block-induced cardiomyopathy. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2022, , .	0.4	0
2555	Sodium-glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease. <i>ESC Heart Failure</i> , 0, , .	1.4	1
2556	Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 753-760.	0.9	2
2558	Management of Heart Failure in Patients with Chronic Kidney Disease. <i>European Cardiology Review</i> , 0, 17, .	0.7	5
2559	DAPA-HF: Dapagliflozin is safe and efficacious in frail patients. , 0, , .		0
2560	Sodium-glucose co-transporter 2 inhibitors beyond diabetes. <i>Australian Prescriber</i> , 2022, 45, 121-124.	0.5	0
2561	Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
2562	Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. <i>Cardiovascular Research</i> , 2023, 118, 3451-3466.	1.8	9
2563	Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-16.	1.3	2
2564	2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1153-1167.	0.8	17
2565	Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
2567	Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1589-1599.	0.9	5
2568	A practical guide for the analysis, standardization and interpretation of oxygen consumption measurements. <i>Nature Metabolism</i> , 2022, 4, 978-994.	5.1	28
2569	SGLT2 inhibition reduces myocardial oxygen consumption. <i>Metabolism Open</i> , 2022, 15, 100207.	1.4	0

#	ARTICLE	IF	CITATIONS
2570	New Decongestion Strategies in an Evolving Heart Failure Landscape. <i>New England Journal of Medicine</i> , 2022, 387, 1231-1233.	13.9	4
2571	Liver tests and outcomes in heart failure with reduced ejection fraction: findings from <scp>DAPAâ€HF</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 1856-1868.	2.9	13
2572	Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial. <i>BMJ Open</i> , 2022, 12, e054100.	0.8	3
2574	SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9559.	1.8	6
2575	Therapeutic advances in guidelineâ€directed medical therapy for heart failure: the idealistic versus the pragmatic truth for vulnerable patients. <i>Postgraduate Medicine</i> , 2022, 134, 641-643.	0.9	1
2576	Empagliflozin in patients hospitalized for acute heart failure. <i>European Heart Journal</i> , 0, , .	1.0	2
2577	Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and metaâ€analysis. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	10
2578	SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 989-996.	1.3	7
2579	Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. <i>European Heart Journal</i> , 2022, 43, 4469-4479.	1.0	16
2580	SGLT2 Inhibitorsâ€A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	0
2581	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
2582	Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?. <i>Journal of Nephrology</i> , 2023, 36, 31-43.	0.9	4
2583	Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	18
2584	Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?. <i>Herz</i> , 0, , .	0.4	1
2585	Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 327-340.	1.1	4
2586	Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathy. <i>European Heart Journal</i> , 0, , .	1.0	1
2587	Management of heart failure with reduced ejection fraction. <i>Heart</i> , 0, , heartjnl-2020-318811.	1.2	4
2588	Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. <i>European Journal of Heart Failure</i> , 2022, 24, 1623-1624.	2.9	1

#	ARTICLE	IF	CITATIONS
2589	The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study. <i>BMC Endocrine Disorders</i> , 2022, 22, .	0.9	5
2590	New and developing pharmacotherapies for hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 647-666.	0.6	1
2591	Quality of life in patients with heart failure and improved ejection fraction: one-year changes and prognosis. <i>ESC Heart Failure</i> , 2022, 9, 3804-3813.	1.4	5
2592	Sodium-glucose co-transporter-2 inhibitors reduce the risk of new-onset stroke in patients with type 2 diabetes: A population-based cohort study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2594	Evaluating Digital Technologies for Implementation Science. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	0
2595	Early Clinical Experience with Dapagliflozin in Children with Heart Failure. <i>Pediatric Cardiology</i> , 2023, 44, 146-152.	0.6	6
2596	Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1892-1901.	2.9	13
2597	â€œDipâ€-in eGFR: Stay the Course With SGLT-2 Inhibition. <i>Circulation</i> , 2022, 146, 463-465.	1.6	3
2598	Revisiting â€™intensiveâ€™ blood glucose control: A causal directed acyclic graphâ€™guided systematic review of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2341-2352.	2.2	4
2599	Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. <i>Journal of Clinical Medicine</i> , 2022, 11, 4660.	1.0	6
2600	The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. <i>Pharmaceutics</i> , 2022, 14, 1730.	2.0	18
2601	Decongestion Models and Metrics in Acute Heart Failure: ESCAPE Data in the Age of the Implantable Cardiac Pressure Monitor. <i>Texas Heart Institute Journal</i> , 2022, 49, .	0.1	0
2602	SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease. <i>Current Medicinal Chemistry</i> , 2023, 30, 2039-2060.	1.2	4
2603	Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. <i>Cardiovascular Research</i> , 2023, 118, 3536-3555.	1.8	29
2604	Early changes in renal function after sodiumâ€™glucose cotransporter 2 inhibitor initiation in <scp>EMPERORâ€™Reduced</scp>: the end ofâ€™the dilemma?. <i>European Journal of Heart Failure</i> , 2022, 24, 1840-1843.	2.9	1
2605	The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1201-1210.	0.8	12
2606	SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 601-613.	1.0	3
2607	Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3

#	ARTICLE	IF	CITATIONS
2608	Is the benefit of sodium-glucose cotransporter inhibitors over heart failure progression on the kidney side?. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0
2609	Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management. <i>Current Heart Failure Reports</i> , 2022, 19, 303-315.	1.3	3
2610	Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control. <i>International Journal of Cardiology</i> , 2022, 367, 81-89.	0.8	3
2611	Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-10.	1.0	5
2612	Implantable Cardioverter-Defibrillator Therapy in the Contemporary Era of Heart Failure Therapeutics. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 1031-1033.	1.3	1
2613	Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming. <i>EBioMedicine</i> , 2022, 83, 104215.	2.7	26
2614	SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, F361-F369.	1.3	11
2615	Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.. <i>European Journal of Pharmacology</i> , 2022, 931, 175194.	1.7	8
2616	Dapagliflozin for patients with heart failure and reduced ejection fraction. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, 35, 51-53.	0.1	1
2617	The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents. <i>International Immunopharmacology</i> , 2022, 111, 109080.	1.7	28
2618	Divergent effect of blood glucose dysregulation on long-term clinical outcome in acute decompensated heart failure: A reappraisal in contemporary practice. <i>International Journal of Cardiology</i> , 2022, 365, 91-99.	0.8	4
2619	Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. <i>IJC Heart and Vasculature</i> , 2022, 42, 101103.	0.6	4
2620	Benefits of heart failure-specific pharmacotherapy in frail hospitalised patients: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e059905.	0.8	3
2621	NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10632.	1.8	12
2622	Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	19
2623	Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1711-1722.	1.1	17
2624	Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1671-1685.	5.7	2
2625	Initial experience of vericiguat add-on therapy upon fantastic four medical therapy in a patient with systolic heart failure. <i>Journal of Cardiology Cases</i> , 2022, 26, 429-431.	0.2	3



#	ARTICLE	IF	CITATIONS
2626	Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. <i>Journal of Endocrinology Metabolism and Diabetes of South Africa</i> , 2023, 28, 7-13.	0.4	1
2627	Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1302-1310.	1.2	49
2628	Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. <i>Pharmacological Research</i> , 2022, 184, 106448.	3.1	20
2629	Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113677.	2.5	10
2630	Evidencia molecular y clínica del beneficio cardiovascular de los inhibidores SGLT2: estado del arte. <i>Medicina UPB</i> , 2022, 41, 145-156.	0.1	1
2631	Sodium-Glucose Cotransporter-2 (SGLT2) Expression in Diabetic and Non-Diabetic Failing Human Cardiomyocytes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2632	SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 62-72.	0.5	3
2633	Interaction Between Heart Failure and Atrial Fibrillation. <i>International Journal of Heart Failure</i> , 2022, 4, 139.	0.9	1
2634	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial). <i>Journal of the Practice of Cardiovascular Sciences</i> , 2022, 8, 77.	0.0	0
2635	Renal Effects of SGLT2 Inhibitors and Potential Clinical Implications: Beyond the Heart. <i>International Journal of Heart Failure</i> , 0, 4, .	0.9	0
2636	Herz und Diabetes. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0
2637	Overview of trials from AHA 2021. <i>Global Cardiology Science &amp; Practice</i> , 2021, 2021, .	0.3	0
2638	Renoprotection by Dapagliflozin in a Non-Diabetic Model of Cardiorenal Syndrome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2639	Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients. <i>International Journal of Heart Failure</i> , 0, 4, .	0.9	7
2640	Cardiorenal Syndrome. <i>Nephrology Self-assessment Program: NephSAP</i> , 2022, 21, 29-40.	3.0	0
2641	Flozins in heart failure – a new reimbursement indication. , 2022, 20, 19-25.		1
2642	Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1167.	0.8	4
2644	Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. <i>Nature Medicine</i> , 2022, 28, 1956-1964.	15.2	111

#	ARTICLE	IF	CITATIONS
2645	Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure. <i>European Heart Journal</i> , 2022, 43, 4433-4435.	1.0	2
2646	Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	32
2647	Empagliflozin in acute myocardial infarction: the EMMY trial. <i>European Heart Journal</i> , 2022, 43, 4421-4432.	1.0	93
2648	Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	3
2649	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction. <i>JAMA Cardiology</i> , 2022, 7, 1067.	3.0	12
2650	Sex Differences in Frequency of Instrumental Activities of Daily Living after Cardiac Rehabilitation and Its Impact on Outcomes in Patients with Heart Failure. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 289.	0.8	2
2651	Diabetes Mellitus Type 2, Prediabetes, and Chronic Heart Failure. , 0, , .		0
2652	Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. <i>Medicina (Lithuania)</i> , 2022, 58, 1128.	0.8	4
2653	Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 5027.	1.0	3
2654	Meta-analysis of the association between new hypoglycemic agents and digestive diseases. <i>Medicine (United States)</i> , 2022, 101, e30072.	0.4	2
2655	Glifozins and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, , .	1.2	0
2656	How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. <i>International Journal of Cardiology</i> , 2023, 371, 236-243.	0.8	4
2657	SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. <i>Lancet, The</i> , 2022, 400, 757-767.	6.3	307
2658	A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena. <i>World Journal of Diabetes</i> , 2022, 13, 683-695.	1.3	2
2659	Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	4
2661	Patient-Reported Outcome Measures in Cardiovascular Disease: An Evidence Map of the Psychometric Properties of Health Status Instruments. <i>Annals of Internal Medicine</i> , 2022, 175, 1431-1439.	2.0	10
2662	Disturbed Cardiac Metabolism Triggers Atrial Arrhythmogenesis in Diabetes Mellitus: Energy Substrate Alternate as a Potential Therapeutic Intervention. <i>Cells</i> , 2022, 11, 2915.	1.8	1
2663	Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 259-266.	1.0	1

#	ARTICLE	IF	CITATIONS
2664	Cardiopulmonary functional capacity: another piece of the puzzle of sodium-glucose cotransporter 2 inhibition in heart failure?. <i>European Journal of Heart Failure</i> , 2022, 24, 1827-1828.	2.9	0
2665	Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors. <i>Biomolecules</i> , 2022, 12, 1349.	1.8	4
2666	SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study. <i>Diabetes Care</i> , 2022, 45, 2718-2728.	4.3	21
2668	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2022, 65, 1925-1966.	2.9	273
2669	JCS 2022 Guideline on Management and Re-Interventional Therapy in Patients With Congenital Heart Disease Long-Term After Initial Repair. <i>Circulation Journal</i> , 2022, 86, 1591-1690.	0.7	6
2670	Edema formation in congestive heart failure and the underlying mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
2671	SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?. <i>European Heart Journal</i> , 0, , .	1.0	1
2672	Impact of breakthrough trials on prescription trends of sodium-glucose cotransporter-2 inhibitors in Japan: An interrupted time-series analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 0, , .	0.7	1
2673	Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10146.	1.8	26
2674	Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling. <i>BMC Medicine</i> , 2022, 20, .	2.3	9
2675	Impact of Worsening Heart Failure on Long-Term Prognosis in Patients With Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2022, 184, 63-71.	0.7	2
2676	Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
2677	New Strategies to Prevent Rehospitalizations for Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 199-212.	0.4	2
2678	Death without Previous Hospital Readmission in Patients with Heart Failure with Reduced Ejection Fraction—A New Endpoint from Old Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5518.	1.0	0
2679	“Acute Heart Failure™: Should We Abandon the Term Altogether?. <i>Current Heart Failure Reports</i> , 2022, 19, 425-434.	1.3	3
2680	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2022, 45, 2753-2786.	4.3	435
2681	(Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i> 2022, 64, 441-454.	0.1	0
2682	Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation. <i>JACC: Heart Failure</i> , 2023, 11, 1-14.	1.9	51

#	ARTICLE	IF	CITATIONS
2683	Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease. <i>International Journal of Cardiology</i> , 2023, 370, 294-299.	0.8	4
2684	Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
2685	How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?. , 2022, 1, .		0
2686	Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the <scp>EMPULSE</scp> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1844-1852.	2.9	21
2687	Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern?. <i>Kidney360</i> , 2022, 3, 1991-1993.	0.9	3
2688	The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 57-68.	1.3	2
2689	NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction. <i>Antioxidants</i> , 2022, 11, 1822.	2.2	14
2690	Sex and Gender Bias as a Mechanistic Determinant of Cardiovascular Disease Outcomes. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1865-1880.	0.8	13
2691	Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	1
2692	New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
2693	Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	0.5	0
2694	Emerging Treatment Approaches to Improve Outcomes in Patients with Heart Failure. , 0, Publish Ahead of Print, .		0
2695	Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	30
2696	The Sodiumâ€“Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. <i>Antioxidants</i> , 2022, 11, 1878.	2.2	6
2697	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. <i>Biomedicines</i> , 2022, 10, 2274.	1.4	22
2698	Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease. <i>Molecules</i> , 2022, 27, 6221.	1.7	9
2699	Current Management of Heart Failure with Preserved Ejection Fraction. <i>International Journal of Angiology</i> , 2022, 31, 166-178.	0.2	0
2700	Ethnic and socioeconomic disparities in initiation of secondâ€“line antidiabetic treatment for people with type 2 diabetes in England: A crossâ€“sectional study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 282-292.	2.2	7

#	ARTICLE	IF	CITATIONS
2701	In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	28
2702	Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. <i>Circulation</i> , 2022, 146, 980-994.	1.6	55
2703	The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 1185-1199.	0.6	1
2704	Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 602-610.	2.2	17
2706	The grand challenge of discovering new cardiovascular drugs. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	3
2707	Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain. <i>Journal of Clinical Medicine</i> , 2022, 11, 5199.	1.0	12
2708	Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction. <i>International Heart Journal</i> , 2022, 63, 852-856.	0.5	4
2709	Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives. <i>Pharmaceutics</i> , 2022, 14, 1964.	2.0	0
2710	A Network Pharmacology to Explore the Potential Targets of Canagliflozin and Dapagliflozin in Treating Atherosclerosis. , 2022, 1, 53-70.		0
2711	Vericiguat "Filling the Gaps in Heart Failure Management. <i>Indian Journal of Clinical Cardiology</i> , 2022, 3, 133-134.	0.3	0
2712	Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
2713	Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?. <i>Metabolism: Clinical and Experimental</i> , 2022, , 155309.	1.5	0
2714	Accuracy of the Number Needed to Treat Compared With Diagnostic Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, , .	1.2	0
2715	Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes. <i>International Journal of Cardiology</i> , 2023, 370, 300-308.	0.8	3
2716	A review of cardiovascular benefits of SGLT2 inhibitors. <i>Medicine (United States)</i> , 2022, 101, e30310.	0.4	1
2717	The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
2718	A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 1342-1350.	1.0	2
2719	Use of Glucose-Lowering Agents in Diabetes and CKD. <i>Kidney International Reports</i> , 2022, 7, 2589-2607.	0.4	7

#	ARTICLE	IF	CITATIONS
2720	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11336.	1.8	3
2721	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. <i>Journal of Clinical Hypertension</i> , 2022, 24, 1218-1225.	1.0	1
2722	Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2022, 387, 1089-1098.	13.9	843
2724	Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. <i>Annales D'Endocrinologie</i> , 2023, 84, 57-68.	0.6	2
2725	A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 293-301.	2.2	7
2726	SGLT2 Inhibitors for treating diabetes in people with chronic kidney disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	1
2727	Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. <i>Heart Failure Clinics</i> , 2022, 18, 645-654.	1.0	3
2728	SGLT2 Inhibitors in Heart Failure. <i>Heart Failure Clinics</i> , 2022, 18, 587-596.	1.0	6
2729	Part Six: Antidiabetic Medication Benefits Beyond Glucose Lowering in Older People. , 2022, 37, 477-487.		0
2730	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3442-3451.	1.8	7
2731	Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 223-233.	1.4	6
2732	Inhibiting the proximal nephron in acute heart failure—Emerging data on kidney safety and efficacy. <i>European Journal of Heart Failure</i> , 2022, 24, 1853-1855.	2.9	0
2733	Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of <sc>EMPEROR-Reduced</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 2297-2304.	2.9	13
2734	Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1883-1891.	2.9	10
2735	Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. <i>Heart Failure Clinics</i> , 2022, 18, 597-607.	1.0	2
2736	Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 444-453.	2.2	19
2737	Actualization of Positions of Gliflozins in Treatment Algorithms for Patients with Heart Failure: Chronology of Success. <i>IP Pavlov Russian Medical Biological Herald</i> , 2022, 30, 411-421.	0.2	1
2738	Association between class of foundational medication for heart failure and prognosis in heart failure with reduced/mildly reduced ejection fraction. <i>Scientific Reports</i> , 2022, 12, .	1.6	0

#	ARTICLE	IF	CITATIONS
2739	Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age: A Danish Nationwide Study. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	3
2740	SGLT-2 inhibition a useful tool in the treatment of heart failure with reduced and preserved ejection fraction. <i>Vnitřní Lekarství</i> , 2022, 68, 393-397.	0.1	0
2741	SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction. <i>Heart Failure Clinics</i> , 2022, 18, 561-577.	1.0	2
2742	Management of Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1346.	3.8	11
2743	Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. <i>Heart Failure Reviews</i> , 2023, 28, 949-959.	1.7	7
2744	The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. <i>Age and Ageing</i> , 2022, 51, .	0.7	13
2745	SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2022, 18, 579-586.	1.0	3
2746	Sodium-Glucose Cotransporter-2 Inhibitors: Risks vs. Rewards When Caring for Older Adults. <i>Journal of Gerontological Nursing</i> , 2022, 48, 7-13.	0.3	0
2747	Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 1227.	3.0	17
2748	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. <i>Current Heart Failure Reports</i> , 2022, 19, 467-475.	1.3	2
2749	Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure. <i>Pharmacotherapy</i> , 0, , .	1.2	0
2750	SGLT2 Inhibitors Are Lifesavers in Heart Failure. <i>Heart Failure Clinics</i> , 2022, 18, xi-xiv.	1.0	0
2751	SGLT2 Inhibitors and Safety in Older Patients. <i>Heart Failure Clinics</i> , 2022, 18, 635-643.	1.0	9
2752	Acetylation and phosphorylation changes to cardiac proteins in experimental HFpEF due to metabolic risk reveal targets for treatment. <i>Life Sciences</i> , 2022, 309, 120998.	2.0	4
2753	â€œA Missed Therapeutic Opportunity? SGLT-2 Inhibitor Use in General Medicine Patients With Heart Failure: A Retrospective Audit of Admissions to a Tertiary Health Serviceâ€™. <i>Clinical Medicine Insights: Cardiology</i> , 2022, 16, 117954682211336.	0.6	1
2754	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). <i>Eurasian Heart Journal</i> , 2022, , 6-56.	0.2	0
2755	The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11987.	1.8	7
2756	Baroreflex activation therapy in advanced heart failure therapy: insights from a realâ€‘world scenario. <i>ESC Heart Failure</i> , 2023, 10, 284-294.	1.4	8

#	ARTICLE	IF	CITATIONS
2757	Toward Revision of the "Best Practice for Diabetic Patients on Hemodialysis 2012"™. <i>Kidney and Dialysis</i> , 2022, 2, 495-511.	0.5	3
2758	Diabetes Mellitus and Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 1698.	1.1	4
2759	Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure. <i>Healthcare (Switzerland)</i> , 2022, 10, 2133.	1.0	1
2760	Network <sc>Meta-Interpolation</sc> : Effect modification adjustment in network meta-analysis using subgroup analyses. <i>Research Synthesis Methods</i> , 0, , .	4.2	0
2761	Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. <i>PLoS ONE</i> , 2022, 17, e0269414.	1.1	4
2762	Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1260-1270.	0.4	5
2763	Pooled analysis of DAPA-HF and DELIVER. , 0, , .		0
2764	Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice. <i>Journal of Cardiology</i> , 2023, 81, 347-355.	0.8	3
2765	The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 134-144.	1.5	11
2766	Physicians's™ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 6051.	1.0	3
2767	Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction. <i>ESC Heart Failure</i> , 0, , .	1.4	4
2768	Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. <i>Journal of Cardiac Failure</i> , 2023, 29, 87-107.	0.7	8
2769	New principles for the treatment of chronic heart failure: the phenomenon of sodium-glucose cotransporter type 2 inhibitors. <i>Meditsinskiy Sovet</i> , 2022, , 44-51.	0.1	0
2770	The role of bioelectrical phase angle in patients with heart failure. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 465-477.	2.6	8
2771	SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice. <i>Biomedicines</i> , 2022, 10, 2458.	1.4	9
2772	Updates on Pharmacologic Management of Microvascular Angina. <i>Cardiovascular Therapeutics</i> , 2022, 2022, 1-19.	1.1	4
2774	SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. <i>ESC Heart Failure</i> , 2023, 10, 397-404.	1.4	9
2775	Effect of Dapagliflozin on Left Ventricular Diastolic Function in Diabetics - A Prospective Interventional Study. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 0, 7, 137-142.	0.1	0



#	ARTICLE	IF	CITATIONS
2778	Ketones: the double-edged sword of SGLT2 inhibitors?. <i>Diabetologia</i> , 2023, 66, 23-32.	2.9	14
2779	Obesity as a risk factor for cardiac arrhythmias. , 2022, 1, e000308.		4
2780	Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics. <i>Cells</i> , 2022, 11, 3372.	1.8	7
2781	Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications. <i>Biomedicines</i> , 2022, 10, 2471.	1.4	9
2782	Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	13
2783	Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 532-541.	0.4	8
2784	Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2023, 28, 925-936.	1.7	8
2785	Metabolomics implicate eicosanoids in severe functional mitral regurgitation. <i>ESC Heart Failure</i> , 2023, 10, 311-321.	1.4	3
2786	Benefits of SGLT2 inhibitors in arrhythmias. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
2787	Left Ventricular Remodeling and Heart Failure Predictors in Acute Myocardial Infarction Patients with Preserved Left Ventricular Ejection Fraction after Successful Percutaneous Intervention in Western Romania. <i>Life</i> , 2022, 12, 1636.	1.1	1
2788	Consensus validation of a screening tool for cardiovascular pharmacotherapy in geriatric patients: the RASP_CARDIO list (Rationalization of Home Medication by an Adjusted STOPP list in Older) Tj ETQq0 0 0 rgBT /Overlock 20 Tf 50 33		
2789	Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , 2022, 12, e060655.	0.8	15
2790	Optimized dosing of guideline-directed medical therapies is essential in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2023, 370, 325-326.	0.8	0
2791	One size fits all: The story of SGLT2 inhibitors in heart failure. <i>Med</i> , 2022, 3, 735-739.	2.2	3
2792	Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. <i>European Journal of Heart Failure</i> , 2022, 24, 2029-2036.	2.9	11
2793	Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	3
2794	Promising directions in the treatment of chronic heart failure: improving old or developing new ones?. <i>Bulletin of Siberian Medicine</i> , 2022, 21, 181-197.	0.1	1
2795	Clinical implications and guidelines for CKD in type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 542-550.	0.4	4

#	ARTICLE	IF	CITATIONS
2796	Clinical inertia in heart failure care – Should we worry? Insights from –real-world–practice. Revista Portuguesa De Cardiologia, 2022, , .	0.2	0
2797	The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents. REC: CardioClinics, 2022, , .	0.1	0
2798	Safety of sodium–glucose cotransporter–2 inhibitors in Asian type–2 diabetes populations. Journal of Diabetes Investigation, 2023, 14, 167-182.	1.1	3
2799	New paradigm for the management of cardio-nephro-metabolic syndrome: multidisciplinary approach and role of telemedicine. Minerva Medica, 2023, 114, .	0.3	2
2800	A practical approach to the guideline–directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Failure, 2023, 10, 24-31.	1.4	9
2801	Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms. International Journal of Molecular Sciences, 2022, 23, 12325.	1.8	12
2802	Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?. Nephrology Dialysis Transplantation, 2023, 38, 1355-1365.	0.4	2
2803	SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials. European Journal of Pharmacology, 2022, 936, 175354.	1.7	4
2804	Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	15
2805	The association between beta–blockers and outcomes in patients with heart failure and concurrent Alzheimer’s disease and related dementias. Journal of the American Geriatrics Society, 0, , .	1.3	2
2806	Gaps in our knowledge of managing inpatient dysglycaemia and diabetes in non–critically ill adults: A call for further research. Diabetic Medicine, 2023, 40, .	1.2	3
2807	Emerging roles of sodium–glucose cotransporter inhibitors. The Prescriber, 2022, 33, 11-17.	0.1	0
2808	Value of SGLT-2 inhibitors in the treatment of chronic kidney disease. Wiener Klinische Wochenschrift, 2023, 135, 97-109.	1.0	1
2809	Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement. Current Molecular Pharmacology, 2022, 16, .	0.7	2
2810	Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 186, 150-155.	0.7	5
2811	Biochemical profiling, pharmacological management and clinical outcomes in type 2 diabetes in Danish primary care from 2001 to 2015. Primary Care Diabetes, 2022, 16, 818-823.	0.9	1
2812	Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2022, 108, 221-231.	1.8	10
2813	Low blood pressure and guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2023, 370, 255-262.	0.8	3

#	ARTICLE	IF	CITATIONS
2815	Expert opinion on the cooperation of diabetologists and internists with nephrologists in the care of patients with chronic kidney diseases. <i>Vnitřní Lekarství</i> , 2022, 68, 426-431.	0.1	1
2816	Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12823.	1.8	9
2817	Acute decompensation of heart failure: state of the problem. <i>Terapevticheski Arkhiv</i> , 2022, 94, 1047-1051.	0.2	3
2818	Cardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management. <i>Clinical Therapeutics</i> , 2022, 44, 1394-1416.	1.1	13
2819	The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
2820	The role of blood pressure management in stroke prevention: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 829-838.	0.6	3
2823	Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e2235995.	2.8	10
2824	Prognostic value of right ventricular strain and peak oxygen consumption in heart failure with reduced ejection fraction. <i>International Journal of Cardiovascular Imaging</i> , 0, , .	0.7	2
2825	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2022, 102, S1-S127.	2.6	246
2826	Cardiorenal disease management in type 2 diabetes: An expert consensus. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102661.	1.8	1
2827	Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from <sc>EMPEROR&lt;/sc>. <i>European Journal of Heart Failure</i> , 2023, 25, 117-127.	2.9	19
2828	Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2829	Target heart rate in heart failure with reduced ejection fraction and atrial fibrillation: Goldilocks zone. <i>American Heart Journal Plus</i> , 2022, 23, 100218.	0.3	1
2830	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1957-1974.	0.9	0
2831	Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. <i>Kidney International</i> , 2022, 102, 990-999.	2.6	78
2832	Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives. <i>International Journal of Nephrology and Renovascular Disease</i> , 0, Volume 15, 289-308.	0.8	3
2833	An exploration of the experience of dapagliflozin in clinical practice. <i>Future Science OA</i> , 2022, 8, .	0.9	1
2834	Myocardial Viability Testing in the Management of Ischemic Heart Failure. <i>Life</i> , 2022, 12, 1760.	1.1	6

#	ARTICLE	IF	CITATIONS
2835	Dapagliflozin attenuates residual cardiac remodeling after surgical ventricular reconstruction in mice with an enlarged heart after myocardial infarction. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113765.	2.5	1
2836	Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes. <i>Biochemical Pharmacology</i> , 2022, 206, 115304.	2.0	5
2837	Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism. <i>Molecular Metabolism</i> , 2022, 66, 101620.	3.0	8
2838	Pharmacotherapy of type 2 diabetes: An update and future directions. <i>Metabolism: Clinical and Experimental</i> , 2022, 137, 155332.	1.5	35
2839	Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. <i>Journal of Kidney Care</i> , 2022, 7, 216-224.	0.1	0
2840	Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 869-881.	5.5	15
2841	Univariate and Multivariate Determination of Dapagliflozin and Saxagliptin in Bulk and Dosage Form. <i>Journal of AOAC INTERNATIONAL</i> , 2023, 106, 794-803.	0.7	5
2842	Cu-catalyzed Stereoselective Borylation and Pd-catalyzed Stereospecific Cross-Coupling to Give Aryl Glycosides. <i>Chemistry - A European Journal</i> , 0, , .	1.7	2
2843	Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. <i>Circulation</i> , 2023, 147, 624-634.	1.6	18
2845	Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. <i>Clinical Science</i> , 2022, 136, 1631-1651.	1.8	2
2846	Estimated Glomerular Filtration Rate (eGFR) Slope Assessment as a Surrogate End-point in Cardiovascular trials: Impediments, and Future Directions. <i>Current Problems in Cardiology</i> , 2023, 48, 101508.	1.1	1
2847	Contemporary Data on the Status and Medical Management of Acute Heart Failure. <i>Current Cardiology Reports</i> , 0, , .	1.3	2
2848	Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	4
2849	SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis. <i>Clinical Drug Investigation</i> , 0, , .	1.1	0
2850	Sequencing of medical therapy in heart failure with a reduced ejection fraction. <i>Heart</i> , 0, , heartjnl-2022-321497.	1.2	1
2851	Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. <i>Current Problems in Cardiology</i> , 2023, 48, 101509.	1.1	5
2852	Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	0
2853	Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes. <i>Endocrine Reviews</i> , 2023, 44, 357-378.	8.9	14

#	ARTICLE	IF	CITATIONS
2854	Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Internal Medicine</i> , 2022, 182, 1278.	2.6	26
2855	Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. <i>Lancet</i> , The, 2022, 400, 1788-1801.	6.3	249
2856	Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. <i>Transplantation Reviews</i> , 2023, 37, 100729.	1.2	6
2857	Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. <i>Journal of Pharmacy Practice</i> , 2024, 37, 410-414.	0.5	1
2858	Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges. <i>European Heart Journal</i> , 0, , .	1.0	0
2859	Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	3
2860	Prescribing Trends of the Sodium-Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015-2021). <i>Canadian Journal of Diabetes</i> , 2023, 47, 153-161.	0.4	1
2861	SGLT2 inhibitors in heart failure: insights from plasma proteomics. <i>European Heart Journal</i> , 2022, 43, 5003-5005.	1.0	4
2862	Does exercise training improve exercise tolerance, quality of life, and echocardiographic parameters in patients with heart failure with preserved ejection fraction? A systematic review and meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2023, 28, 795-806.	1.7	2
2863	Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes. <i>ESC Heart Failure</i> , 2023, 10, 552-567.	1.4	3
2864	Diabetic cardiomyopathy: a brief summary on lipid toxicity. <i>ESC Heart Failure</i> , 2023, 10, 776-790.	1.4	6
2865	Heart Failure with Improved Ejection Fraction: Insight into the Variable Nature of Left Ventricular Systolic Function. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14400.	1.2	9
2866	Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial. <i>Hypertension Research</i> , 2023, 46, 495-506.	1.5	2
2867	Successful conservative management of left ventricular assist device candidates. <i>ESC Heart Failure</i> , 0, , .	1.4	1
2868	Instituting a Successful Discharge Plan for Patients With Type 2 Diabetes: Challenges and Solutions. <i>Diabetes Spectrum</i> , 2022, 35, 440-451.	0.4	2
2869	Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire <sc>HF</sc> trial. <i>European Journal of Heart Failure</i> , 2023, 25, 226-234.	2.9	26
2870	Empagliflozin: A Review in Symptomatic Chronic Heart Failure. <i>Drugs</i> , 2022, 82, 1591-1602.	4.9	4
2871	Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. <i>Heart</i> , 2023, 109, 470-477.	1.2	14

#	ARTICLE	IF	CITATIONS
2872	Risk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
2873	Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2023, 11, 44-54.	1.9	1
2874	Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. <i>JAMA Cardiology</i> , 2023, 8, 66.	3.0	10
2875	Sodium-glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome. <i>European Heart Journal Supplements</i> , 2022, 24, I68-I71.	0.0	3
2876	Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
2877	Perioperative changes in left ventricular systolic function following surgical revascularization. <i>PLoS ONE</i> , 2022, 17, e0277454.	1.1	1
2878	Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	16
2879	Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. <i>Circulation</i> , 2023, 147, 284-295.	1.6	13
2880	IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2023, 11, 291-304.	1.9	5
2881	Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 761-769.	0.6	4
2882	Sodium-glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside. <i>Fundamental and Clinical Pharmacology</i> , 2023, 37, 481-492.	1.0	2
2883	Impact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14296.	1.8	4
2884	Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 0, .	4.3	0
2885	Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. <i>Diabetologia</i> , 2023, 66, 642-656.	2.9	7
2888	Meta-Analysis on the Safety and Efficacy of Sodium Glucose Cotransporters 2 Inhibitors in Patients With Heart Failure With and Without Diabetes. <i>American Journal of Cardiology</i> , 2023, 187, 93-99.	0.7	2
2889	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 40-53.	0.5	0
2890	Corrigendum to "Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes" [Biochem. Pharmacol. 206 (2022) 115304]. <i>Biochemical Pharmacology</i> , 2023, 207, 115349.	2.0	0
2891	Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. <i>Pharmacological Research</i> , 2023, 187, 106597.	3.1	37

#	ARTICLE	IF	CITATIONS
2892	Efficacy of SGLT2 Inhibitors in Patients With Diabetes and Nonobstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2023, 188, 80-86.	0.7	2
2893	Impact of a Medication Optimization Clinic on Heart Failure Hospitalizations. <i>American Journal of Cardiology</i> , 2023, 188, 102-109.	0.7	3
2894	Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2023, 188, 52-60.	0.7	1
2895	The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. , 2023, 14, 46.		9
2896	Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). <i>Eurasian Heart Journal</i> , 2022, , 6-56.	0.2	0
2897	Impacting Management of Chronic Kidney Disease Through Primary Care Practice Audits: A Quality Improvement Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, 205435812211448.	0.6	1
2898	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium-Glucose Co-transporter-2 Inhibitors. <i>European Endocrinology</i> , 2022, 18, 106.	0.8	4
2899	FisiopatologÃa y alteraciones clÃnicas de la diabetes mellitus tipo 2. <i>Nova</i> , 2022, 20, 65-103.	0.2	1
2901	The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder. <i>IHJ Cardiovascular Case Reports (CVCR)</i> , 2022, 6, 158-162.	0.0	0
2902	Sodium-Glucose Co-transporter 2 Inhibitors/Gliflozins: A New Miracle Therapy for Heart Failure Patients Irrespective of Diabetes Status?. <i>Cureus</i> , 2022, , .	0.2	1
2903	VPS34-dependent control of apical membrane function of proximal tubule cells and nutrient recovery by the kidney. <i>Science Signaling</i> , 2022, 15, .	1.6	5
2904	Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2905	Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease. <i>Terapevticheski Arkhiv</i> , 2022, 94, 1188-1196.	0.2	0
2906	Comparative evaluation new glucagon-like peptide 1 receptor agonist semaglutide and sodium-glucose cotransporter-2 inhibitors empagliflozin on left ventricular diastolic function in patients with arterial hypertension, obesity and type 2 diabetes mellitus. <i>Systemic Hypertension</i> , 2022, 19, 39-48.	0.1	0
2907	Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. <i>Current Atherosclerosis Reports</i> , 2022, 24, 925-937.	2.0	2
2908	The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 166.	0.6	2
2909	Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 419.	0.8	5
2910	Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Nephrilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report. <i>Journal of Pharmacy Practice</i> , 2024, 37, 495-499.	0.5	1

#	ARTICLE	IF	CITATIONS
2911	Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens From a Cardiologist's View. <i>Journal of Clinical Medicine</i> , 2022, 11, 7041.	1.0	7
2912	Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14598.	1.8	5
2913	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. <i>Nature Reviews Endocrinology</i> , 2023, 19, 151-163.	4.3	21
2914	Empagliflozin versus dapagliflozin in heart failure patients – preliminary results from the Dubrava University Hospital Registry. <i>Cardiologia Croatica</i> , 2022, 17, 267-267.	0.0	0
2915	Empagliflozin and Dapagliflozin Increase Na <sup>+</sup> and Inward Rectifier K <sup>+</sup> Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs). <i>Cells</i> , 2022, 11, 3707.	1.8	4
2916	Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis. <i>World Journal of Cardiology</i> , 0, 14, 599-616.	0.5	1
2917	Mechanisms of GLP-1 Receptor Agonists on the Cardio-Renal Protective Effects. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2022, 53, 249-262.	0.1	0
2918	Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. <i>Pharmaceutics</i> , 2022, 14, 2629.	2.0	1
2919	Effects of sodium-glucose cotransporter-2 inhibitors on nutritional status in heart failure with reduced ejection fraction. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1576-1581.	0.3	0
2920	Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews. <i>International Journal of Cardiology</i> , 2022, , .	0.8	1
2921	SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials. <i>Healthcare (Switzerland)</i> , 2022, 10, 2356.	1.0	1
2922	Secular trends in the utility of SGLT2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South East Queensland. <i>Internal Medicine Journal</i> , 0, , .	0.5	0
2923	Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial. <i>Journal of Cardiology</i> , 2022, , .	0.8	0
2924	How to Initiate and Uptitrate GDMT in Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 992-995.	1.9	4
2925	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. <i>Diabetes Therapy</i> , 0, , .	1.2	0
2926	Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
2927	Multicenter, Open Label, Randomized Controlled Superiority Trial for Availability to Reduce Nocturnal Urination Frequency: Study Protocol for a TOP-STAR Study. <i>International Journal of Diabetology</i> , 2022, 3, 620-633.	0.9	1
2928	Elevated circulating level of $\beta$ -aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	3



#	ARTICLE	IF	CITATIONS
2929	C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
2930	Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. <i>Journal of Pharmacy Practice</i> , 2024, 37, 435-441.	0.5	0
2931	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Circulation</i> , 2022, 146, 1882-1894.	1.6	58
2932	Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. <i>Cardiovascular Research</i> , 2023, 118, 3467-3481.	1.8	4
2933	A Critical Evaluation of Patient Pathways and Missed Opportunities in Treatment for Heart Failure. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 455.	0.8	1
2934	The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2023, 42, e1-e141.	0.3	78
2935	Cardiorenal prevention as the key player in the reduction of all-cause mortality. <i>Nefrologia</i> , 2023, 43, 514-515.	0.2	0
2936	Cardiorenal protections of SGLT2 inhibitors in the treatment of type 2 diabetes. <i>Current Diabetes Reviews</i> , 2022, 19, .	0.6	1
2937	Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis. <i>Diabetes Therapy</i> , 0, , .	1.2	0
2938	Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 113-126.	1.0	2
2939	Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
2940	Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure. <i>Circulation: Heart Failure</i> , 0, , .	1.6	0
2941	Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. <i>European Heart Journal Supplements</i> , 2022, 24, L29-L37.	0.0	0
2943	Heart failure with preserved left ventricular ejection fraction amidst diabetes mellitus: from general mechanisms to possible therapy tactics. <i>Cardiosomatics</i> , 2022, 13, 115-123.	0.2	0
2944	Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial. <i>American Heart Journal</i> , 2023, 257, 85-92.	1.2	1
2945	SGLT-2 inhibitors: new effective drugs for treatment of heart failure. <i>Journal of Education, Health and Sport</i> , 2022, 13, 55-61.	0.0	0
2946	The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 15-34.	0.6	4
2947	Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent. <i>British Journal of Diabetes</i> , 2022, 22, 87-94.	0.1	0

#	ARTICLE	IF	CITATIONS
2948	10. Cardiovascular Disease and Risk Management: <i>Standards of Care in Diabetesâ€™2023</i>. Diabetes Care, 2023, 46, S158-S190.	4.3	156
2949	Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women. Journal of the Endocrine Society, 2022, 7, .	0.1	2
2951	Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction. Nefrologia, 2022, , .	0.2	0
2952	A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction. European Journal of Health Economics, 2023, 24, 1441-1454.	1.4	9
2953	Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. Journal of the American Heart Association, 0, , .	1.6	1
2954	Polypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist. Cardiac Failure Review, 0, 8, .	1.2	1
2955	A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetology International, 2023, 14, 1-14.	0.7	8
2956	The Optimization of Guideline-Directed Medical Therapy during Hospitalization among Patients with Heart Failure with Reduced Ejection Fraction in Daily Clinical Practice. Cardiology, 2023, 148, 27-37.	0.6	3
2957	Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease. Annals of Internal Medicine, 2023, 176, 59-66.	2.0	7
2958	Getting ahead of the game: in-hospital initiation of HFrEF therapies. European Heart Journal Supplements, 2022, 24, L38-L44.	0.0	3
2959	Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 2022, 28, 2504-2511.	15.2	16
2960	The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest. Life, 2022, 12, 2062.	1.1	5
2961	Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. , 2023, 242, 108330.		5
2962	Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
2963	Prevalence and treatment of diabetes and pre-diabetes in a real-world heart failure population: a single-centre cross-sectional study. Open Heart, 2022, 9, e002133.	0.9	3
2964	Combining Iron Supplements With SGLT2 Inhibitor-Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events?. Journal of Cardiac Failure, 2023, 29, 403-406.	0.7	6
2965	The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy. Antioxidants, 2022, 11, 2500.	2.2	4
2966	ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Failure, 2023, 10, 1531-1544.	1.4	19

#	ARTICLE	IF	CITATIONS
2967	Are arrhythmias the drivers of sudden cardiac death in heart failure with preserved ejection fraction? A review. <i>ESC Heart Failure</i> , 2023, 10, 1555-1569.	1.4	3
2968	Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure. <i>JAMA Cardiology</i> , 2023, 8, 150.	3.0	7
2969	Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure. <i>Case Reports in Cardiology</i> , 2022, 2022, 1-5.	0.1	2
2970	Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms. <i>Pharmacological Reports</i> , 2023, 75, 44-68.	1.5	6
2971	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. <i>European Heart Journal Supplements</i> , 2022, 24, L10-L19.	0.0	6
2972	Effects of Dapagliflozin on Echocardiographic Measures of Cardiac Structure and Function in Patients with CKD. <i>Kidney360</i> , 0, 4, 10.34067/KID.0006982022.	0.9	0
2973	Aiming at harmony. Comparing and contrasting International HFrEF Guidelines. <i>European Heart Journal Supplements</i> , 2022, 24, L20-L28.	0.0	7
2974	New Insights into the Use of Empagliflozin—A Comprehensive Review. <i>Biomedicines</i> , 2022, 10, 3294.	1.4	6
2975	Sodium-glucose cotransporter-2 inhibitor prescribing practices. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1136-1139.	2.2	0
2976	Comprehensive Oral Diabetes Medication Resource 2022. <i>ADCES in Practice</i> , 2023, 11, 42-49.	0.2	0
2977	Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2978	Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. <i>Heart</i> , 2023, 109, 823-831.	1.2	7
2979	Changes in the use of glucose-lowering drugs: A Danish nationwide study. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1002-1010.	2.2	12
2980	Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. <i>Journal of Cardiac Failure</i> , 2023, 29, 389-402.	0.7	5
2981	Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 785-795.	2.2	4
2983	Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>Open Heart</i> , 2022, 9, e002069.	0.9	0
2984	Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2023, 12, 42.	1.0	7
2985	Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	0.6	3

#	ARTICLE	IF	CITATIONS
2986	Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?. <i>Revista Romana De Cardiologie</i> , 2022, 32, 167-173.	0.0	1
2987	Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 0, , .	1.0	0
2988	A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2023, 14, 151-164.	1.1	15
2989	The impact of catheter ablation in patientâ€™s heart failure and atrial fibrillation: a meta-analysis of randomized clinical trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2023, 66, 1487-1497.	0.6	1
2991	Bibliometric and visualized analysis of sodiumâ€™Glucose cotransporter 2 inhibitors. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2992	Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	15
2993	Diabetes Mellitus at an Elderly Age. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 0, , .	0.6	1
2994	Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca <sup>2+</sup> handling in ventricular cardiomyocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2023, 324, H341-H354.	1.5	9
2995	Use of Guideline-Directed Medical Therapy in Patients Aged 80 Years or Older with Heart Failure with Reduced Ejection Fraction. <i>CJC Open</i> , 2023, , .	0.7	0
2996	Tests and Interventions. , 2022, , 55-69.		0
2997	Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms. <i>Pharmacological Research</i> , 2023, 188, 106667.	3.1	6
2998	Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization. <i>JACC: Heart Failure</i> , 2023, 11, 596-606.	1.9	4
2999	Prognostic Implications of Left Atrial Stiffness Index in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Cardiovascular Imaging</i> , 2023, 16, 435-445.	2.3	11
3000	Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. <i>European Journal of Heart Failure</i> , 0, , .	2.9	3
3001	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. <i>Vascular Medicine</i> , 2023, 28, 62-76.	0.8	4
3002	The effect of dapagliflozin on myocardial ischemiaâ€™reperfusion injury in diabetic rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 0, , .	0.7	0
3003	Nephrilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. <i>Cancers</i> , 2023, 15, 312.	1.7	8
3004	Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. <i>Annals of Internal Medicine</i> , 2023, 176, 381-387.	2.0	35

#	ARTICLE	IF	CITATIONS
3005	Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes. <i>European Journal of Heart Failure</i> , 2023, 25, 347-357.	2.9	7
3006	Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 1429-1439.	1.8	3
3007	Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure. <i>Kidney and Dialysis</i> , 2023, 3, 56-72.	0.5	3
3008	Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. <i>Journal of Cardiovascular Pharmacology</i> , 2023, 81, 4-14.	0.8	11
3009	Canagliflozin Pretreatment Attenuates Myocardial Dysfunction and Improves Postcardiac Arrest Outcomes After Cardiac Arrest and Cardiopulmonary Resuscitation in Mice. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	1
3010	Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. <i>World Journal of Gastroenterology</i> , 0, 29, 61-74.	1.4	5
3011	Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. <i>Clinical Research in Cardiology</i> , 2023, 112, 1044-1055.	1.5	5
3012	The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	3
3013	Diuretics and Ultrafiltration in Heart Failure. <i>CardioRenal Medicine</i> , 2023, , 56-65.	0.7	5
3014	Little at a time: trying to understand the battery of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2023, 25, 235-237.	2.9	2
3015	Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. <i>Drugs in Context</i> , 0, 12, 1-14.	1.0	1
3016	Emerging concepts in heart failure management and treatment: focus on vericiguat. <i>Drugs in Context</i> , 0, 12, 1-11.	1.0	1
3017	Diabetic Chronic Kidney Disease in Type 2 Diabetes Mellitus (Albuminuric/Non-albuminuric). <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 243-269.	0.1	1
3018	Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 214.	3.8	59
3019	Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. <i>Swiss Medical Weekly</i> , 2023, 153, 40004.	0.8	4
3020	Control of Blood Glucose and Cardiovascular Risk Profile. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2023, , 451-469.	0.1	0
3021	Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 1-13.	0.7	4
3022	Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis. <i>Acta Diabetologica</i> , 2023, 60, 435-445.	1.2	5

#	ARTICLE	IF	CITATIONS
3023	Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1229-1240.	2.2	1
3024	Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. <i>Drugs in Context</i> , 0, 12, 1-16.	1.0	2
3025	Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics. <i>Kaohsiung Journal of Medical Sciences</i> , 2023, 39, 416-425.	0.8	1
3026	Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. <i>Journal of Clinical Medicine</i> , 2023, 12, 379.	1.0	4
3027	Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome. <i>Pharmacological Research</i> , 2023, 188, 106659.	3.1	18
3028	Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. <i>Diabetes and Metabolism</i> , 2023, 49, 101419.	1.4	9
3029	Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial. <i>Metabolism: Clinical and Experimental</i> , 2023, 140, 155396.	1.5	11
3030	Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension. , 0, , 8.		1
3032	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials. <i>Medicine (United States)</i> , 2022, 101, e32489.	0.4	1
3033	The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure. <i>Özget Baysal Tıp Fakültesi Dergisi</i> , 2022, 11, 337-336.	0.0	2
3035	Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events. <i>Cureus</i> , 2022, , .	0.2	0
3036	Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2i) during the month of Ramadan in patients with type 2 diabetes mellitus in Pakistani population—an observational study from a tertiary care center in Karachi. <i>Endocrine</i> , 2023, 80, 64-70.	1.1	3
3037	New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside and Back. <i>Biomedicines</i> , 2023, 11, 70.	1.4	1
3038	Emerging molecular imaging targets and tools for myocardial fibrosis detection. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 261-275.	0.5	12
3039	Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
3042	SGLT2 Inhibitors: The Sweet Success for Kidneys. <i>Annual Review of Medicine</i> , 2023, 74, 369-384.	5.0	14
3043	Chronic heart failure management in adult patients with congenital heart disease. <i>Current Opinion in Cardiology</i> , 0, Publish Ahead of Print, .	0.8	0
3044	Cardiac magnetic resonance shows increased adverse ventricular remodeling in younger patients after ST-segment elevation myocardial infarction. <i>European Radiology</i> , 0, , .	2.3	0

#	ARTICLE	IF	CITATIONS
3045	Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods. <i>ESC Heart Failure</i> , 2023, 10, 1231-1241.	1.4	5
3046	Clifozinas en el tratamiento de la diabetes tipo 2: más allá de los beneficios en el control metabólico. <i>Anatomía Digital</i> , 2023, 6, 49-64.	0.0	1
3047	Efficacy and safety of empagliflozin: a real-world experience from Saudi Arabia. <i>Annals of Saudi Medicine</i> , 2023, 43, 50-56.	0.5	2
3048	Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2023, 24, 327-343.	2.6	10
3049	SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. <i>Biomedicines</i> , 2023, 11, 279.	1.4	7
3050	Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO registry. <i>ESC Heart Failure</i> , 2023, 10, 1193-1204.	1.4	9
3051	The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥75 years): a retrospective, pharmacovigilance study. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	9
3052	Medications for When the Heart Fails. <i>Physician Assistant Clinics</i> , 2023, , .	0.1	0
3053	Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	6
3054	Recent Advances in Remote Pulmonary Artery Pressure Monitoring for Patients with Chronic Heart Failure: Current Evidence and Future Perspectives. <i>Sensors</i> , 2023, 23, 1364.	2.1	4
3055	The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis. <i>Current Problems in Cardiology</i> , 2023, 48, 101602.	1.1	4
3056	Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. <i>Diabetes Care</i> , 2023, 46, 602-607.	4.3	5
3057	Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1341-1350.	2.2	7
3058	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 10-26.	1.8	4
3059	Medical therapy. , 2023, , 353-361.		0
3061	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. <i>Canadian Journal of Kidney Health and Disease</i> , 2023, 10, 205435812211505.	0.6	3
3062	Effects of ertugliflozin on kidney outcomes in patients with heart failure at baseline in the VERTIS CV trial. <i>Kidney International Reports</i> , 2023, , .	0.4	0
3063	Heart Failure Pharmacological Management: Gaps and Current Perspectives. <i>Journal of Clinical Medicine</i> , 2023, 12, 1020.	1.0	8

#	ARTICLE	IF	CITATIONS
3064	Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus. PLoS ONE, 2023, 18, e0280359.	1.1	3
3065	Management of Heart Failure With Reduced Ejection Fraction. Current Problems in Cardiology, 2023, 48, 101596.	1.1	5
3066	Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 343-352.	1.4	2
3067	Advances in contemporary medical management to treat patients with heart failure. Current Opinion in Cardiology, 2023, 38, 136-142.	0.8	4
3068	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
3069	Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for postâ€transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation. Clinical Transplantation, 2023, 37, .	0.8	5
3070	Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor. Journal of the Endocrine Society, 2023, 7, .	0.1	3
3071	Worsening HeartÂFailure: Nomenclature, Epidemiology, and Future Directions. Journal of the American College of Cardiology, 2023, 81, 413-424.	1.2	50
3072	Prevalence and prognostic impact of left ventricular systolic dysfunction or pulmonary congestion after acute myocardial infarction. ESC Heart Failure, 2023, 10, 1347-1357.	1.4	6
3073	Sodium-Glucose Cotransporter-2ÂInhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology, 2023, 48, 101597.	1.1	4
3074	Research Progress of SGLT2 Inhibitors in the Treatment of Heart Failure Complicated with Atrial Fibrillation. Advances in Clinical Medicine, 2023, 13, 2632-2642.	0.0	0
3075	Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure. ESC Heart Failure, 2023, 10, 1635-1642.	1.4	3
3076	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines, 2023, 11, 662.	1.4	3
3077	Sodium-Glucose Cotransporter 2 Inhibitors in Frail Patients with Heart Failure: Clinical Experience of a Heart Failure Unit. Drugs and Aging, 2023, 40, 293-299.	1.3	2
3078	The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. Journal of Clinical Medicine, 2023, 12, 2253.	1.0	3
3079	Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. International Journal of Cardiology, 2023, 376, 83-89.	0.8	8
3080	Transcatheter Left Ventricular Restoration in Patients With Heart Failure. Journal of Cardiac Failure, 2023, 29, 1046-1055.	0.7	4
3081	Impact of Inpatient Initiation of SGLT2 Inhibitors on Diuretic Requirements in Patients With Heart Failure. Journal of Pharmacy Practice, 0, , 089719002311597.	0.5	0



#	ARTICLE	IF	CITATIONS
3082	Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. <i>Ageing Research Reviews</i> , 2023, 86, 101884.	5.0	3
3083	Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies. <i>Pharmaceutics</i> , 2023, 15, 1246.	2.0	0
3084	Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study. <i>Clinical Diabetes</i> , 0, , .	1.2	0
3085	Sacubitril/Valsartan Improves Left Atrial and Ventricular Strain and Strain Rate in Patients with Heart Failure with Reduced Ejection Fraction. <i>Life</i> , 2023, 13, 995.	1.1	2
3086	Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2814.	1.0	5
3087	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 3-14.	2.2	4
3088	Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 2096-2104.	2.2	4
3089	Long-term follow-up of survivors of a first acute coronary syndrome: Results from the French MONICA registries from 2009 to 2017. <i>International Journal of Cardiology</i> , 2023, 378, 138-143.	0.8	0
3090	Regional management of worsening heart failure: rationale and design of the CHAIN-HF registry. <i>ESC Heart Failure</i> , 2023, 10, 2074-2083.	1.4	2
3091	The role of trigger factors in the occurrence of appropriate ICD shocks and their clinical and prognostic implications. <i>Journal of Cardiovascular Electrophysiology</i> , 0, , .	0.8	0
3092	Potential global impact of sodium-glucose cotransporter2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2023, 25, 999-1009.	2.9	9
3093	Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 323-328.	1.0	2
3094	Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients – DACAMI (a randomized controlled clinical trial). <i>International Journal of Cardiology</i> , 2023, 379, 9-14.	0.8	4
3095	Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. <i>Translational and Clinical Pharmacology</i> , 2022, 30, 212.	0.3	3
3096	Recent developments in adjunct therapies for type 1 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1311-1320.	1.9	3
3097	Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore. <i>Value in Health Regional Issues</i> , 2023, 34, 108-117.	0.5	1
3098	Clinical pharmacology of SGLT-2 inhibitors in heart failure. <i>Expert Review of Clinical Pharmacology</i> , 2023, 16, 149-160.	1.3	5
3099	SGLT2 Inhibitors for Nephrologists. , 0, , 114-119.		0

#	ARTICLE	IF	CITATIONS
3100	Latest Standard Management for Heart Failure with Guideline-Directed Medical Therapy (GDMT). , 2022, 3, 35-40.		0
3101	Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC: Heart Failure, 2023, 11, 375-388.	1.9	1
3102	Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2023, , .	1.9	0
3103	The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. ESC Heart Failure, 2023, 10, 1314-1325.	1.4	3
3104	Cardiovascular Manifestations in Rheumatoid Arthritis. Cardiology in Review, 2024, 32, 146-152.	0.6	1
3105	Medication-Attributable Adverse Events in Heart Failure Trials. JACC: Heart Failure, 2023, 11, 425-436.	1.9	1
3106	Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy. Therapeutics and Clinical Risk Management, 0, Volume 19, 133-142.	0.9	1
3107	Innovations in medical therapy of heart failure with reduced ejection fraction. Journal of Cardiovascular Medicine, 2023, 24, e47-e54.	0.6	3
3108	Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist. Nutrients, 2023, 15, 748.	1.7	2
3109	Dapagliflozin attenuates myocardial remodeling in hypertension by activating the circadian rhythm signaling pathway. Archives of Pharmacal Research, 2023, 46, 117-130.	2.7	3
3110	Heart Failure With Stable Mildly-reduced Ejection Fraction: Prognosis and Predictors of Outcomes. Current Problems in Cardiology, 2023, 48, 101631.	1.1	3
3111	Advances in Heart Failure with Preserved Ejection Fraction Management - The Role of Sacubitril-Valsartan, Pirfenidone, Spironolactone and Empagliflozin: Is Success a Series of Small Victories?. Current Pharmaceutical Design, 2023, 29, 502-508.	0.9	3
3112	Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?. Archives of Medical Science, 2023, 19, 528-531.	0.4	0
3113	Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction. ESC Heart Failure, 2023, 10, 1358-1371.	1.4	3
3114	Misconceptions and Facts about Heart Failure with Reduced Ejection Fraction. American Journal of Medicine, 2023, , .	0.6	0
3115	Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial. American Heart Journal Plus, 2023, 26, 100264.	0.3	0
3116	Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	9
3117	Vericiguat in HFrEF. JACC: Heart Failure, 2023, 11, 224-226.	1.9	1

#	ARTICLE	IF	CITATIONS
3118	EMMY: The continued expansion of clinical applications of SGLT2 inhibitors. <i>Global Cardiology Science &amp; Practice</i> , 2023, 2023, .	0.3	1
3119	Treatment of Advanced (Stage D) Heart Failure in the New Era. <i>JACC: Heart Failure</i> , 2023, 11, 258-260.	1.9	0
3120	Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2023, 37, 956-963.	0.6	4
3121	Comparative efficacy of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1614-1623.	2.2	8
3122	Patients with osteoporosis: children of a lesser god. <i>RMD Open</i> , 2023, 9, e002973.	1.8	0
3123	Pharmacotherapy treatment patterns at hospital discharge and clinical outcomes among patients with heart failure with reduced ejection fraction. <i>Chronic Diseases and Translational Medicine</i> , 2023, 9, 154-163.	0.9	0
3125	Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 911-922.	1.5	3
3126	The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1919-1955.	5.7	13
3127	Interest and place of new therapeutic classes in the treatment of elderly diabetic patients. <i>Diabetes and Metabolism</i> , 2023, 49, 101431.	1.4	1
3128	Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors. <i>Life</i> , 2023, 13, 497.	1.1	5
3129	Acute Biomechanical Effects of Empagliflozin on Living Isolated Human Heart Failure Myocardium. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	3
3130	Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. <i>Heart</i> , 0, , heartjnl-2022-321702.	1.2	3
3131	Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
3132	Cá»p nhá»t vai trã» cá»sa thuá»c á»c chá» SGLT2 trong dá»± phã»ng vã» Æ»u trá» suy tim. , 2022, , 10-17.		0
3133	Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure. <i>Cardiology Journal</i> , 2023, 30, 153-154.	0.5	0
3135	Kidney function changes in acute heart failure: a practical approach to interpretation and management. <i>CKJ: Clinical Kidney Journal</i> , 2023, 16, 1587-1599.	1.4	2
3137	Evaluation of heart failure admission as a surrogate for mortality in randomized clinical trials: A meta-analysis. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	1.7	2
3138	SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. <i>Medicina (Lithuania)</i> , 2023, 59, 388.	0.8	4

#	ARTICLE	IF	CITATIONS
3139	Metabolic Impact of Frailty Changes Diabetes Trajectory. <i>Metabolites</i> , 2023, 13, 295.	1.3	9
3140	Transcatheter interventions for heart failure. <i>EuroIntervention</i> , 2023, 18, 1135-1149.	1.4	3
3141	Commentary on glucose reduction in type 2 diabetes (<scp>GRADE</scp>). <i>Journal of Diabetes Investigation</i> , 2023, 14, 741-743.	1.1	0
3142	Change in Systemic Arterial Pulsatility index (SAPi) during heart failure hospitalization is associated with improved outcomes. <i>American Heart Journal Plus</i> , 2023, 27, 100275.	0.3	0
3143	Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction. <i>Annals of Pharmacotherapy</i> , 2023, 57, 1291-1301.	0.9	1
3144	The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 133-140.	1.0	1
3145	Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4144.	1.8	4
3146	Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin. <i>JACC: Heart Failure</i> , 2023, 11, 702-712.	1.9	1
3147	Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	13
3148	Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors. <i>Circulation</i> , 2023, 147, 635-637.	1.6	0
3149	Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. <i>JCI Insight</i> , 2023, 8, .	2.3	5
3150	Functional assessment based on cardiopulmonary exercise testing in mild heart failure: A multicentre study. <i>ESC Heart Failure</i> , 2023, 10, 1689-1697.	1.4	4
3151	Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1 $\alpha$ -mediated mitochondrial biogenesis. <i>Toxicology Research</i> , 2023, 12, 216-223.	0.9	9
3152	The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. <i>Current Pharmaceutical Design</i> , 2023, 29, 481-493.	0.9	1
3153	Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout. <i>JAMA Cardiology</i> , 2023, 8, 386.	3.0	13
3154	Incidence, determinants, and outcomes of recovered left ventricular ejection fraction (LVEF) in patients with non-ischemic systolic heart failure; a hospital-based cohort study. <i>Indian Heart Journal</i> , 2023, 75, 128-132.	0.2	1
3155	Dynamic evolution of left ventricular strain and microvascular perfusion assessed by speckle tracking echocardiography and myocardial contrast echocardiography in diabetic rats: Effect of dapagliflozin. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
3156	Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. <i>Advances in Clinical Medicine</i> , 2023, 13, 2736-2743.	0.0	0

#	ARTICLE	IF	CITATIONS
3157	Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. <i>American Journal of Preventive Cardiology</i> , 2023, 13, 100477.	1.3	2
3158	Assessing Correlation Between Thoracic Impedance and Remotely Monitored Pulmonary Artery Pressure in Chronic Systolic Heart Failure. <i>Cardiology Research</i> , 2023, 14, 32-37.	0.5	0
3159	Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?. <i>Circulation</i> , 2023, 147, 759-767.	1.6	4
3160	Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Clinical and Laboratory Variables in Heart Failure Patients with Reduced Left Ventricular Ejection Fraction in a Latin American Hospital: A Retrospective Study. <i>Hearts</i> , 2023, 4, 20-27.	0.4	0
3161	Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. <i>Hypertension Research</i> , 2023, 46, 1195-1201.	1.5	7
3162	Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study. <i>ESC Heart Failure</i> , 2023, 10, 1745-1756.	1.4	5
3163	Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2023, 11, 541-551.	1.9	10
3164	Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. <i>Current Heart Failure Reports</i> , 2023, 20, 101-112.	1.3	0
3165	Sex and gender differences in myocarditis and dilated cardiomyopathy: An update. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	33
3166	Estimating the value of sodium-glucose cotransporter 2 inhibitors within the context of contemporary guidelines and the totality of evidence. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1830-1838.	2.2	5
3167	Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2023, 8, 419.	3.0	21
3168	Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. <i>Psychopharmacology</i> , 2023, 240, 983-1000.	1.5	4
3169	SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. <i>Journal of Internal Medicine</i> , 2023, 293, 550-558.	2.7	0
3170	The Prognostic Role of Spot Urinary Sodium and Chloride in a Cohort of Hospitalized Advanced Heart Failure Patients: A Pilot Study. <i>Life</i> , 2023, 13, 698.	1.1	1
3171	Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1680-1693.	1.2	17
3172	Safety and cardiometabolic efficacy of novel antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 119-124.	1.0	1
3173	Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. <i>Circulation</i> , 2023, 147, 1067-1078.	1.6	3
3174	Implantable Cardioverter-Defibrillator for Primary Prevention in Asia. <i>JACC Asia</i> , 2023, , .	0.5	0

#	ARTICLE	IF	CITATIONS
3175	Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology and Metabolism, 0, , .	1.2	0
3176	Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology and Metabolism, 2023, 18, 131-142.	1.2	0
3177	T lymphocyte characteristics and immune repertoires in the epicardial adipose tissue of heart failure patients. Frontiers in Immunology, 0, 14, .	2.2	2
3178	Reply to: Central apnoeas, sympathetic activation and mortality in heart failure: look before you leap. European Respiratory Journal, 2023, 61, 2300042.	3.1	0
3179	Paradigm sift of the medical care in diabetes. Nihon Ika Daigaku Igakkai Zasshi, 2023, 19, 32-41.	0.0	0
3180	Identifying the patient with heart failure to be treated with vericiguat. Current Medical Research and Opinion, 2023, 39, 661-669.	0.9	1
3182	Holistic approach to drug therapy in a patient with heart failure. Heart, 2023, 109, 1183-1191.	1.2	1
3183	Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. Journal of Cardiovascular Development and Disease, 2023, 10, 114.	0.8	0
3184	Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts. Revista Espanola De Cardiologia (English Ed ), 2023, , .	0.4	1
3185	Leveraging Biomarkers for Precision Medicine in Heart Failure. Journal of Cardiac Failure, 2023, 29, 459-462.	0.7	2
3186	Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure. Biomedicines, 2023, 11, 876.	1.4	1
3187	Dramatic disease regression in a case of HFrEF with endâ€stage renal failure treated with sacubitril/valsartan and SGLT2i. ESC Heart Failure, 2023, 10, 2099-2106.	1.4	3
3188	Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study. , 2023, 27, 77-87.		1
3190	Efficacy of sodiumâ€glucose cotransporter 2 inhibitors and angiotensin <sc>receptorâ€neprilysin</sc> inhibitors for heart failure in black patients: a systematic review and <sc>metaâ€analysis</sc> of randomized controlled trials. European Journal of Heart Failure, 2023, 25, 591-593.	2.9	0
3191	Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review. Current Pharmaceutical Design, 2023, 29, 509-518.	0.9	1
3192	Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGINâ€HF study. ESC Heart Failure, 0, , .	1.4	2
3193	Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy. Pharmacy (Basel, Switzerland), 2023, 11, 58.	0.6	0
3194	SGLT2 Inhibitorâ€Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism. Pharmaceutics, 2023, 15, 965.	2.0	2

#	ARTICLE	IF	CITATIONS
3195	Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. <i>Lancet Regional Health - Europe</i> , The, 2023, 29, 100617.	3.0	5
3196	Heart failure with reduced ejection fraction and atrial fibrillation: a Sub-Saharan African perspective. <i>ESC Heart Failure</i> , 2023, 10, 1580-1596.	1.4	3
3197	Mechanisms of renoprotective action of sodium-glucose cotransporter-2 inhibitors (gliflozins): a clinician's view. <i>Mã¼narodnij Endokrinologã¼nj Å½urnal</i> , 2023, 19, 39-44.	0.1	0
3198	Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2023, 12, 2410.	1.0	2
3199	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. <i>Frontiers in Clinical Drug Research Diabetes and Obesity</i> , 2023, , 117-167.	0.1	0
3200	Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. <i>Pharmaceutics</i> , 2023, 15, 1002.	2.0	1
3201	Contemporary issues and lifetime management in patients underwent transcatheter aortic valve replacement. <i>Cardiovascular Intervention and Therapeutics</i> , 2023, 38, 275-286.	1.2	2
3202	Beyond Stage C: Considerations in the Management of Patients With Heart Failure Progression and Gaps in Evidence. <i>Journal of Cardiac Failure</i> , 2023, 29, 818-831.	0.7	0
3203	Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction. <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	0.0	0
3204	Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
3205	A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5983.	1.8	2
3206	Management of patients with heart failure and preserved ejection fraction. <i>Heart</i> , 2023, 109, 874-883.	1.2	9
3207	Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	3
3208	SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. <i>International Journal of Heart Failure</i> , 2023, 5, 82.	0.9	14
3209	SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials. <i>Journal of Cardiovascular Electrophysiology</i> , 2023, 34, 1277-1285.	0.8	14
3210	The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives. <i>Biomedicines</i> , 2023, 11, 998.	1.4	3
3211	Heart failure therapy challenges in obese patients. <i>Medicinski Glasnik Specijalne Bolnice Za Bolesti Åtitaste Å½lezde I Bolesti Metabolizma Zlatibor</i> , 2023, 28, 21-42.	0.1	0
3212	Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension. <i>American Journal of Nephrology</i> , 2023, 54, 136-144.	1.4	0

#	ARTICLE	IF	CITATIONS
3213	Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat. Patient Preference and Adherence, 0, Volume 17, 839-849.	0.8	0
3214	Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization. Expert Opinion on Pharmacotherapy, 2023, 24, 705-713.	0.9	0
3215	Prescribing trends of sodium-glucose cotransporter 2 inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction. European Heart Journal - Cardiovascular Pharmacotherapy, 0, , .	1.4	0
3216	Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction. Cardiovascular Diabetology, 2023, 22, .	2.7	6
3217	Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. ESC Heart Failure, 2023, 10, 1499-1530.	1.4	8
3218	Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers. Clinical Drug Investigation, 2023, 43, 241-250.	1.1	0
3219	EFFECTIVENESS OF DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC HEART FAILURE. World Science, 2023, , .	0.0	0
3220	Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System. Clinical Drug Investigation, 2023, 43, 265-275.	1.1	3
3221	Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial. BMJ Open, 2023, 13, e069641.	0.8	1
3222	Management of Heart Failure with Reduced Ejection Fraction Globally and in Lebanon: Where Do SGLT-2is Stand?. World Journal of Cardiovascular Diseases, 2023, 13, 138-169.	0.0	0
3223	Ketones and the Heart: Metabolic Principles and Therapeutic Implications. Circulation Research, 2023, 132, 882-898.	2.0	25
3224	The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. Pharmaceutics, 2023, 15, 1092.	2.0	1
3225	Safety of SGLT2 Inhibitors in Three Chronic Diseases. International Heart Journal, 2023, 64, 246-251.	0.5	1
3226	The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 858-868.	2.2	0
3227	Chronic Heart Failure in Children: State of the Art and New Perspectives. Journal of Clinical Medicine, 2023, 12, 2611.	1.0	2
3228	Treatment Strategies of Improving Quality of Care in Patients With Heart Failure. Korean Circulation Journal, 2023, 53, 294.	0.7	4
3229	Type 2 diabetes management: from a glucose-centric approach to cardio-renal risk reduction. , 2023, , 221-232.		0
3230	Cardiac energy metabolism in heart failure. , 2023, , 175-198.		0



#	ARTICLE	IF	CITATIONS
3231	Heart failure: pathophysiology and the emergence of novel therapies. , 2023, , 441-458.		0
3232	Diabetes: evolution of multifactorial vascular risk reduction. , 2023, , 311-335.		0
3233	Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. , 2023, , 337-363.		0
3234	Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 748-758.	2.2	0
3235	The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!. Postgraduate Medical Journal, 0, , .	0.9	0
3237	Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. American Journal of Cardiology, 2023, 196, 89-98.	0.7	4
3238	Embedding guidelines into clinical practice. Practical Diabetes, 2023, 40, 28.	0.1	0
3239	New perspectives in the treatment of chronic heart failure. Vnitri Lekarstvi, 2023, 69, 82-87.	0.1	0
3240	Sodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure. Chinese Medical Journal, 0, Publish Ahead of Print, .	0.9	0
3241	Evolving Diagnostic and Management Advances in Coronary Heart Disease. Life, 2023, 13, 951.	1.1	3
3242	Chronic Kidney Disease Management in the Middle East and Africa: Concerns, Challenges, and Novel Approaches. International Journal of Nephrology and Renovascular Disease, 0, Volume 16, 103-112.	0.8	3
3243	Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling. International Journal of Molecular Sciences, 2023, 24, 6842.	1.8	3
3244	Do Women Physicians Accept and Follow Heart Failure Guidelines More Than Men?. Current Heart Failure Reports, 0, , .	1.3	0
3245	Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice. Cureus, 2023, , .	0.2	0
3246	Ketones and the cardiovascular system. , 2023, 2, 425-437.		8
3247	Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies. Biomedicines, 2023, 11, 1126.	1.4	9
3248	Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review. Cureus, 2023, , .	0.2	0
3249	Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?. Medicina (Lithuania), 2023, 59, 742.	0.8	3

#	ARTICLE	IF	CITATIONS
3250	Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence. <i>Kidney Diseases (Basel, Switzerland)</i> , 2023, 9, 326-341.	1.2	0
3251	Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?. <i>Cardiology</i> , 2023, 148, 195-206.	0.6	2
3252	Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. <i>Circulation</i> , 2023, 147, 1670-1683.	1.6	6
3253	Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling. <i>ESC Heart Failure</i> , 0, , .	1.4	1
3254	Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Chronic Heart Failure. , 0, 2, .		4
3255	IGFBP7 and left ventricular mass regression: a subanalysis of the EMPA-HEART CardioLink randomized clinical trial. <i>ESC Heart Failure</i> , 2023, 10, 2113-2119.	1.4	1
3256	Impact of diabetes duration on left ventricular mass regression with empagliflozin. <i>ESC Heart Failure</i> , 2023, 10, 2134-2140.	1.4	3
3257	Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. <i>JACC: Heart Failure</i> , 2023, 11, 583-592.	1.9	1
3258	Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2023, 12, 2824.	1.0	1
3259	Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2023, 10, 2010-2018.	1.4	2
3260	A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospects. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 33-47.	2.2	0
3261	Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2023, 11, 749-759.	1.9	3
3262	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. <i>Korean Circulation Journal</i> , 2023, 53, 217.	0.7	4
3263	Cardiac Regenerative Therapy Using Human Pluripotent Stem Cells for Heart Failure: A State-of-the-Art Review. <i>Journal of Cardiac Failure</i> , 2023, 29, 503-513.	0.7	0
3264	Acute effects of empagliflozin on open-loop baroreflex function and urine glucose excretion in Goto-Kakizaki diabetic rats. <i>Journal of Physiological Sciences</i> , 2023, 73, .	0.9	2
3265	Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. <i>International Journal of Heart Failure</i> , 2023, 5, 66.	0.9	9
3266	Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>Cardiosomatics</i> , 2023, 13, 198-205.	0.2	0
3267	Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 975-986.	1.1	3

#	ARTICLE	IF	CITATIONS
3268	Speckle tracking echocardiography in early disease stages: a therapy modifier?. Journal of Cardiovascular Medicine, 2023, 24, e55-e66.	0.6	3
3269	Cardiac Reverse Remodeling in Ischemic Heart Disease with Novel Therapies for Heart Failure with Reduced Ejection Fraction. Life, 2023, 13, 1000.	1.1	1
3270	The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. Circulation Research, 2023, 132, 902-914.	2.0	11
3271	SGLT2 breast expression could affect the cardiovascular performance in pre-menopausal women with fatty vs. non fatty breast via over-inflammation and sirtuins™ down regulation. European Journal of Internal Medicine, 2023, 113, 57-68.	1.0	5
3272	Correlation between the Six-Minute Walk Test and Subjective Functional Class in Patients with Heart Failure. World Journal of Cardiovascular Diseases, 2023, 13, 205-213.	0.0	0
3273	CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. Wiadomości Lekarskie, 2023, 76, 645-650.	0.1	0
3274	Updates in Cardiorenal Syndrome. Medical Clinics of North America, 2023, , .	1.1	1
3275	Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1 glucagon dual agonism. Diabetes Research and Clinical Practice, 2023, 199, 110669.	1.1	1
3276	Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the <scp>EMPEROR-Pre</scp> trial. European Journal of Heart Failure, 2023, 25, 1337-1348.	2.9	12
3277	Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Leads to a Shorter Hospital Stay in Patients With Acute Decompensated Heart Failure. Circulation Reports, 2023, , .	0.4	0
3278	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. Life, 2023, 13, 1024.	1.1	1
3279	Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of <scp>PARADIGM-HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2023, 25, 687-697.	2.9	2
3280	Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action. Journal of Cardiovascular Pharmacology and Therapeutics, 2023, 28, 107424842311622.	1.0	0
3281	Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease. Expert Opinion on Pharmacotherapy, 2023, 24, 935-945.	0.9	1
3282	The Role of SGLT2 Inhibitors in Cardiovascular Management. Cardiology in Review, 0, Publish Ahead of Print, .	0.6	0
3283	Sodium-Glucose Co-Transporter Type 2 Inhibitors and Heart Failure: A Review of the State of the Art. Iberoamerican Journal of Medicine, 2023, 5, 68-77.	0.1	1
3284	Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus. Scientific Reports, 2023, 13, .	1.6	2
3285	Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial. Circulation, 2023, 147, 1654-1669.	1.6	15

#	ARTICLE	IF	CITATIONS
3286	Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial. <i>Journal of Cardiovascular Pharmacology</i> , 2023, Publish Ahead of Print, .	0.8	0
3287	Therapeutic Innovations for Heart Failure. <i>Cardiac and Vascular Biology</i> , 2023, , 337-353.	0.2	0
3288	SGLT 2 inhibitors: Searching for the best in class. <i>International Journal of Cardiology</i> , 2023, 384, 48-49.	0.8	2
3289	Adoption of sodium-glucose cotransporter-2 inhibitors among prescribers caring for nursing home residents. <i>Journal of the American Geriatrics Society</i> , 2023, 71, 2585-2592.	1.3	1
3290	Heart failure therapy: the fifth card. <i>European Heart Journal Supplements</i> , 2023, 25, B140-B143.	0.0	1
3291	Therapeutic choices in elderly diabetic patients. <i>Annales D'Endocrinologie</i> , 2023, , .	0.6	0
3293	Recent advances in the treatment of patients with obesity and chronic kidney disease. <i>Annals of Medicine</i> , 2023, 55, .	1.5	4
3354	Empagliflozin in Diastolic Heart Failure (EMPEROR)-2021. , 2023, , 65-68.		0
3364	Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?. <i>Hypertension Research</i> , 0, , .	1.5	0
3369	SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2023, , 923-968.	0.0	0
3370	COVID-19, Diabetes, and Cardiovascular Disease. , 2023, , 787-791.		0
3388	Overview of Inpatient Management of Diabetes and COVID-19. <i>Contemporary Endocrinology</i> , 2023, , 111-122.	0.3	0
3396	The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type-2 Diabetes: A Narrative Review. <i>Advances in Therapy</i> , 0, , .	1.3	0
3458	Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges. <i>Nature Reviews Cardiology</i> , 2023, 20, 812-829.	6.1	14
3467	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. <i>Contemporary Cardiology</i> , 2023, , 1043-1070.	0.0	0
3468	Introduction: Epidemiology, Definitions, and Pathophysiology. <i>Contemporary Cardiology</i> , 2023, , 3-14.	0.0	0
3470	Heart Failure and Cardiac Dysfunction in Diabetes. <i>Contemporary Cardiology</i> , 2023, , 747-781.	0.0	0
3476	Systematic Review of the Economic Evaluation of Sodium-glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure. <i>Clinical Drug Investigation</i> , 2023, 43, 463-474.	1.1	0

#	ARTICLE	IF	CITATIONS
3541	Heart Failure Management in Developing Countries. , 2023, , 1-28.		0
3551	The anti-inflammatory and immunological properties of SGLT-2 inhibitors. Journal of Endocrinological Investigation, 2023, 46, 2445-2452.	1.8	5
3582	Challenges in developing Geroscience trials. Nature Communications, 2023, 14, .	5.8	8
3587	Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure. American Journal of Cardiovascular Drugs, 0, , .	1.0	0
3600	Is Using Sodium-Glucose Cotransporter-2 Inhibitors to Treat Adults with Chronic Heart Failure Cost-Effective? A Systematic Review of Cost-Effectiveness Studies. Applied Health Economics and Health Policy, 2023, 21, 857-875.	1.0	1
3603	Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines. Cardiology and Therapy, 0, , .	1.1	0
3606	Immunomodulation and immunopharmacology in heart failure. Nature Reviews Cardiology, 2024, 21, 119-149.	6.1	1
3611	Unmet Needs in the Treatment of Childhood Type 2 Diabetes: A Narrative Review. Advances in Therapy, 2023, 40, 4711-4720.	1.3	1
3626	Management of type 2 diabetes in the new era. Hormones, 0, , .	0.9	1
3629	Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review. Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262, 717-752.	1.0	2
3636	Glycaemic Control and Weight Reduction: A Narrative Review of New Therapies for Type 2 Diabetes. Diabetes Therapy, 2023, 14, 1771-1784.	1.2	1
3640	Recent successes in heart failure treatment. Nature Medicine, 2023, 29, 2424-2437.	15.2	4
3687	Beginning and Managing Underlying Comorbidities. , 2023, , 49-63.		0
3733	Intensivtherapie bei akuter Herzinsuffizienz, kardiogenem Schock und Herzbeuteltamponade. Springer Reference Medizin, 2023, , 1-31.	0.0	0
3781	Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors. Advances in Therapy, 0, , .	1.3	1
3825	Der Stoff aus der Apfelrinde im Kampf gegen Diabetes (Gliflozine). , 2023, , 79-91.		0
3837	Natriuretic peptide testing strategies in heart failure: A 2023 update. Advances in Clinical Chemistry, 2023, , .	1.8	0
3860	Effect of SGLT2 Inhibitors on Improving Glucolipid Metabolism and Reproductive Hormone Status in Overweight/Obese Women with PCOS: A Systematic Review and Meta-Analysis. Reproductive Sciences, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
3900	Herz und Niere. Springer Reference Medizin, 2023, , 175-189.	0.0	0
3901	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
3949	Antiarrhythmic Treatment in Heart Failure. Current Heart Failure Reports, 2024, 21, 22-32.	1.3	0
4059	Reversibility of Cardiac Remodeling in Hypertensive Patients with Heart Failure. Updates in Hypertension and Cardiovascular Protection, 2023, , 357-370.	0.1	0
4061	Unmet Needs in Drug Treatment of Heart Failure in Hypertension. Updates in Hypertension and Cardiovascular Protection, 2023, , 409-422.	0.1	0
4073	Age-related disease: Kidneys. , 2024, , 91-117.		0
4097	Clinical Implications of Ventricular-Arterial Coupling and the Role of Therapeutic Interventions. , 2024, , 401-416.		0